WO2002016536A1 - Bactericidal antifouling detergent for hard surface - Google Patents
Bactericidal antifouling detergent for hard surface Download PDFInfo
- Publication number
- WO2002016536A1 WO2002016536A1 PCT/JP2001/006869 JP0106869W WO0216536A1 WO 2002016536 A1 WO2002016536 A1 WO 2002016536A1 JP 0106869 W JP0106869 W JP 0106869W WO 0216536 A1 WO0216536 A1 WO 0216536A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- carbon atoms
- weight
- acid
- component
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/48—Medical, disinfecting agents, disinfecting, antibacterial, germicidal or antimicrobial compositions
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D1/00—Detergent compositions based essentially on surface-active compounds; Use of these compounds as a detergent
- C11D1/38—Cationic compounds
- C11D1/62—Quaternary ammonium compounds
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/37—Polymers
- C11D3/3746—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
- C11D3/3769—(Co)polymerised monomers containing nitrogen, e.g. carbonamides, nitriles or amines
Definitions
- the present invention relates to a cleaning composition for hard surfaces that can disinfect hard surfaces and prevent soiling, that is, prevent adhesion of dirt, and easily remove attached dirt.
- a cleaning composition for hard surfaces that can disinfect hard surfaces and prevent soiling, that is, prevent adhesion of dirt, and easily remove attached dirt.
- Conventional technology can disinfect hard surfaces and prevent soiling, that is, prevent adhesion of dirt, and easily remove attached dirt.
- Conventional technology can disinfect hard surfaces and prevent soiling, that is, prevent adhesion of dirt, and easily remove attached dirt.
- Japanese Unexamined Patent Publication No. 2-1456977 discloses a flush toilet detergent containing a sulfobetaine-type amphoteric surfactant having a specific structure
- Japanese Unexamined Patent Publication No. 3-35097 discloses a flush toilet detergent containing a sulfobetaine-type amphoteric surfactant having a specific structure
- Hei 10-16797 discloses a water-based toilet cleaner containing a sulfosuccinic acid ester, which is excellent in loose stool adhesion and has a high cleaning effect. Detergents to be mixed in proportions are described.
- Japanese Unexamined Patent Application Publication No. Hei 9-16995 describes that a cleaning agent having a water contact angle of 30 degrees or less with a hard surface after treatment shows excellent antifouling property.
- an antifouling base a combination of an anionic surfactant with a surfactant containing a quaternary ammonium group in a molecule or a water-soluble polymer is mentioned.
- An object of the present invention is to provide home use, and in cleaning hard surfaces such as toilets, bathrooms, and kitchen surroundings, not only excellent detergency but also sterilization and antifouling properties can be imparted at a satisfactory level. Agent. Disclosure of the present invention
- the present invention relates to (a) a compound having a weight-average molecular weight of 1,000 to 6,000, and at least one group selected from a quaternary ammonium group and a tertiary amino group; A polymer having a monomer unit content of 0.1 to 100 mol% with respect to one monomer unit; (b) a sterilizer having a molecular weight of less than 1,000 and having a quaternary ammonium group (CA) / (b) when the surfactant contains (cA) anionic surfactant, and (cA) a surfactant. It is a germicidal and antifouling detergent for hard surfaces not exceeding 1.0 by weight.
- the present invention relates to a method for cleaning and disinfecting a hard surface by applying the above composition to a hard surface and for preventing the adhesion of dirt to the hard surface. Provide use for preventing the adhesion of dirt to the surface.
- the component (a) of the present invention is a polymer containing 10 to 100 mol% of a monomer unit having a quaternary ammonium group and / or a tertiary amino group (hereinafter, referred to as a monomer unit A).
- Monomer unit A is obtained by polymerizing a monomer (hereinafter, referred to as monomer A) containing a quaternary ammonium group (or a plurality of monomers) or a tertiary amino group (or a plurality of monomers).
- the monomer unit may be a monomer unit obtained by polymerizing a contained monomer (hereinafter, referred to as monomer A ′), or may be a quaternary ammonium obtained by quaternizing a tertiary amino group.
- the monomer A having a quaternary ammonium group that is, as an example from which the monomer unit A is derived, a compound represented by the following formula (4) can be mentioned.
- X represents an alkylene group having 1 to 12 carbon atoms , —COOR 18 —, — CONHR 18 —, — OCOR 18 —, — R 19 — ⁇ CO—R 18 — where R 18 and R 19 are each independently carbon An alkylene group having a number of 1 to 5.
- R 16 has a carbon number
- R 17 is an alkyl group having 1 to 3 alkyl groups, hydroxyalkyl group, or benzyl group
- R 17 is an alkyl group having 1 to 10 carbon atoms which may be substituted with a hydroxy group, a carbonyl group, a sulfonic acid group or a sulfate group.
- Y— represents an anion.
- R 17 contains a carboxyl group, a sulfonic acid group, or a sulfate group
- Y— does not exist, and these groups in R 17 become anions.
- anion of Y— include a halogen ion, a sulfate ion, an alkyl sulfate ion having 1 to 3 carbon atoms, an aromatic sulfonate ion optionally substituted by an alkyl group having 1 to 3 carbon atoms, and a hydroxy ion. Can be mentioned.
- Preferred examples of the tertiary amino group monomer A ′ that is, a compound derived from a monomer unit ⁇ ′, include a compound represented by the following formula (5). (Five)
- R l2, R l3, R l R 15 and R 16 are the same as above described.
- N N-dialkyl (C1-3) aminoalkyl (C1-5) acrylate (or methacrylate), N, N-dialkyl (C1-3) aminoalkyl (C1-5) ) Acrylamide, N, N-di ( ⁇ -alkenyl (C 3 -L 0))- ⁇ -methylamine is preferred, and diarylmethylamine is particularly preferred.
- quaternizing agents such as methyl chloride, methyl bromide, benzyl chloride, dimethyl sulfate, getyl sulfate, monochloroacetic acid or a salt thereof, chlorsulfuric acid or a salt thereof, and 3-chloro-2 -It is preferably carried out using hydroxypropanesulfonic acid or a salt thereof, ethylene oxide, propylene oxide, or glycidyl ether.
- ethylene oxide, propylene oxide, or glycidyl ether When ethylene oxide, propylene oxide, or glycidyl ether is used, it is preferable to react after neutralizing the monomer units with sulfuric acid, hydrochloric acid, a carboxylic acid having 1 to 12 carbon atoms, or arylsulfonic acid in advance. .
- the component (a) of the present invention includes not only a polymer composed of monomer units A (a plurality of types may be used), but also a monomer unit A (a plurality of types may be used) and another monomer unit (hereinafter, referred to as “a”). Or a polymer composed of 6 units. (When monomer A 'is used, it may have an amine type monomer unit.) In this case, the arrangement of monomer unit A and monomer unit B (there may be plural types) , Block, alternating, periodic, statistical (including random), or graft type.
- the polymer composed of the monomer units A and B can be obtained, for example, by copolymerizing the respective precursor monomers.
- the monomer unit B is preferably a monomer unit derived from a monomer selected from the following monomer groups (i) to (V), and is preferably a monomer unit derived from the monomers described in (i) to (iii) or (V).
- a monomer unit is more preferred, and a monomer unit derived from the monomer (i), (ii) or (V) is most preferred, particularly from the viewpoint of antifouling effect.
- Acrylic acid or a salt thereof methacrylic acid or a salt thereof, maleic acid or a salt thereof, maleic anhydride, styrenesulfonate, sulfopropyl methacrylate, 2-acrylamide-2-methylpropanesulfonic acid or a salt thereof
- Anion group-containing compounds selected from mono- ⁇ -methacryloyloxyalkyl phosphates (1 to 12 carbon atoms)
- the polymer having the monomer unit ⁇ and the monomer unit ⁇ may be synthesized by the above-mentioned copolymerization method, or may be formed into a polymer containing the monomer unit A by one of the monomers (i) to (
- It may be obtained by graft polymerization of the monomers of (i) and (ii), or may be obtained by graft polymerization of the monomer of the general formula (4) to a polymer containing the monomers of (i) to (v). Or a polymer containing the monomers (i) to (V), particularly preferably a polymer containing the monomers (i) and (ii), graft-polymerized with the monomer of the general formula (5). After that, it may be quaternized.
- the most preferred monomer unit B of the present invention is a monomer having one or more groups selected from a carboxylic acid group and a sulfonic acid group (but not having a quaternary ammonium group), ie, the monomer of the above (i) Monomer unit (hereinafter referred to as monomer unit B ').
- the polymer constituting the component (a) of the present invention may be obtained by any polymerization method, a radical polymerization method is particularly preferable, and the polymerization can be carried out in a bulk, solution, or emulsion system.
- Radical polymerization may be initiated by heating, but the initiators are 2,2'-azobis (2-amidinopropane) dihydrochloride and 2,2'-azobis (N, N-dimethyleneisobutylamidine).
- Azo initiators such as dihydrochloride, and organic peroxides such as hydrogen peroxide and benzoyl peroxide, t-butyl hydroperoxide, cumene hydroperoxide, methylethylketone peroxide, perbenzoic acid, etc.
- radical initiators such as oxides, persulfates such as sodium persulfate, potassium persulfate, ammonium persulfate, etc.
- redox initiators such as hydrogen peroxide-Fe 3+ , etc.
- Polymerization may be started by light irradiation or radiation irradiation in the presence or absence of a compound.
- the component (a) of the present invention may be a homopolymer of the monomer unit A or a mixture of plural kinds of polymers selected from a copolymer of the monomer unit A and the monomer-unit B.
- a more preferred constitution in the component (a) of the present invention is that the total of the monomer units A and B ′ is 50 to 100 mol% based on all the monomer units, and most preferably the monomer unit A,
- Component (a) of the present invention contains another water-soluble polymer that does not contain polymer A, as long as it does not significantly inhibit the bactericidal and antifouling properties of the germicidal and antifouling detergent for hard surfaces of the present invention. You may.
- the component (a) of the present invention has a weight average molecular weight of 1,000 to 6,000,000, preferably 10,000 to 6,000,000, particularly preferably 100,000 to 6,000,000, The weight average molecular weight was obtained by gel permeation chromatography using polyethylene glycol as a standard substance, using a mixed solvent of acetate nitrile and water (phosphate buffer) as a developing solvent.
- the component (a) is preferably present in the germicidal and antifouling detergent of the present invention in an amount of 0.01 to 30% by weight.
- the concentration of the component (a) is 0.01 to 10% by weight, more preferably 0.02 to 5% by weight.
- the concentration of the component (a) in the tank is preferably from 0.1 to 10 ppm.
- the component (b) of the present invention is a fungicidal compound having at least one quaternary ammonium group having a molecular weight of less than 1000, preferably 500 or less.
- the bactericidal compound referred to in the present invention refers to a compound having a property that the number of mouths measured by the following method is 10 or less.
- Escherichia coli IF ⁇ 3972
- Staphylococcus aureus Staphylococcus aureus: IFQ12732
- IF03972 and IF012732 have been deposited at the Institute for Fermentation, Osaka, located at 17-85, Jusanhoncho, Yodogawa-ku, Osaka, Japan and can be sold.
- Prepare a 1% by weight aqueous solution of the test compound [component (b)] add 50 ⁇ l of 10 8 to 10 9 bacterial suspensions to 2 ml of the aqueous solution, mix well, and allow to stand for 5 minutes.
- bactericidal compound having a molecular weight of less than 1000 as the component (b) compounds represented by the following formulas (1) to (3) are preferable, and among them, water-soluble compounds are particularly preferable.
- water-soluble means that the amount dissolved in 1 L of water at 20 is 1 g or more.
- R 1 and R s are each independently an alkyl group or alkenyl group having 6 to 18 carbon atoms, preferably 8 to 16 carbon atoms, preferably an alkyl group
- R 3 and R 4 are each independently It is an alkyl group or a hydroxyalkyl group having 1 to 3 carbon atoms.
- X is an aromatic ring or an ester group or an amide group selected from —COO—, one CONH—, one OC ⁇ -one, and one NHCO—
- R 2 is a hydroxyl group when X is an ester group or an amide group.
- An alkylene group having 1 to 6 carbon atoms which may be substituted, and when X.
- R 11 is an ethylene group or a propylene group, preferably an ethylene group, and k is an average number of 1 to 10, preferably an average number of 1 to 5.
- R 5 is an alkylene group having 1 to 3 carbon atoms.
- R 7 to R 1! Is one or more, preferably one or two of them, an alkyl group having 8 to 18, preferably 8 to 14, more preferably 8 to 12 carbon atoms, and the remaining Is an alkyl group or a hydroxyalkyl group having 1 to 3 carbon atoms.
- M is a number of 0 or 1.
- Y— is an anion, particularly preferably a halogen ion, a sulfate ion, an alkyl sulfate ion having 1 to 3 carbon atoms, or an aromatic sulfonate ion which may be substituted with an alkyl group having 1 to 3 carbon atoms.
- More preferred component (b) is a compound of the above general formula (1) or (3), most preferably a compound of the following general formula.
- R represents an alkyl group having 8 to 6 carbon atoms.
- R represents an optionally branched alkyl group having 6 to 12 carbon atoms
- m represents a number of 1 to 5 on average.
- two Rs represent an alkyl group having 8 to 12 carbon atoms which may be different.
- the component (b) is preferably 0.001 to 30% by weight in the disinfectant and antifouling detergent of the present invention. Specifically, the hard surface of the object is washed by a spraying device such as a trigger or an aerosol, or by a method such as application. In the case of cleaning, the concentration of the component (b) is 0.001 to 5% by weight, more preferably 0.005 to 2% by weight. On the other hand, in the cleaning method using water in the toilet tank, When it is used in a toilet cleaner that can administer an appropriate amount of cleaning liquid to the water in the tank by providing a device in the water supply path, it is contained in an amount of 0.1 to 30% by weight, more preferably 1 to 20% by weight. You. The concentration of the component (b) in the tank is preferably 0.01 to: LOp pm.
- the component (a) / component (b) is preferably 3'0Zl to 1Z50 in weight ratio, and 20/1 to 1/20 in order to obtain a bactericidal effect while maintaining sufficient antifouling properties. More preferably, 10/1 to 1/10 is most preferable.
- the germicidal antifouling detergent for hard surfaces of the present invention further contains (c) a surfactant other than the component (b) [hereinafter referred to as the component (c)].
- a surfactant other than the component (b) hereinafter referred to as the component (c).
- Nonionic surfactants, amphoteric surfactants It is preferable to add one or more surfactants selected from surfactants and anionic surfactants.
- nonionic surfactant examples include compounds represented by the following formulas (c1) to (c3).
- R ′′ 11 is a primary linear alkyl group, a branched alkyl group or a secondary alkyl group having an average carbon number of 10 to 20, preferably 10 to 18.
- EO is ethylene oxide and n Is 5 to 20 as an average number of added moles.
- R c2 is a primary alkyl group having an average carbon number of 10 to 20, preferably 10 to 18; EO indicates ethylene oxide, and PO indicates propylene oxide. k and 1 are the average number of added models, p is 5 to 15, and q is 1 to 5. EO and PO may be added randomly, or PO may be added after adding EO, or vice versa. Further, the block additional body may be three or more blocks. ]
- R e3 is a linear or branched alkyl or alkenyl group having 8 to 18 carbon atoms or an alkylphenyl group having an alkyl group having 8 to 18 carbon atoms, is an alkylene group having 2 to 4 carbon atoms
- G is a residue derived from a reducing sugar having 5 or 6 carbon atoms, preferably a glucose residue
- X is a number having an average value of 0 to 6
- y is a number having an average value of 1 to 10.
- amphoteric surfactant examples include an aminoxide represented by the following general formula (c4) and a betaine represented by the following general formula (c5).
- R c 5 is an alkyl or alkenyl group having 8 to 18 carbon atoms
- R c6 is an alkylene group having 5 to several atoms
- R c7 and R c8 are each independently an alkyl group having 1 to 3 carbon atoms or a hydroxyalkyl group.
- A is a group selected from one COO—, one CONH—, one C—one, —NH CO—, —0—, and r is a number of 0 or 1.
- R c5 , R c6 , R c7 , R′K A and r are the same as those described in the general formula (c 4).
- R c9 is an alkylene group which ⁇ 1 carbon atoms which may be 5 substituted by a hydroxyl group, T is ten S 0 3 -, - CO_ ⁇ -, an anionic group selected from a S Of. r is a number of 0 or 1. ].
- anionic surfactant examples include alkylbenzene sulfonates having 8 to 18 carbon atoms in the alkyl group, alkane sulfonates, ⁇ '-olefin sulfonates, alkyl sulfates, polyoxyethylene alkyl ether sulfates, and the like. Polyoxyethylene alkyl ether acetate And the like.
- blending one or more of the surfactants selected from the above formulas (c3), (c4) and (c5) provides excellent detergency without impairing the antifouling effect. It is preferable for obtaining.
- the amount of the surfactant is preferably 0.01% by weight or more and less than 50% by weight, more preferably less than 50% by weight, in order to obtain sufficient detergency and foaming power without impairing the disinfecting and antifouling effects. Is 0.1% by weight or more, particularly preferably 0.1 to 30% by weight.
- the anionic surfactant (hereinafter referred to as (cA)] should be blended in an amount that has no effect in order to reduce the bactericidal and antifouling properties.
- (cA) ) / (b) must be present in a proportion by weight not exceeding 1.0, preferably not exceeding 0.75. Beyond this range, both antifouling and disinfecting effects cannot be obtained.
- the component (c) is preferably 0.1 to 30% by weight in the germicidal and antifouling detergent of the present invention.
- the target hard surface is directly cleaned by a spraying device such as a trigger or an aerosol, or by a method such as application.
- the concentration of the component (j) is 0.1 to 20% by weight, more preferably 0.2 to 10% by weight.
- the content is 0.5 to 30% by weight, more preferably 1 to 30% by weight. .
- the concentration of the component (c) in the toilet tank is preferably 0.1 to 20 ppm.
- a water-soluble solvent [hereinafter referred to as “component (d)”] is preferably blended as an optional component for the purpose of improving detergency against organic stains.
- component (d) a water-soluble solvent
- a polyhydric alcohol having 4 to 12 carbon atoms [3] a compound represented by the following general formula (dl), [4] a compound represented by the following general formula (d2), and [5]
- One or more compounds selected from the compounds represented by the following general formula (d3) are preferable.
- R dl and R d2 each independently represent a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, a phenyl group or a benzyl group, and both R dl l and R d2 are hydrogen atoms Except in cases. s and t each independently represent a number from 0 to 10, except when both s and t are 0.
- R d3 and R d4 represent an alkyl group having 1 to 3 carbon atoms.
- R d5 represents an alkyl group having 1 to 3 carbon atoms. Show.
- Examples of the monohydric alcohol having 2 to 5 carbon atoms in [1] generally include ethanol, propyl alcohol, and isopropyl alcohol. By incorporating these lower alcohols, the stability of the system at low temperatures can be further improved.
- polyhydric alcohol having 4 to 12 carbon atoms of [2] examples include isoprene glycol, 2,2,4-trimethyl-1,3-pentanediol, 1,5-pentanediol, 1,8-octanediol, In addition to 9-nonanediol, ethylene glycol, propylene glycol, diethylene glycol, dipropylene glycol, and glycerin, monoalkyl glyceryl ethers having an alkyl group having 3 to 8 carbon atoms and the like are included.
- the number of carbon atoms is particularly preferably 1 to 4.
- s and t which are the average addition mole numbers of ethylene oxide (hereinafter, referred to as EO) and propylene oxide (hereinafter, referred to as PO), are 0 to 10, respectively.
- the order of addition is not particularly limited, and may be randomly added.
- glycol phenyl ether are preferred from the viewpoints of detergency and usability.
- 1,3-dimethyl-2-imidazolidinone and 1,3-dimethyl-2-imidazolidinone are exemplified as preferable ones, and as the compound of [5], 3- (3-dimethyl-2-imidazolidinone) is used. Preference is given to methoxy-3-methylbutanol, 3-ethoxy-3-methylbutanol and the like.
- a water-soluble solvent selected from the compounds of [1], [2] and [3] is preferable from the viewpoint of damage to the base material, and in particular, ethanol, isopropyl alcohol, ethylenedaricol, propylene glycol, diethylene glycol, dipropylene Glycol, daliserine, isoplendaricol, propylene glycol monomethyl ether, propylene dalicol monoethyl ether, propylene glycol monopropyl ether, propylene glycol monobutyl ether, and monoalkyl glyceryl ether having 3 to 8 carbon atoms in the alkyl group
- a water-soluble solvent selected from the compounds of [1], [2] and [3] is preferable from the viewpoint of damage to the base material, and in particular, ethanol, isopropyl alcohol, ethylenedaricol, propylene glycol, diethylene glycol, dipropylene Glycol, daliserine, isoplendaricol, propylene glycol
- the component (d) is preferably 0.1 to 50% by weight in the germicidal antifouling detergent of the present invention. In such cases, the concentration of component (d) is 0.! 20% by weight, more preferably 0.5% to 10% by weight.
- an appropriate amount of water in the tank is provided by installing a device in the tank or an arbitrary water supply path. When it is used for an auto cleaner for a toilet which can administer a suitable washing liquid, it is contained in an amount of 1 to 50% by weight, more preferably 5 to 30% by weight.
- the concentration of the component (d) in the toilet tank is preferably 0.01 to 20 ppm.
- a chelating agent for the purpose of dissolving the inorganic dirt, and improving the detergency and the sterilizing effect, (e) It is preferable to add a chelating agent as a component.
- the chelating agent include (1) tripolyphosphoric acid, pyrophosphoric acid, orthophosphoric acid, hexametaphosphoric acid and alkali metal salts thereof, (2) ethylenediaminetetraacetic acid, hydroxyiminodiacetic acid, dihydroxyethyldalicin, nitrilotriacetic acid, Hydroxyethylene diamine triacetic acid, diethylene triamine pentaacetic acid, triethylene tetramine hexaacetic acid and their metal salts or alkaline earth metal salts, (3) aminotrimethylene phosphonic acid, 1-hydroxyethylidene 1,1-diphosphonic acid, ethylenediaminetetramethylenephosphonic acid, diethylenetriaminepentamethylenephosphonic acid, N-oxide of aminotrimethylenephospho
- the component (e) is preferably 0.1 to 20% by weight in the germicidal antifouling detergent of the present invention. More specifically, the hard surface of the object is sprayed with a trigger or aerosol, or by a method such as coating.
- the concentration of the component (e) is 0.1 to 10% by weight, more preferably 0.3 to 7% by weight.
- the washing method using water in the toilet tank 1-20% by weight, more preferably 2-20% by weight when used in toilet auto cleaners that can supply an appropriate amount of cleaning liquid to the water in the tank by installing a device inside or in an optional water supply path It is contained.
- the concentration of the component (e) in the toilet tank is preferably 0.01 to 20 ppm.
- the present invention may use a pH adjuster when adjusting pH.
- pH adjusters include inorganic acids such as hydrochloric acid and sulfuric acid, acid agents such as citric acid, co-octanoic acid, malic acid, fumaric acid, tartaric acid, malonic acid, and maleic acid; sodium hydroxide; Alkaline agents such as sodium carbonate and potassium carbonate, such as potassium hydroxide, ammonia and derivatives thereof, and amine salts such as monoethanolamine diethanolamine and triethanolamine, may be used alone or in combination. Further, these acid agents and alkali agents may be used in combination as a buffer system. .
- the hard surface sterilizing and antifouling detergent of the present invention is preferably adjusted by the above-mentioned pH adjuster so that ⁇ 1 in 20 becomes 2 to 12 and particularly pH 3 to 1 It is preferable to set it to 1 from the viewpoint of the antifouling effect.
- one or more water-soluble polymers can be added for the purpose of imparting adhesion during use and improving ease of use.
- the water-soluble polymer is not particularly limited, but may be one selected from water-soluble polymers described in JP-A-8-209194, page 6, column 10 to page 7, column 11. The above is preferred.
- the hard surface sterilizing and antifouling detergent of the present invention contains additives, such as fragrances, antibacterial agents, and viscosity modifiers, which are blended with ordinary detergents within a range that does not impair the effects of the present invention.
- additives such as fragrances, antibacterial agents, and viscosity modifiers, which are blended with ordinary detergents within a range that does not impair the effects of the present invention.
- Agents, pigments, dyes, suspending agents and the like can be added.
- at least one selected from foaming aids such as toluene sulfonic acid, xylene sulfonic acid, cumene sulfonic acid, arkeel succinic acid, and metal salts of these metals is added. I can do it.
- any one of the optional agents may be used in combination with the optional component.
- One or more powders or tablets may be used in the form of one or more powders which can be immediately dissolved in a solvent such as water or provided with sustained release by combining optional components.
- any one of the component (a) and the component (b) or the optional component may be used in a liquid state, and the other may be used in a solid state such as a powder.
- the form of the sterilizing and antifouling detergent of the present invention at the time of use is not particularly limited, but is preferably a liquid composition containing component (a), component (b) and optional components, with the balance being water.
- a solid or gel composition may be formed using a coagulant such as polyethylene glycol, polyethylene glycol fatty acid ester, polyethylene glycol fatty acid diester, fatty acid, or salt.
- the content of water is preferably 10 to 98% by weight, more preferably 20 to 95% by weight in the case of a liquid composition or a gel composition. In the case of a solid composition, it is preferably at most 30%, more preferably at most 20%.
- a germicidal antifouling detergent having the composition shown in Table 1 was prepared, and its antifouling property and bactericidal property were evaluated by the following methods. Table 1 shows the results.
- Stain removal is 80% or more
- Stain removal is 60% or more and less than 80%
- Stain removal is 40% or more and less than 60%
- Stain removal is 20% or more and less than 40%
- Stain removal is less than 20%.
- Escherichia coli IFO 3972
- Staphylococcus aureus Staphylococcus cauruseus: IFO 12732
- the bactericidal test was conducted by adding 50 ⁇ l of 10 8 to 10 3 bacterial suspensions to 2 ml of the germicidal antifouling agent shown in Table 1 and mixing well. Was. After standing, the mixture 0.1 ml is collected and added to 0.9 ml of LP diluent and mixed well to reduce the effect of the washing solution on the bacteria, then this mixture is spread on S CDLP agar medium, and the E. coli is 37t: Incubate for 24 hours at 37 ° C for 48 hours. Count the number of grown colonies after culture. In the sterilization test, the same sterilizing and antifouling agent was tested in five test plots for each standing time, and the sterilizing property was evaluated according to the following scores.
- 'Polymer B Mercoat 550 [diallyldimethylammonium chloride and acrylamide (mole ratio 30/70) copolymer (Ca1gon, weight average molecular weight 5,000,000, measured by gel permeation chromatogram, Polyethylene glycol is used as standard)]
- 'Polymer A Mercoat 100 [Homopolymer of diaryldimethylammonium chloride (Ca1gon, weight average molecular weight 400,000, measured by gel permeation chromatogram) Use polyethylene glycol as standard)]
- Fungicidal compound A Sanizole C [cocoalkyl dimethyl benzylammonium chloride (manufactured by Kao Corporation)]
- -Bactericidal compound B Koyinmin D 10 P [didecyldimethylammonium chloride (manufactured by Kao Corporation)]
- Fungicidal compound C Benzetonium chloride [Wako reagent, cationic compound with the following structure]
- Alkyl darcoside (a mixture of straight chain alkyl groups with 12 and 14 carbon atoms, average saccharide condensation degree 1.2 [mixture of condensation degrees 1 and 2])
- ES Polyoxyethylene lauryl ether sulfate with an average number of moles of added EO of 2.2 moles
- Betaine N-lauroylaminopropyl-N, N-dimethyl-N-potoxymethylammonium betaine
- ED TA-4 Na Ethylenediaminetetraacetic acid tetrasodium salt
- pH adjuster hydrochloric acid and / or sodium hydroxide (all used in aqueous solution)
- the toilet auto-cleaner composition shown in Table 2 was prepared and poured into a toilet tank with a spot so that the value in Kazuko (ppm) was obtained.
- the antifouling property when flushing was evaluated by the following method did.
- Table 2 shows the results.
- a commercially available toilet bowl (C730B, manufactured by Tohoku Kikai Co., Ltd.) was used to evaluate the difficulty of getting dirty. That is, the toilet was washed with the composition, and the hardiness of the toilet when allowed to stand for one week was visually measured based on the following criteria.
- Table 2 of well sales added a suspension 0. 05Ml and SCD medium 0. lml of Staphylococcus aureus which had been adjusted to 10 4 cfu / ral to adjust the composition 2 ml concentration in Katsuko, 3 7. After standing at C for 18 hours, the bacteriostatic activity value was determined by the following formula.
- Bacteriostatic activity value log (number of viable cells after blank culture)-log (number of viable cells after culture of evaluation sample) ⁇ evaluation>
- Fungicidal compound D 0.1 0.3 0.5 1 1 0.5 1 1 2
Abstract
A bactericidal antifouling detergent for hard surfaces which comprises (a) a polymer which has a weight-average molecular weight of 1,000 to 6,000,000 and in which monomer units having at least one group selected among quaternary ammonium groups and tertiary amino groups account for 10 to 100 mol% of all the monomer units, (b) a bactericidal compound having a molecular weight lower than 1,000 and having a quaternary ammonium group, and (c) a surfactant, and in which when the surfactant comprises an anionic surfactant (cA), the proportion of (cA) to (b) by weight does not exceed 1.0. The bactericidal antifouling detergent sterilizes hard surfaces and shows antifouling properties, i.e., prevents fouling substances from adhering thereto and enables fouling substances adherent thereto to be easily removed. When used in a whole house, especially when applied to the walls and floors of the kitchen, bathroom, toilet, washstand, etc. and to instruments and apparatuses placed therein, the detergent enables sterilization, prevention of fouling substance adhesion, and easy cleaning.
Description
明細書 硬質表面用殺菌防汚洗浄剤 発明の属する技術分野 Description Sterilizing and antifouling detergent for hard surfaces Technical field to which the invention pertains
本発明は、 硬質表面の殺菌、 及び防汚性、 すなわち汚れの付着の防止、 及び付着した汚 れを容易に除去することを可能にする硬質表面用の洗浄剤組成物に関し、 住居内全般、 特 に台所や浴室、 トイレ、 洗面台などの、 壁や床、 器具、 機器などに使用した際に、 殺菌並 びに汚れの付着防止及び易洗浄を可能にする硬質表面用殺菌防汚洗浄剤に関する。 従来の技術 The present invention relates to a cleaning composition for hard surfaces that can disinfect hard surfaces and prevent soiling, that is, prevent adhesion of dirt, and easily remove attached dirt. In particular, when used on walls, floors, utensils, equipment, etc. in kitchens, bathrooms, toilets, washbasins, etc. . Conventional technology
生活場面では様々な場所で汚れが発生する。 それらの汚れを除去するために各種の洗浄 剤が開発され、 その洗浄力を強化すべく検討がなされてきた。 これら努力により、 頑固な 汚れを落とすための手段が多く提案されている。 Dirt occurs in various places in daily life. Various cleaning agents have been developed to remove such dirt, and studies have been made to enhance their cleaning power. With these efforts, many measures have been proposed to remove stubborn dirt.
また、 このように汚れの除去性に優れた洗浄剤を開発する一方で、 汚れを付きにくくす る技術及び処理を施すことで付いた汚れを落とし易くする技術 (以後防汚性とする) に関 する技術も多く検討されており、 洗浄剤として応用する技術が見出されている。 例えば、 特開平 2— 1 4 5 6 9 7号公報には、 特定構造のスルホベタイン型両性界面活性剤を配合 する水洗トイレ用清浄剤が、 特開平 3— 3 5 0 9 7号公報には、 スルホコハク酸ジエステ ルを含有する軟便付着防止性に優れ洗浄効果の高い水性トイレ用清浄剤が、 特開平 1 0— 1 6 9 7号公報には、 特定の界面活性剤と水溶性溶剤を特定比率で配合する洗浄剤が記載 されている。 特に、 特開平 9一 1 6 9 9 9 5号公報には、 処理後の硬質表面に対する水の 接触角が 3 0度以下となるような洗浄剤が優れた防汚性を示し、 具体的に、 防汚基剤とし て、 ァニオン界面活性剤と分子中に 4級アンモニゥム基を含む界面活性剤又は水溶性ポリ マーとの組み合わせが挙げられている。 In addition, while developing a cleaning agent that is excellent in the removal of dirt, a technology that makes it difficult to remove dirt and a technology that makes it easy to remove dirt attached to it (hereinafter referred to as antifouling properties) Many related technologies are also being studied, and technologies applied as cleaning agents have been found. For example, Japanese Unexamined Patent Publication No. 2-1456977 discloses a flush toilet detergent containing a sulfobetaine-type amphoteric surfactant having a specific structure, and Japanese Unexamined Patent Publication No. 3-35097. Japanese Patent Laid-Open Publication No. Hei 10-16797 discloses a water-based toilet cleaner containing a sulfosuccinic acid ester, which is excellent in loose stool adhesion and has a high cleaning effect. Detergents to be mixed in proportions are described. In particular, Japanese Unexamined Patent Application Publication No. Hei 9-16995 describes that a cleaning agent having a water contact angle of 30 degrees or less with a hard surface after treatment shows excellent antifouling property. As an antifouling base, a combination of an anionic surfactant with a surfactant containing a quaternary ammonium group in a molecule or a water-soluble polymer is mentioned.
以上のように、 従来から防汚性に関する技術は多く検討されてきている。 し力しながら、 従来の技術は、 水垢や便等の付着による汚れの発生を中心に抑制するものであり、 微生物 ゃカビ由来の黒ずみに関する汚れについては不十分である。 加えて最近では、 生活環境の 改善にともなって、 目に見える汚れに加えて、 衛生面での問題を懸念する人が増えてきて おり、 殺菌に対する要求も高まってきている。 As described above, many antifouling technologies have been studied. However, the conventional technology mainly suppresses the generation of stains due to adhesion of water scales and stool, etc., and is insufficient for stains related to darkening caused by microorganisms and mold. In addition, recently, with the improvement of living environment, more and more people are concerned about hygiene problems in addition to visible dirt, and the demand for sterilization is increasing.
このような殺菌に関する考え方として殺菌剤の配合が 案される。 しかしながら、 家庭 用に使用することが一般的である殺菌剤を前記洗浄剤に配合した場合、 防汚性と殺菌性の 両方の効果を相殺してしまい、 満足できる殺菌性及び防汚性を達成することは極めて困難 であった。 As a concept regarding such disinfection, the formulation of a disinfectant is proposed. However, when a bactericide, which is generally used for home use, is added to the above-mentioned cleaning agent, the effects of both the antifouling property and the bactericidal property are offset, and satisfactory bactericidal properties and antifouling properties are achieved. It was extremely difficult to do so.
本発明の課題は、 家庭で使用でき、 .トイレ、 浴室、 台所まわりなどの硬質表面の洗浄に おいて、 優れた洗浄力のみならず殺菌性と防汚性の両方を満足できる水準で付与できる剤 を提供することにある。 本発明の開示 An object of the present invention is to provide home use, and in cleaning hard surfaces such as toilets, bathrooms, and kitchen surroundings, not only excellent detergency but also sterilization and antifouling properties can be imparted at a satisfactory level. Agent. Disclosure of the present invention
本発明は、 (a ) 重量平均分子量が 1, 0 0 0〜6, 0 0 0, 0 0 0であって、 4級アン モニゥム基及び 3級ァミノ基より選ばれた少なくとも 1ケの基を有するモノマー単位をそ の比率が全モノマ一単位に対して.1 0〜1 0 0モル%含む重合体、 ( b ) 分子量が 1 , 0 0 0未満であって、 4級アンモニゥム基を有する殺菌性化合物、 及び (c ) 界面活性剤を含 有し、 界面活性剤として (c A) 陰イオン界面活性剤を含有する場合、 (c A) / (b ) が
重量比率で、 1. 0を越えない硬質表面用殺菌防汚洗浄剤である。 The present invention relates to (a) a compound having a weight-average molecular weight of 1,000 to 6,000, and at least one group selected from a quaternary ammonium group and a tertiary amino group; A polymer having a monomer unit content of 0.1 to 100 mol% with respect to one monomer unit; (b) a sterilizer having a molecular weight of less than 1,000 and having a quaternary ammonium group (CA) / (b) when the surfactant contains (cA) anionic surfactant, and (cA) a surfactant. It is a germicidal and antifouling detergent for hard surfaces not exceeding 1.0 by weight.
(a) 成分を 0. 01~30重量%、 (b) 成分を 0. 001~30重量%、 及び ( c ) 成分を 0. 01〜50重量%含有することが好ましい。 It is preferable to contain 0.01 to 30% by weight of the component (a), 0.001 to 30% by weight of the component (b), and 0.01 to 50% by weight of the component (c).
本発明は、 上記組成物を硬質表面に適用することにより硬質表面を洗浄、 殺菌しそして 硬質表面への汚れの付着を防止する方法と上記組成物を硬質表面を洗浄、 殺菌しそして硬 質表面への汚れの付着を防止する用途を提供する。 発明の詳細な説明 The present invention relates to a method for cleaning and disinfecting a hard surface by applying the above composition to a hard surface and for preventing the adhesion of dirt to the hard surface. Provide use for preventing the adhesion of dirt to the surface. Detailed description of the invention
本発明の (a) 成分は、 4級アンモニゥム基及び/又は 3級アミノ基を有するモノマー 単位 (以下、 モノマー単位 Aとする) を 10~100モル%含有す ¾重合体である。 The component (a) of the present invention is a polymer containing 10 to 100 mol% of a monomer unit having a quaternary ammonium group and / or a tertiary amino group (hereinafter, referred to as a monomer unit A).
モノマ一単位 Aは、 4級アンモニゥム基(複数であってもよい) を含有するモノマ一 (以 下、 モノマー Aとする) を重合するか又は 3級ァミノ基 (複数であってもよい) を含有す るモノマー (以下、 モノマー A' とする) を重合して得られるモノマー単位であってもよ く、 3級アミノ基を 4級化して 4級アンモニゥム化したものであってもよい。 Monomer unit A is obtained by polymerizing a monomer (hereinafter, referred to as monomer A) containing a quaternary ammonium group (or a plurality of monomers) or a tertiary amino group (or a plurality of monomers). The monomer unit may be a monomer unit obtained by polymerizing a contained monomer (hereinafter, referred to as monomer A ′), or may be a quaternary ammonium obtained by quaternizing a tertiary amino group.
4級アンモニゥム基を有するモノマー Aの好ましい例として、 即ち、 モノマー単位 Aが 由来する例として、 下記式 (4) の化合物を挙げることができる。 As a preferred example of the monomer A having a quaternary ammonium group, that is, as an example from which the monomer unit A is derived, a compound represented by the following formula (4) can be mentioned.
R12R13Q二 C(FS4 )— X\ R15 、 γ-R12R13Q2 C (FS4) — X \ R15, γ-
R>6 R17 式中、 R12、 R13、 R "は、 それぞれ独立して、 水素原子、 水酸基又は炭素数 1〜3のァ ルキル基である。 Xは炭素数 1〜12のアルキレン基、 — COOR18—、 — CONHR18—、 — OCOR18—、 一 R19—〇CO— R18—から選ばれる基である。 ここで R18、 R19は、 それ ぞれ独立して、 炭素数 1~5のアルキレン基である。 R 15は炭素数 1〜3のアルキル基もし くはヒドロキシアルキル基又は R12R13C = C (R14)— X—である。 R16は炭素数 1〜3のァ ルキル基、 ヒドロキシアルキル基、 ベンジル基であり、 R17はヒドロキシ基、 力ルポキシル 基、 スルホン酸基もしくは硫酸エステル基で置換されていてもよい炭素数 1~10のアル キル基又はべンジル基であり、 R17がアルキル基、 ヒドロキシアルキル基又はべンジル基の 場合は、 Y—は陰イオンを示す。 R> in 6 R 17 formula, R 12, R 13, R " are each independently hydrogen atom, a hydroxyl group or a § alkyl group having 1 to 3 carbon atoms. X represents an alkylene group having 1 to 12 carbon atoms , —COOR 18 —, — CONHR 18 —, — OCOR 18 —, — R 19 —〇CO—R 18 — where R 18 and R 19 are each independently carbon An alkylene group having a number of 1 to 5. R 15 is an alkyl group or a hydroxyalkyl group having 1 to 3 carbon atoms or R 12 R 13 C = C (R 14 ) —X— R 16 has a carbon number R 17 is an alkyl group having 1 to 3 alkyl groups, hydroxyalkyl group, or benzyl group; and R 17 is an alkyl group having 1 to 10 carbon atoms which may be substituted with a hydroxy group, a carbonyl group, a sulfonic acid group or a sulfate group. Or, when R 17 is an alkyl group, a hydroxyalkyl group or a benzyl group, Y— represents an anion.
また、 R17がカルボキシル基、 スルホン酸基、 硫酸エステル基を含む場合、 Y—は存在せ ず、 R17中のこれらの基は陰イオンとなる。 Y—の陰イオンとしては、 ハロゲンイオン、 硫 酸イオン、 炭素数 1~ 3のアルキル硫酸エステルイオン、 炭素数 1〜 3のアルキル基で置 換されていてもよい芳香族スルホン酸イオン、 ヒドロキシイオンを挙げることができる。 これらの中でもァクリロイル (又はメ夕クリロイル) アミノアルキル (炭素数 1〜5) -N, N, N—トリアルキル (炭素数 1~3) 4級アンモニゥム塩、 ァクリロイル (又は メ夕クリロイル) 才キシアルキル (炭素数 1〜5) -N, N, N—トリアルキル (炭素数 1-3) 4級アンモニゥム塩、 N— (ω—アルケニル (炭素数 3〜: L 0)) — Ν, Ν, Ν- トリアルキル (炭素数 1〜3) 4級アンモニゥム塩、 Ν, Ν—ジ (ω—アルケニル (炭素 数 3〜10)) — Ν, Ν—ジアルキル (炭素数 1〜3) 4級アンモニゥム塩が好ましく、 特 にジァリルジメチルアンモニゥム埠が良好である。 When R 17 contains a carboxyl group, a sulfonic acid group, or a sulfate group, Y— does not exist, and these groups in R 17 become anions. Examples of the anion of Y— include a halogen ion, a sulfate ion, an alkyl sulfate ion having 1 to 3 carbon atoms, an aromatic sulfonate ion optionally substituted by an alkyl group having 1 to 3 carbon atoms, and a hydroxy ion. Can be mentioned. Among them, acryloyl (or methacryloyl) aminoalkyl (1 to 5 carbon atoms) -N, N, N-trialkyl (1 to 3 carbon atoms) quaternary ammonium salt, acryloyl (or methacryloyl) 1-5 carbon atoms) -N, N, N-trialkyl (1-3 carbon atoms) quaternary ammonium salt, N— (ω-alkenyl (3-3 carbon atoms: L 0)) — Ν, Ν, Ν- Trialkyl (1 to 3 carbon atoms) quaternary ammonium salt, Ν, —-di (ω-alkenyl (3 to 10 carbon atoms)) — ジ, Ν-dialkyl (1 to 3 carbon atoms) quaternary ammonium salt is preferred Especially, the diaryl dimethyl ammonium pier is good.
3級ァミノ基のモノマー A' の好ましい例として、 即ち、 モノマ一単位 Α 'が由来する 化合物として、 下記式 (5) の化合物を挙げることができる
(5) Preferred examples of the tertiary amino group monomer A ′, that is, a compound derived from a monomer unit Α ′, include a compound represented by the following formula (5). (Five)
R 2R13C:R 2 R 13 C:
式中、 Rl2、 Rl3、 Rl R15及び R16は、 前記記載と同じである。 Wherein, R l2, R l3, R l R 15 and R 16 are the same as above described.
これらの中でも N, N—ジアルキル (炭素数 1~3) アミノアルキル (炭素数 1~5) ァクリレート (又はメタクリレート)、 N, N—ジアルキル (炭素数 1〜3) アミノアルキ ル (炭素数 1~5) アクリルアミド、 N, N—ジ (ω—アルケニル (炭素数 3〜: L 0)) - Ν—メチルァミンが好ましく、 ジァリルメチルァミンが特に好ましい。 Among them, N, N-dialkyl (C1-3) aminoalkyl (C1-5) acrylate (or methacrylate), N, N-dialkyl (C1-3) aminoalkyl (C1-5) ) Acrylamide, N, N-di (ω-alkenyl (C 3 -L 0))-Ν-methylamine is preferred, and diarylmethylamine is particularly preferred.
モノマー A' を 4級化する場合は、 4級化剤としてメチルクロリド、 メチルプロミド、 ベンジルクロリド、 ジメチル硫酸、 ジェチル硫酸、 モノクロ口酢酸又はその塩、 クロルス ルホン酸又はその塩、 3—クロ口— 2—ヒドロキシプロパンスルホン酸又はその塩、 ェチ レンォキシド、 プロピレンォキシド、 グリシジルェ一テルを用いて行うことが好ましい。 尚、 エチレンォキシド、 プロピレンォキシド、 グリシジルェ一テルを使用する場合は、 予 め硫酸、 塩酸、 炭素数 1~12のカルボン酸、 ァリルスルホン酸などでモノマー単位を中 和した後反応させることが好ましい。 When quaternizing monomer A ', quaternizing agents such as methyl chloride, methyl bromide, benzyl chloride, dimethyl sulfate, getyl sulfate, monochloroacetic acid or a salt thereof, chlorsulfuric acid or a salt thereof, and 3-chloro-2 -It is preferably carried out using hydroxypropanesulfonic acid or a salt thereof, ethylene oxide, propylene oxide, or glycidyl ether. When ethylene oxide, propylene oxide, or glycidyl ether is used, it is preferable to react after neutralizing the monomer units with sulfuric acid, hydrochloric acid, a carboxylic acid having 1 to 12 carbon atoms, or arylsulfonic acid in advance. .
本発明の (a) 成分は、 モノマー単位 A (複数種であってもよい) からなる重合体のみ ならず、 モノマ一単位 A (複数種であってもよい) と他のモノマー単位 (以下、 モノマー 単位 Bとする) とか 6構成された重合体であってもよい。 (モノマ一 A' を使用する場合は、 ァミン型のモノマー単位を有していてもよい。) この場合、 モノマ一単位 Aとモノマー単位 B (複数種であってもよい) との配列様式は、 ブロック、 交互、 周期、 統計 (ランダムを 含む)、 グラフト型の何れであってもよい。 The component (a) of the present invention includes not only a polymer composed of monomer units A (a plurality of types may be used), but also a monomer unit A (a plurality of types may be used) and another monomer unit (hereinafter, referred to as “a”). Or a polymer composed of 6 units. (When monomer A 'is used, it may have an amine type monomer unit.) In this case, the arrangement of monomer unit A and monomer unit B (there may be plural types) , Block, alternating, periodic, statistical (including random), or graft type.
モノマー単位 Aとモノマー単位 Bとから構成される重合体は、 例えば、 それぞれの前駆 体モノマ一を共重合することによって得ることができる。 この場合、 モノマ一単位 Bとし ては、 下記のモノマー群 (i ) ~ (V) から選ばれるモノマー由来のモノマー単位が好ま しく、 (i ) ~ (iii) 又は (V) 記載のモノマー由来のモノマ一単位がより好ましく、 特 に防汚効果の点から ( i)、 (ii) 又は (V) のモノマー由来のモノマー単位が最も好まし い。 The polymer composed of the monomer units A and B can be obtained, for example, by copolymerizing the respective precursor monomers. In this case, the monomer unit B is preferably a monomer unit derived from a monomer selected from the following monomer groups (i) to (V), and is preferably a monomer unit derived from the monomers described in (i) to (iii) or (V). A monomer unit is more preferred, and a monomer unit derived from the monomer (i), (ii) or (V) is most preferred, particularly from the viewpoint of antifouling effect.
( i) アクリル酸又はその塩、 メ夕クリル酸又はその塩、 マレイン酸又はその塩、 無水マ レイン酸、 スチレンスルホン酸塩、 スルホプロピルメタクリレート、 2—アクリルアミド - 2—メチルプロパンスルホン酸またはその塩、 リン酸モノ一 ω—メタクリロイルォキシ アルキル (炭素数 1〜12) から選ばれる陰イオン基含有化合物 (i) Acrylic acid or a salt thereof, methacrylic acid or a salt thereof, maleic acid or a salt thereof, maleic anhydride, styrenesulfonate, sulfopropyl methacrylate, 2-acrylamide-2-methylpropanesulfonic acid or a salt thereof Anion group-containing compounds selected from mono-ω-methacryloyloxyalkyl phosphates (1 to 12 carbon atoms)
(ii) アクリル (又はメタクリル) アミド、 N, N—ジメチルァミノプロピルアクリル酸 (又はメタクリル酸) アミド、 N, N—ジメチルアクリル (又はメタクリル) アミド、 N 一ビニル一2—力プロラクタム、 N—ビニルー 2—ピロリ ドンから選ばれるアミド基含有 化合物 (ii) Acrylic (or methacrylic) amide, N, N-dimethylaminopropylacrylic acid (or methacrylic acid) amide, N, N-dimethylacrylic (or methacrylic) amide, N-vinyl-1-2-prolactam, N -Amide-containing compounds selected from vinyl-2-pyrrolidone
(iii) アクリル酸 (又はメ夕クリル酸) アルキル (炭素数 1〜5)、 アクリル酸 (又はメ タクリル酸) 2—ヒドロキシェチル、 アクリル酸 (又はメ夕クリル酸) 一 N, N—ジメチ ルァミノアルキル (炭素数 1〜5)、 酢酸ビニルから選ばれるエステル基含有化合物 (iii) Alkyl acrylate (or methacrylic acid) alkyl (1-5 carbon atoms), acrylic acid (or methacrylic acid) 2-hydroxyethyl, acrylic acid (or methacrylic acid) 1 N, N-dimethyl Ester group-containing compounds selected from luminoalkyl (C1-5) and vinyl acetate
(iv) エチレン、 プロピレン、 N—プチレン、 イソプチレン、 N—ペンテン、 イソプレン、 2—メチル— 1ーブテン、 N—へキセン、 2—メチル一 1—ペンテン、 3—メチルー 1一 ペンテン、 4ーメチルー 1一ペンテン、 2—ェチル一 1—ブテン、 スチレン、 ビニルトル
ェン、 α—メチルスチレン、 ァリルアミン、 Ν, Ν—ジァリルァミン、 Ν, Ν—ジァリル 一 Ν—アルキル (炭素数 1~5) ァミン、 エチレンォキシド、 プロピレンォキシド、 2— ビニルピリジン、 4 -ビニルピリジンから選ばれる化合物 (iv) Ethylene, propylene, N-butylene, isobutylene, N-pentene, isoprene, 2-methyl-1-butene, N-hexene, 2-methyl-1-pentene, 3-methyl-1-pentene, 4-methyl-11 Penten, 2-ethyl 1-butene, styrene, vinyl tol Benzene, α-methylstyrene, arylamine, Ν, Ν-diallylamine, Ν, Ν-diaryl-l-alkyl (1-5 carbon atoms) amine, ethyleneoxide, propyleneoxide, 2-vinylpyridine, 4-vinyl Compound selected from pyridine
(V) 二酸化硫黄。 (V) Sulfur dioxide.
モノマー単位 Αとモノマー単位 Βを有する重合体は前記のような共重合による合成方法 の他、 モノマー単位 Aを含む重合体に前記 (i) ~ ( のモノマ一、 特に好ましくは前記 The polymer having the monomer unit Α and the monomer unit は may be synthesized by the above-mentioned copolymerization method, or may be formed into a polymer containing the monomer unit A by one of the monomers (i) to (
(i)、 (ii) のモノマーをグラフト重合して得てもよいし、 前記 (i) ~ (v) のモノマー を含む重合体に前記一般式 (4) のモノマ一をグラフト重合して得てもよいし、 前記 (i) 〜 (V) のモノマーを含む重合体、 特に好ましくは前記 (i)、 (ii) のモノマーを含む重合 体に前記一般式 (5) のモノマ一をグラフト重合した後、 これを 4級化してもよい。 It may be obtained by graft polymerization of the monomers of (i) and (ii), or may be obtained by graft polymerization of the monomer of the general formula (4) to a polymer containing the monomers of (i) to (v). Or a polymer containing the monomers (i) to (V), particularly preferably a polymer containing the monomers (i) and (ii), graft-polymerized with the monomer of the general formula (5). After that, it may be quaternized.
本発明のモノマー単位 Bで最も好ましいものは、 カルボン酸基、 スルホン酸基から選ば れる 1つ以上の基を有する [但し 4級アンモニゥム基を有さない] モノマー、 すなわち前 記 (i) のモノマー由来のモノマー単位 (以下モノマー単位 B' とする) である。 The most preferred monomer unit B of the present invention is a monomer having one or more groups selected from a carboxylic acid group and a sulfonic acid group (but not having a quaternary ammonium group), ie, the monomer of the above (i) Monomer unit (hereinafter referred to as monomer unit B ').
本発明の (a) 成分を構成する重合体はいかなる重合法によって得てもよいが、 ラジカ ル重合法が特に好ましく、 塊状、 溶液、 又は乳化系にてこれを行うことができる。 ラジカ ル重合は加熱によりこれを開始してもよいが、 開始剤として、 2, 2 ' ーァゾビス (2— アミジノプロパン) 二塩酸塩、 2, 2' —ァゾビス (N, N—ジメチレンイソブチルアミ ジン) 二塩酸塩、 などのァゾ系開始剤、 過酸化水素及び、 過酸化べンゾィル、 t一ブチル ヒドロパーォキシド、 クメンヒドロパ一ォキシド、 メチルェチルケトンパ一ォキシド、 過 安息香酸などの有機過酸化物、 過硫酸ナトリウム、 過硫酸カリウム、 過硫酸アンモニゥム などの過硫酸塩、 過酸化水素一 Fe3+などのレドックス開始剤、 など既存のラジカル開始剤 を用いてもよいし、 光増感剤の存在ノ又は非存在下での光照射や、 放射線照射により重合 を開始させてもよい。 Although the polymer constituting the component (a) of the present invention may be obtained by any polymerization method, a radical polymerization method is particularly preferable, and the polymerization can be carried out in a bulk, solution, or emulsion system. Radical polymerization may be initiated by heating, but the initiators are 2,2'-azobis (2-amidinopropane) dihydrochloride and 2,2'-azobis (N, N-dimethyleneisobutylamidine). Azo initiators such as dihydrochloride, and organic peroxides such as hydrogen peroxide and benzoyl peroxide, t-butyl hydroperoxide, cumene hydroperoxide, methylethylketone peroxide, perbenzoic acid, etc. Existing radical initiators such as oxides, persulfates such as sodium persulfate, potassium persulfate, ammonium persulfate, etc., redox initiators such as hydrogen peroxide-Fe 3+ , etc. may be used, and photosensitizers may be used. Polymerization may be started by light irradiation or radiation irradiation in the presence or absence of a compound.
本発明の (a) 成分は、 モノマー単位 Aの単一重合体並びにモノマー単位 A及びモノマ —単位 Bのコポリマーから選ばれる重合体の複数種の混合物であつてもよい。 The component (a) of the present invention may be a homopolymer of the monomer unit A or a mixture of plural kinds of polymers selected from a copolymer of the monomer unit A and the monomer-unit B.
本発明の (a) 成分における、 より好ましい構成は、 モノマー単位 Aとモノマー単位 B' の合計が全モノマー単位に対して 50〜100モル%のものであり、 最も好ましくはモノ マ一単位 A、 B' のモル比が、 モノマー単位 A/ [モノマ一単位 A +モノマー単位 B' ] = 0. 3— 0. 99のものであり、 特には 0. 4~0. 99ものである。 A more preferred constitution in the component (a) of the present invention is that the total of the monomer units A and B ′ is 50 to 100 mol% based on all the monomer units, and most preferably the monomer unit A, The molar ratio of B ′ is such that monomer unit A / [monomer unit A + monomer unit B ′] = 0.3-0.99, particularly 0.4-0.99.
本発明の (a) 成分は本発明の硬質表面用殺菌防汚洗浄剤の殺菌性、 防汚性を著しく阻 害しない限りにおいて、 重合体 Aを含有しない他の水溶性重合体を含有していてもよい。 本発明の (a) 成分は重量平均分子量が 1, 000〜6, 000, 000、 好ましくは 10, 000~6 , 000, 000、 特に好ましくは 100, 000~6, 000, 00 0であり、 この重量平均分子量はァセ卜二トリルと水の混合溶媒 (リン酸緩衝液) を展開 溶媒とし、 ゲルパ一ミエーシヨンクロマトグラフィ一でポリエチレングリコ一ルを標準物 質として求めたものである。 Component (a) of the present invention contains another water-soluble polymer that does not contain polymer A, as long as it does not significantly inhibit the bactericidal and antifouling properties of the germicidal and antifouling detergent for hard surfaces of the present invention. You may. The component (a) of the present invention has a weight average molecular weight of 1,000 to 6,000,000, preferably 10,000 to 6,000,000, particularly preferably 100,000 to 6,000,000, The weight average molecular weight was obtained by gel permeation chromatography using polyethylene glycol as a standard substance, using a mixed solvent of acetate nitrile and water (phosphate buffer) as a developing solvent.
(a) 成分は本発明の殺菌防汚洗浄剤中に好ましくは 0. 01〜30重量%でぁり、 詳 しくはトリガ一やエアゾールなどの噴霧装置や、 塗布するような方法にて対象の硬質表面 を洗浄するような場合は、 (a) 成分の濃度は 0.01〜10重量%、 より好ましくは 0.02〜5 重量%であり、 一方、 トイレタンク内の水を利用した洗浄方法において、 タンク内または 任意の給水経路に装置を設けることで夕ンク内の水に適量な洗浄液を投与することができ るトイレ用オートクリーナーに用.いる場合は、 1~30重量%、 より好ましくは 2~20重量% 含有される。 なおタンク内の (a) 成分の濃度は 0. l〜10p pmが好ましい。
本発明の (b) 成分は、 分子量が 1000未満、 好ましくは 500以下の少なくとも 1 つの 4級アンモニゥム基を有する殺菌性化合物である。 本発明でいう殺菌性化合物とは、 下記方法により測定されるコ口二一数が 10以下の性質を示す化合物のことをいう。 The component (a) is preferably present in the germicidal and antifouling detergent of the present invention in an amount of 0.01 to 30% by weight. In the case of cleaning a hard surface, the concentration of the component (a) is 0.01 to 10% by weight, more preferably 0.02 to 5% by weight. On the other hand, in the cleaning method using water in the toilet tank, Or use it as an auto cleaner for toilets that can apply an appropriate amount of cleaning liquid to the water in the evening water by installing a device in an optional water supply channel.If it is used, use 1 to 30% by weight, more preferably 2 to 20% by weight. % By weight. The concentration of the component (a) in the tank is preferably from 0.1 to 10 ppm. The component (b) of the present invention is a fungicidal compound having at least one quaternary ammonium group having a molecular weight of less than 1000, preferably 500 or less. The bactericidal compound referred to in the present invention refers to a compound having a property that the number of mouths measured by the following method is 10 or less.
ぐ殺菌性化合物測定方法 > Germicidal compound measurement method>
供試菌として大腸菌 (Es che r i ch i a c o l l : I F〇 3972 ) と黄色ブド ゥ球菌(S t aphy l oc oc cu s aur eus : I FQ12732)を用いる。 I F03972と I F012732は日本国大阪市淀川区十三本町二町目 17番 85号在の 財団法人発酵研究所 Institute for Fermentation, Osaka に寄託され、 分譲できる。 試験化合物 〔(b) 成分〕 の 1重量%水溶液を調製し、 該水溶液 2ml中に 108〜109 個の細菌浮遊液 50 μ 1を加えよく混合した後、 5分間放置する。 放置後、 この混合液を 0. 1ml採取して 0. 9m 1の LP希釈液中に加えて十分混合し、 前記化合物の菌への 影響を低下させ、 次いでこの混合液を S CD LP寒天培地上に塗布し、 大腸菌は 37でで 24時間、 黄色ブドウ球菌は 37 で 48時間培養する。 培養後の生育したコロニー数を 数える。 なお殺菌試験は同じ化合物についてそれぞれ同時に 5回ずつ行う (5回 X3)。 こ の実験結果において、 大腸菌及び黄色プドウ球菌の両方のコロニー数が 10以下となるも のを殺菌性ありとする。 なお、 前記規定以外の実験条件の詳細は、 防菌防黴ハンドブックAs test bacteria, Escherichia coli (IF と 3972) and Staphylococcus aureus (Staphylococcus aureus: IFQ12732) are used. IF03972 and IF012732 have been deposited at the Institute for Fermentation, Osaka, located at 17-85, Jusanhoncho, Yodogawa-ku, Osaka, Japan and can be sold. Prepare a 1% by weight aqueous solution of the test compound [component (b)], add 50 μl of 10 8 to 10 9 bacterial suspensions to 2 ml of the aqueous solution, mix well, and allow to stand for 5 minutes. After standing, 0.1 ml of this mixture was taken, added to 0.9 ml of LP diluent, and mixed well to reduce the effect of the compound on the bacteria. Culture on E. coli at 37 for 24 hours and Staphylococcus aureus at 37 for 48 hours. Count the number of grown colonies after culture. Perform the sterilization test for the same compound 5 times each (5 times X3). In the results of this experiment, those with less than 10 colonies of both E. coli and Staphylococcus aureus are considered bactericidal. For details of experimental conditions other than the above, see the Handbook
(日本防菌防黴学会編、 技報堂出版) の p 686に記載されている浮遊試験法 (定量的検 査法) に従う。 In accordance with the floating test method (quantitative test method) described in p. 686 of the Japan Society of Antibacterial and Fungicide, edited by Gihodo.
(b) 成分となる分子量 1000未満の殺菌性化合物としては、 下記式 (1) 〜 (3) で示される化合物が好ましく、 それらのうち特に水溶性のものが好ましい。 ここで水溶性 とは 20での水 1 Lに溶解する量が 1 g以上であることを指す。 As the bactericidal compound having a molecular weight of less than 1000 as the component (b), compounds represented by the following formulas (1) to (3) are preferable, and among them, water-soluble compounds are particularly preferable. Here, "water-soluble" means that the amount dissolved in 1 L of water at 20 is 1 g or more.
FT FT
(3) (3)
γ- γ-
10 Ten
R8 R R 8 R
式中、 R1及び Rsは、 それぞれ独立して炭素数 6〜18、 好ましくは 8〜16のアルキル 基又はアルケニル基、 好ましくはアルキル基であり、 R3及び R4は、 それぞれ独立して炭素 数 1〜3のアルキル基又はヒドロキシアルキル基である。 Xは芳香環又は— COO—、 一 CONH—、 一 OC〇一、 一NHCO—から選ばれるエステル基あるいはアミド基であり、 R2は、 Xがエステル基又はアミド基である場合には水酸基で置換されていてもよい炭素数 1~6のアルキレン基であり、 X.が芳香環の場合には、 水酸基で置換されていてもよい炭 素数 1〜 6のアルキレン基又は一(0— RU) k—である。 ここで R11はエチレン基又はプロピ レン基、 好ましくはエチレン基であり、 kは平均 1〜10、 好ましくは平均 1~5の数で
ある。 R5は炭素数 1〜3のアルキレン基である。 R7~R1!)はこれらの内 1つ以上、 好まし くは 1つ又は 2つが炭素数 8〜18、 好ましくは 8〜14、 より好ましくは 8〜12のァ ルキル基であり、 残りが炭素数 1~3のアルキル基又はヒドロキシアルキル基である。 ま た、 mは 0又は 1の数である。 さらに Y—は、 陰イオンであり、 特にハロゲンイオン、 硫酸 イオン、 炭素数 1〜 3のアルキル硫酸イオン、 炭素数 1~3のアルキル基で置換されてい てもよい芳香族スルホン酸イオンが好ましい。 In the formula, R 1 and R s are each independently an alkyl group or alkenyl group having 6 to 18 carbon atoms, preferably 8 to 16 carbon atoms, preferably an alkyl group, and R 3 and R 4 are each independently It is an alkyl group or a hydroxyalkyl group having 1 to 3 carbon atoms. X is an aromatic ring or an ester group or an amide group selected from —COO—, one CONH—, one OC〇-one, and one NHCO—, and R 2 is a hydroxyl group when X is an ester group or an amide group. An alkylene group having 1 to 6 carbon atoms which may be substituted, and when X. is an aromatic ring, an alkylene group having 1 to 6 carbon atoms which may be substituted with a hydroxyl group or one (0-RU) k — Here, R 11 is an ethylene group or a propylene group, preferably an ethylene group, and k is an average number of 1 to 10, preferably an average number of 1 to 5. is there. R 5 is an alkylene group having 1 to 3 carbon atoms. R 7 to R 1!) Is one or more, preferably one or two of them, an alkyl group having 8 to 18, preferably 8 to 14, more preferably 8 to 12 carbon atoms, and the remaining Is an alkyl group or a hydroxyalkyl group having 1 to 3 carbon atoms. M is a number of 0 or 1. Further, Y— is an anion, particularly preferably a halogen ion, a sulfate ion, an alkyl sulfate ion having 1 to 3 carbon atoms, or an aromatic sulfonate ion which may be substituted with an alkyl group having 1 to 3 carbon atoms.
より好ましい (b) 成分は上記一般式 (1) 又は (3) の化合物であり、 最も好ましく は下記の一般式の化合物である。 More preferred component (b) is a compound of the above general formula (1) or (3), most preferably a compound of the following general formula.
式中、 Rは分岐していてもよい炭素数 6〜12のアルキル基、 mは平均 1~5の数を示 す。
式中、 2つの Rは異なっていてもよい炭素数 8〜12のアルキル基を示す。 In the formula, R represents an optionally branched alkyl group having 6 to 12 carbon atoms, and m represents a number of 1 to 5 on average. In the formula, two Rs represent an alkyl group having 8 to 12 carbon atoms which may be different.
(b) 成分は本発明の殺菌防汚洗浄剤中に好ましくは 0. 001~30重量%、 詳しく はトリガ一やエアゾールなどの噴霧装置や、 塗布するような方法にて対象の硬質表面を洗 浄するような場合は、 ( b )成分の濃度は 0.001〜5重量%、より好ましくは 0.005〜2重量% であり、 一方、 トイレタンク内の水を利用した洗浄方法において、 タンク内または任意の 給水経路に装置を設けることでタンク内の水に適量な洗浄液を投与することができるトイ レ用ォ一トクリーナーに用いる場合は、 0.1〜30重量%、 より好ましくは 1〜20重量%含有 される。 なおタンク内の (b) 成分の濃度は 0.01〜: LOp pmが好ましい。 The component (b) is preferably 0.001 to 30% by weight in the disinfectant and antifouling detergent of the present invention. Specifically, the hard surface of the object is washed by a spraying device such as a trigger or an aerosol, or by a method such as application. In the case of cleaning, the concentration of the component (b) is 0.001 to 5% by weight, more preferably 0.005 to 2% by weight. On the other hand, in the cleaning method using water in the toilet tank, When it is used in a toilet cleaner that can administer an appropriate amount of cleaning liquid to the water in the tank by providing a device in the water supply path, it is contained in an amount of 0.1 to 30% by weight, more preferably 1 to 20% by weight. You. The concentration of the component (b) in the tank is preferably 0.01 to: LOp pm.
本発明において、 充分な防汚性を保った上で、 殺菌効果を得るために (a) 成分/ (b) 成分は重量比で 3'0Zl〜lZ50が好ましく、 20/1〜1/20がより好ましく、 10/1〜 1/10が最も好ましい。 In the present invention, the component (a) / component (b) is preferably 3'0Zl to 1Z50 in weight ratio, and 20/1 to 1/20 in order to obtain a bactericidal effect while maintaining sufficient antifouling properties. More preferably, 10/1 to 1/10 is most preferable.
本発明の硬質表面用殺菌防汚洗浄剤は、 更に (c) として (b) 成分以外の 面活性剤 〔以下、 (c) 成分という〕 を含有する。 界面活性剤としては、 非イオン界面活性剤、 両性
界面活性剤、 陰イオン界面活性剤から選ばれる 1種以上の界面活性剤を添加することが好 ましい。 The germicidal antifouling detergent for hard surfaces of the present invention further contains (c) a surfactant other than the component (b) [hereinafter referred to as the component (c)]. Nonionic surfactants, amphoteric surfactants It is preferable to add one or more surfactants selected from surfactants and anionic surfactants.
非イオン界面活性剤としては、 下記式 (c 1) 〜式 (c 3) の化合物が挙げられる。 Rcl-0(EO)nH (c 1) Examples of the nonionic surfactant include compounds represented by the following formulas (c1) to (c3). R cl -0 (EO) n H (c 1)
〔式中、 R"11は平均炭素数 10~20、 好ましくは 10〜18の一級の直鎖アルキル基、 分 岐鎖アルキル基又は二級のアルキル基である。 EOはエチレンオキサイドであり、 nは平 均付加モル数として 5 ~ 20である。〕 [Wherein, R ″ 11 is a primary linear alkyl group, a branched alkyl group or a secondary alkyl group having an average carbon number of 10 to 20, preferably 10 to 18. EO is ethylene oxide and n Is 5 to 20 as an average number of added moles.]
Rc2-0(EO)p/(PO)qH (c 2) R c2 -0 (EO) p / (PO) q H (c 2)
〔式中、 Rc2は平均炭素数 1 0~20、 好ましくは 10~1 8の一級のアルキル基である。 EOはエチレンオキサイド、 POはプロピレンオキサイドを示す。 k及び 1は平均付加モ ル数であり、 pは 5〜 1 5、 qは 1〜5である。 EOと P Oはランダム付加又は EOを付 加した後、 POを付加してもよく、 またその逆のようなブロック付加体でもよい。 また、 ブロック付加体は 3つ以上のブロックであってもよい。〕 [In the formula, R c2 is a primary alkyl group having an average carbon number of 10 to 20, preferably 10 to 18; EO indicates ethylene oxide, and PO indicates propylene oxide. k and 1 are the average number of added models, p is 5 to 15, and q is 1 to 5. EO and PO may be added randomly, or PO may be added after adding EO, or vice versa. Further, the block additional body may be three or more blocks. ]
Rc3—(〇Rc4)xGy (c 3) R c3 — (〇R c4 ) x G y (c 3)
〔式中、 Re3は直鎖又は分岐鎖の炭素数 8〜18のアルキル基もしくはアルケニル基又は炭 素数 8〜18のアルキル基を有するアルキルフエニル基、 は炭素数 2〜4のアルキレン 基、 Gは炭素数 5又は 6の還元糖に由来する残基好ましくはグルコース残基であり、 Xは 平均値 0 ~ 6の数、 yは平均値 1〜 1 0の数を示す。〕。 Wherein R e3 is a linear or branched alkyl or alkenyl group having 8 to 18 carbon atoms or an alkylphenyl group having an alkyl group having 8 to 18 carbon atoms, is an alkylene group having 2 to 4 carbon atoms, G is a residue derived from a reducing sugar having 5 or 6 carbon atoms, preferably a glucose residue, X is a number having an average value of 0 to 6, and y is a number having an average value of 1 to 10. ].
両性界面活性剤としては下記一般式 (c 4) で表されるアミンォキシド及び一般式 (c 5) で表されるベタインを挙げることができる。 Examples of the amphoteric surfactant include an aminoxide represented by the following general formula (c4) and a betaine represented by the following general formula (c5).
式中、 Rc 5は炭素数 8〜18のアルキル基又はアルケニル基であり、 Rc6は炭素数 1〜 5のアルキレン基である。 Rc 7、 Rc 8は、 それぞれ独立して、 炭素数 1〜3のアルキル基 又はヒドロキシアルキル基である。 Aは一 COO—、 一 CONH—、 一〇C〇一、 -NH CO—、 —0—から選ばれる基であり、 rは 0又は 1の数である。 Wherein, R c 5 is an alkyl or alkenyl group having 8 to 18 carbon atoms, R c6 is an alkylene group having 5 to several atoms. R c7 and R c8 are each independently an alkyl group having 1 to 3 carbon atoms or a hydroxyalkyl group. A is a group selected from one COO—, one CONH—, one C—one, —NH CO—, —0—, and r is a number of 0 or 1.
(c 5)
式中、 Rc5、 Rc6、 Rc7, R'K A及び rは前記一般式 (c 4) 記載のものと同じである。 Rc9は水酸基で置換されていてもよい炭素数 1 ~ 5のアルキレン基であり、 Tは一〇 S 03-、 — CO〇—、 一 S Ofから選ばれる陰イオン基である。 rは 0又は 1の数である。〕。 (c 5) In the formula, R c5 , R c6 , R c7 , R′K A and r are the same as those described in the general formula (c 4). R c9 is an alkylene group which ~ 1 carbon atoms which may be 5 substituted by a hydroxyl group, T is ten S 0 3 -, - CO_〇-, an anionic group selected from a S Of. r is a number of 0 or 1. ].
陰イオン界面活性剤としてはアルキル基の炭素数 8 ~1 8のアルキルベンゼンスルホン 酸塩、 アルカンスルホン酸塩、 α'ォレフインスルホン酸塩、 アルキル硫酸エステル塩、 ポ リオキシエチレンアルキルエーテル硫酸塩、 ポリオキシエチレンアルキルエーテル酢酸塩
等を挙げることができる。 Examples of the anionic surfactant include alkylbenzene sulfonates having 8 to 18 carbon atoms in the alkyl group, alkane sulfonates, α'-olefin sulfonates, alkyl sulfates, polyoxyethylene alkyl ether sulfates, and the like. Polyoxyethylene alkyl ether acetate And the like.
本発明では特に前記式 (c 3)、 (c 4) 及び (c 5) 力 ^ら選ばれる界面活性剤の一種以 上を配合することが、 防汚効果を損なうことなく優れた洗浄性を得る上で好ましい。 (c) 成分の界面活性剤の配合量は、 殺菌及び防汚効果を損なうことなく十分な洗浄力や起泡力 を得るために好ましくは 0. 01重量%以上、 50重量%未満、 より好ましくは 0. 1重 量%以上であり、 特に好ましくは 0. 1~30重量%である。 In the present invention, in particular, blending one or more of the surfactants selected from the above formulas (c3), (c4) and (c5) provides excellent detergency without impairing the antifouling effect. It is preferable for obtaining. (C) The amount of the surfactant is preferably 0.01% by weight or more and less than 50% by weight, more preferably less than 50% by weight, in order to obtain sufficient detergency and foaming power without impairing the disinfecting and antifouling effects. Is 0.1% by weight or more, particularly preferably 0.1 to 30% by weight.
但し、 陰イオン界面活性剤 [以下 (cA) とする] は、 殺菌性及び防汚性を低下させる ため、 影響のない量で配合されるべきであり、 (cA) を含有する場合、 (cA) / (b) が重量比率で、 1. 0越えない量、 好ましくは 0. 75を越えない量で配合しなければな らない。 この範囲を越えると、 防汚及び殺菌効果の両方を得ることはできない。 However, the anionic surfactant [hereinafter referred to as (cA)] should be blended in an amount that has no effect in order to reduce the bactericidal and antifouling properties. When (cA) is contained, (cA) ) / (b) must be present in a proportion by weight not exceeding 1.0, preferably not exceeding 0.75. Beyond this range, both antifouling and disinfecting effects cannot be obtained.
(c) 成分は本発明の殺菌防汚洗浄剤中に好ましくは 0.1~30重量%であり、 詳しくは トリガーやエアゾールなどの噴霧装置や、 塗布するような方法にて対象の硬質表面を直接 洗浄するような場合は、 (じ)成分の濃度は0.1〜20重量%、より好ましくは 0.2〜10重量% であり、 一方、 トイレタンク内の水を利用した洗浄方法において、 タンク内または任意の 給水経路に装置を設けることでタンク内の水に適量な洗浄液を投与することができるトイ レ用ォ一トクリーナーに用いる場合は、 0.5〜30重量%、 より好ましくは 1〜30重量%含有 される。 なおトイレのタンク内の (c) 成分の濃度は 0. l〜20p pmが好ましい。 本発明では、 任意成分の成分として、 有機汚れに対する洗浄力向上の目的で水溶性溶剤 [以下 (d) 成分とする] を配合することが好ましく、 [1] 炭素数 1〜5の 1価アルコー ル、 [2] 炭素数 4~12の多価アルコール、 [3] 下記の一般式 (d l) で表される化合 物、 [4] 下記の一般式 (d2) で表される化合物及び [5] 下記の一般式 (d3) で表さ れる化合物から選ばれる一種以上が好ましい。 The component (c) is preferably 0.1 to 30% by weight in the germicidal and antifouling detergent of the present invention. Specifically, the target hard surface is directly cleaned by a spraying device such as a trigger or an aerosol, or by a method such as application. In such a case, the concentration of the component (j) is 0.1 to 20% by weight, more preferably 0.2 to 10% by weight. On the other hand, in the cleaning method using water in the toilet tank, the water in the tank or any water supply When used in toilet cleaners that can administer an appropriate amount of washing liquid to the water in the tank by providing a device in the route, the content is 0.5 to 30% by weight, more preferably 1 to 30% by weight. . The concentration of the component (c) in the toilet tank is preferably 0.1 to 20 ppm. In the present invention, a water-soluble solvent [hereinafter referred to as “component (d)”] is preferably blended as an optional component for the purpose of improving detergency against organic stains. [1] A monovalent alcohol having 1 to 5 carbon atoms [2] a polyhydric alcohol having 4 to 12 carbon atoms, [3] a compound represented by the following general formula (dl), [4] a compound represented by the following general formula (d2), and [5] One or more compounds selected from the compounds represented by the following general formula (d3) are preferable.
RdlO(C2 OHC3 0) Rd、2 (D D R dl O (C 2 OHC 30 ) R d , 2 (D D
Rd5OC(CH3)2C¾C¾OH (d 3) R d5 OC (CH 3 ) 2 C¾C¾OH (d 3)
式中、 Rdl及び Rd2は、 それぞれ独立して、 水素原子、 炭素数 1〜8のアルキル基、 フエ ニル基又はベンジル基を示すが、 Rdll及び Rd2の双方が水素原子となる場合を除く。 s及 び tは、 それぞれ独立して、 0~10の数を示すが、 s及び tの双方が 0である場合を除 く。 Rd3及び Rd4は炭素数 1〜3のアルキル基を示す。 Rd5は炭素数 1〜 3のアルキル基を
示す。 In the formula, R dl and R d2 each independently represent a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, a phenyl group or a benzyl group, and both R dl l and R d2 are hydrogen atoms Except in cases. s and t each independently represent a number from 0 to 10, except when both s and t are 0. R d3 and R d4 represent an alkyl group having 1 to 3 carbon atoms. R d5 represents an alkyl group having 1 to 3 carbon atoms. Show.
[1] の炭素数 2~ 5の 1価アルコールとしては、 一般的にエタノール、 プロピルアル コール、 イソプロピルアルコールが挙げられる。 これらの低級アルコールを配合すること により低温における系の安定性を更に向上させることができる。 Examples of the monohydric alcohol having 2 to 5 carbon atoms in [1] generally include ethanol, propyl alcohol, and isopropyl alcohol. By incorporating these lower alcohols, the stability of the system at low temperatures can be further improved.
[2] の炭素数 4~ 12の多価アルコールとしては、 イソプレングリコール、 2, 2, 4—トリメチルー 1, 3—ペンタンジオール、 1, 5—ペン夕ンジオール、 1, 8ーォク 夕ンジオール、 1, 9ーノナンジオール、 エチレングリコ一ル、 プロピレングリコ一ル、 ジエチレングリコール、 ジプロピレングリコール、 グリセリンの他、 アルキル基の炭素数 が 3〜 8のモノアルキルグリセリルエーテル等が挙げられる。 Examples of the polyhydric alcohol having 4 to 12 carbon atoms of [2] include isoprene glycol, 2,2,4-trimethyl-1,3-pentanediol, 1,5-pentanediol, 1,8-octanediol, In addition to 9-nonanediol, ethylene glycol, propylene glycol, diethylene glycol, dipropylene glycol, and glycerin, monoalkyl glyceryl ethers having an alkyl group having 3 to 8 carbon atoms and the like are included.
[3] の化合物は、 一般式 (dl) において、 Rdl、 Rd2がアルキル基である場合の炭素 数は 1〜4が特に好ましい。 また、 一般式 (d l) 中、 エチレンオキサイド (以下、 EO という) 及びプロピレンオキサイド (以下、 POという) の平均付加モル数の s及び tは、 それぞれ 0~10の数であるが、 EOと POの付加順序は特に限定されず、 ランダム付加 したものであってもよい。 [3] の化合物の具体例としては、 エチレングリコ一ルモノプチ ルェ一テル、 ジプロピレングリコ一ルジメチルエーテル、 ジエチレングリコールモノェチ ルエーテル、 ジエチレングリコールモノブチルエーテル、 プロピレングリコールモノメチ ルエーテル、 プロピレングリコールモノプロピルエーテル、 プロピレングリコ一ルモノブ チルエーテル、 プロピレングリコールモノェチルェ一テル、 プロピレングリコ一ルジメチ ルェ一テル、 ポリオキシエチレン (平均付加モル数 =2〜 3) ポリオキシプロピレン (平 均付加モル数 = 2〜 3 ) グリコールジメチルェ一テル、 ポリオキシエチレン (平均付加モ ル数 = 1〜4) グリコ一ルフエ二ルェ一テル、 フエ二ルカルビトール、 フエ二ルセ口ソル ブ、 ベンジルカルビトール等が挙げられる。 このうち、 洗浄力及び使用感の点から、 プロ ピレンダリコールモノメチルエーテル、 ジエチレングリコールモノブチルエーテル、 ポリ ォキシエチレン (平均付加モル数 = 1〜4) グリコールフエニルエーテルが好ましい。 また、 [4] の化合物としては、 1, 3—ジメチルー 2—イミダゾリジノン、 1, 3—ジ ェチル—2—イミダゾリジノンが好適なものとして例示され、 [5] の化合物としては 3— メ卜キシー 3—メチルブ夕ノール、 3—エトキシー 3—メチルブ夕ノール等が好ましい。 これらのなかでも基材に対する損傷性の点から [1]、 [2] 及び [3] の化合物から選 ばれる水溶性溶剤が好ましく、 特にエタノール、 イソプロピルアルコール、 エチレンダリ コール、 プロピレングリコール、 ジエチレングリコール、 ジプロピレングリコール、 ダリ セリン、 イソプレンダリコール、 プロピレングリコールモノメチルエーテル、 プロピレン ダリコールモノェチルエーテル、 プロピレングリコールモノプロピルエーテル、 プロピレ ングリコ一ルモノブチルエーテル及びアルキル基の炭素数が 3〜 8のモノアルキルグリセ リルェ一テルから選ばれる水溶性溶剤が好ましい。 In the compound of [3], in the general formula (dl), when R dl and R d2 are an alkyl group, the number of carbon atoms is particularly preferably 1 to 4. In the general formula (dl), s and t, which are the average addition mole numbers of ethylene oxide (hereinafter, referred to as EO) and propylene oxide (hereinafter, referred to as PO), are 0 to 10, respectively. The order of addition is not particularly limited, and may be randomly added. Specific examples of the compound of [3] include ethylene glycol monobutyl ether, dipropylene glycol dimethyl ether, diethylene glycol monoethyl ether, diethylene glycol monobutyl ether, propylene glycol monomethyl ether, propylene glycol monopropyl ether, propylene glycol Monobutyl ether, propylene glycol monoethyl ether, propylene glycol dimethyl ether, polyoxyethylene (average number of moles = 2-3) polyoxypropylene (average number of moles = 2-3) glycol dimethyl Ether, polyoxyethylene (average number of added moles = 1 to 4) Glycol phenyl ether, phenyl carbitol, phenyl sorbitol, benzyl carbitol and the like. Among these, propylene glycol monomethyl ether, diethylene glycol monobutyl ether, and polyoxyethylene (average number of moles = 1 to 4) glycol phenyl ether are preferred from the viewpoints of detergency and usability. Further, as the compound of [4], 1,3-dimethyl-2-imidazolidinone and 1,3-dimethyl-2-imidazolidinone are exemplified as preferable ones, and as the compound of [5], 3- (3-dimethyl-2-imidazolidinone) is used. Preference is given to methoxy-3-methylbutanol, 3-ethoxy-3-methylbutanol and the like. Among these, a water-soluble solvent selected from the compounds of [1], [2] and [3] is preferable from the viewpoint of damage to the base material, and in particular, ethanol, isopropyl alcohol, ethylenedaricol, propylene glycol, diethylene glycol, dipropylene Glycol, daliserine, isoplendaricol, propylene glycol monomethyl ether, propylene dalicol monoethyl ether, propylene glycol monopropyl ether, propylene glycol monobutyl ether, and monoalkyl glyceryl ether having 3 to 8 carbon atoms in the alkyl group And a water-soluble solvent selected from
(d) 成分は本発明の殺菌防汚洗浄剤中に好ましくは 0.1〜50重量%であり、 詳しくは トリガ一やエアゾールなどの噴霧装置や、 塗布するような方法にて対象の硬質表面を洗浄 するような場合は、 (d) 成分の濃度は 0.!〜 20重量%、 より好ましくは 0.5〜10重量%で あり、 一方、 トイレタンク内の水を利用した洗浄方法において、 タンク内または任意の給 水経路に装置を設けることでタンク内の水に適量な洗浄液を投与することができるトイレ 用オートクリーナーに用いる場合は、 1〜50重量%、 より好ましくは 5〜30重量%含有され る。 なおトイレのタンク内の (d) 成分の濃度は 0.01~20p pmが好ましい。 本発明では無機汚れを溶解し、 洗浄力及び殺菌効果を向上させる目的で、 さらに (e)
成分として、 キレート剤を配合することが好ましい。 キレート剤としては (1 ) トリポリ リン酸、 ピロリン酸、 オルソリン酸、 へキサメタリン酸及びこれらのアルカリ金属塩、 (2 ) エチレンジァミン四酢酸、 ヒドロキシィミノ二酢酸、 ジヒドロキシェチルダリシン、 ニト リロ三酢酸、 ヒドロキシエチレンジァミン三酢酸、 ジエチレントリアミン五酢酸、 トリェ チレンテトラミン六酢酸及びこれらのアル力リ金属塩もしくはアル力リ土類金属塩、 ( 3 ) アミノトリメチレンホスホン酸、 1ーヒドロキシェチリデン一 1 , 1ージホスホン酸、 ェ チレンジアミンテトラメチレンホスホン酸、 ジエチレントリアミンペンタメチレンホスホ ン酸、 ァミノトリメチレンホスホン酸の N—ォキサイド及びこれらのアルカリ金属塩もし くはアルカリ土類金属塩、 (4 ) アクリル酸及びメタクリル酸から選ばれるモノマーの単一 重合体又は共重合体、 アクリル酸—マレイン酸共重合体、 ポリ α—ヒドロキアクリル酸及 びそのアルカリ金属塩、 (5 ) クェン酸、 コハク酸、 リンゴ酸、 フマル酸、 酒石酸、 マロン 酸、 マレイン酸から選ばれる多価カルボン酸及びそれらのアルカリ金属塩から選ばれる 1 種以上、 (6 ) アルキルグリシン一 Ν, Ν—ジ酢酸、 ァスパラギン酸— Ν, Ν—ジ酢酸、 セ リン一 Ν, Ν—ジ酢酸、 グルタミン酸二酢酸、 エチレンジアミンジコハク酸又はこれらの 塩が好ましく、 特に (2 )、 (3 )、 ( 5 ) の化合物が好ましい。 The component (d) is preferably 0.1 to 50% by weight in the germicidal antifouling detergent of the present invention. In such cases, the concentration of component (d) is 0.! 20% by weight, more preferably 0.5% to 10% by weight. On the other hand, in a cleaning method using water in the toilet tank, an appropriate amount of water in the tank is provided by installing a device in the tank or an arbitrary water supply path. When it is used for an auto cleaner for a toilet which can administer a suitable washing liquid, it is contained in an amount of 1 to 50% by weight, more preferably 5 to 30% by weight. The concentration of the component (d) in the toilet tank is preferably 0.01 to 20 ppm. In the present invention, for the purpose of dissolving the inorganic dirt, and improving the detergency and the sterilizing effect, (e) It is preferable to add a chelating agent as a component. Examples of the chelating agent include (1) tripolyphosphoric acid, pyrophosphoric acid, orthophosphoric acid, hexametaphosphoric acid and alkali metal salts thereof, (2) ethylenediaminetetraacetic acid, hydroxyiminodiacetic acid, dihydroxyethyldalicin, nitrilotriacetic acid, Hydroxyethylene diamine triacetic acid, diethylene triamine pentaacetic acid, triethylene tetramine hexaacetic acid and their metal salts or alkaline earth metal salts, (3) aminotrimethylene phosphonic acid, 1-hydroxyethylidene 1,1-diphosphonic acid, ethylenediaminetetramethylenephosphonic acid, diethylenetriaminepentamethylenephosphonic acid, N-oxide of aminotrimethylenephosphonic acid and alkali metal or alkaline earth metal salts thereof, (4) acrylic Select from acid and methacrylic acid Homopolymers or copolymers of monomers, acrylic acid-maleic acid copolymer, poly-α-hydroxyacrylic acid and its alkali metal salts, (5) citric acid, succinic acid, malic acid, fumaric acid, tartaric acid, At least one selected from the group consisting of polycarboxylic acids selected from malonic acid and maleic acid and alkali metal salts thereof; (6) alkyl glycine mono-, di-acetic acid, aspartic acid-Ν, di-acetic acid, and serine Mono-, di-acetic acid, glutamic acid diacetate, ethylenediamine disuccinic acid or salts thereof are preferred, and the compounds of (2), (3) and (5) are particularly preferred.
( e ) 成分は本発明の殺菌防汚洗浄剤中に好ましくは 0. 1〜20 重量%であり、 詳しくは トリガーやエアゾールなどの噴霧装置や、 塗布するような方法にて対象の硬質表面を洗浄 するような場合は、 (e ) 成分の濃度は 0. 1〜10重量%、 より好ましくは 0. 3〜7重量%で あり、 一方、 トイレタンク内の水を利用した洗浄方法において、 タンク内または任意の給 水経路に装置を設けることでタンク内の水に適量な洗浄液を投与することができるトイレ 用オートクリーナーに用いる場合は、 1〜20重量%、 より好ましくは 2〜20重量%含有され る。 なおトイレのタンク内の (e ) 成分の濃度は 0. 01〜20 p pmが好ましい。 The component (e) is preferably 0.1 to 20% by weight in the germicidal antifouling detergent of the present invention. More specifically, the hard surface of the object is sprayed with a trigger or aerosol, or by a method such as coating. In the case of washing, the concentration of the component (e) is 0.1 to 10% by weight, more preferably 0.3 to 7% by weight. On the other hand, in the washing method using water in the toilet tank, 1-20% by weight, more preferably 2-20% by weight when used in toilet auto cleaners that can supply an appropriate amount of cleaning liquid to the water in the tank by installing a device inside or in an optional water supply path It is contained. The concentration of the component (e) in the toilet tank is preferably 0.01 to 20 ppm.
本発明は、 p Hを調整する場合に p H調整剤を使用してもよい。 p H調整剤としては塩 酸や硫酸など無機酸や、 クェン酸、 コ八ク酸、 リンゴ酸、 フマル酸、 酒石酸、 マロン酸、 マレイン酸などの有機酸などの酸剤や、 水酸化ナトリウムや水酸化カリウム、 アンモニア やその誘導体、 モノエタノールアミンゃジエタノールァミン、 トリエタノールァミンなど のァミン塩など、 炭酸ナトリウム、 炭酸カリウムなどのアルカリ剤を、 単独もしくは複合 して用いても構わない。 また、 これらの酸剤とアルカリ剤を組み合わせて緩衝剤系として 用いても構わない。 . The present invention may use a pH adjuster when adjusting pH. Examples of pH adjusters include inorganic acids such as hydrochloric acid and sulfuric acid, acid agents such as citric acid, co-octanoic acid, malic acid, fumaric acid, tartaric acid, malonic acid, and maleic acid; sodium hydroxide; Alkaline agents such as sodium carbonate and potassium carbonate, such as potassium hydroxide, ammonia and derivatives thereof, and amine salts such as monoethanolamine diethanolamine and triethanolamine, may be used alone or in combination. Further, these acid agents and alkali agents may be used in combination as a buffer system. .
本発明の硬表面用殺菌防汚洗浄剤は、 上記の p H調整剤により、 2 0でにぉける ^1が 2〜1 2になるように調整することが好ましく、 特に p H 3〜l 1になるようにすること が防汚効果の点から好ましい。 The hard surface sterilizing and antifouling detergent of the present invention is preferably adjusted by the above-mentioned pH adjuster so that ^ 1 in 20 becomes 2 to 12 and particularly pH 3 to 1 It is preferable to set it to 1 from the viewpoint of the antifouling effect.
本発明では使用時の付着性を持たせ使いやすさ向上の目的で、 水溶性高分子の 1種以上 を添加することが出来る。 水溶性高分子としては特に限定されるものではないが、 特開平 8 - 2 0 9 1 9 4号公報 6頁 1 0欄〜 7頁 1 1欄に記載の水溶性高分子から選ばれる 1種 以上が好ましい。 In the present invention, one or more water-soluble polymers can be added for the purpose of imparting adhesion during use and improving ease of use. The water-soluble polymer is not particularly limited, but may be one selected from water-soluble polymers described in JP-A-8-209194, page 6, column 10 to page 7, column 11. The above is preferred.
本発明の硬表面用殺菌防汚洗浄剤には、 上記成分の他に、 本発明の効果を損なわない範 囲で通常の洗浄剤に配合されている添加剤、 例えば香料、 抗菌剤、 粘度調整剤、 顔料、 染 料、 懸濁剤などを添加することができる。 また、 使用時の起泡性を高める目的で、 トルェ ンスルホン酸、 キシレンスルホン酸、 クメンスルホン酸、 ァルケエルコハク酸及びこれら のアル力リ金属塩などの起泡助剤から選ばれる 1種以上を添加することが出来る。 In addition to the above-mentioned components, the hard surface sterilizing and antifouling detergent of the present invention contains additives, such as fragrances, antibacterial agents, and viscosity modifiers, which are blended with ordinary detergents within a range that does not impair the effects of the present invention. Agents, pigments, dyes, suspending agents and the like can be added. In addition, for the purpose of enhancing the foaming property at the time of use, at least one selected from foaming aids such as toluene sulfonic acid, xylene sulfonic acid, cumene sulfonic acid, arkeel succinic acid, and metal salts of these metals is added. I can do it.
本発明を使用する際には、 (a ) 成分の重合体と (b ) 成分の殺菌化合物とを、 溶媒中に 一剤として溶解または分散させても、 任意成分との組み合わせによる、 任意の剤数にして
も構わない。 また、 任意成分を組み合わせることにより、 水などの溶媒に対して、 直ちに 溶解する、 あるいは徐放性を付与した、 一剤以上の粉末や錠剤の形状で用いても構わない。 さらに、 (a) 成分と (b) 成分、 あるいは任意成分のいずれかが液状で他方が粉末などの 固体状で用いることもできる。 When the present invention is used, even if the polymer of the component (a) and the germicidal compound of the component (b) are dissolved or dispersed as a single agent in a solvent, any one of the optional agents may be used in combination with the optional component. In numbers No problem. One or more powders or tablets may be used in the form of one or more powders which can be immediately dissolved in a solvent such as water or provided with sustained release by combining optional components. Further, any one of the component (a) and the component (b) or the optional component may be used in a liquid state, and the other may be used in a solid state such as a powder.
本発明の殺菌防汚洗浄剤の使用時の形態は、 特に問わないが、 (a) 成分、 (b) 成分及 び任意成分を含有し残部が水の液体組成物であることが好ましく、 オートクリ一ナ一とし て用いる場合は、 ポリエチレングリコール、 ポリエチレングリコール脂肪酸エステル、 ポ リエチレングリコール脂肪酸ジエステル、 脂肪酸、 又は塩等の凝固剤を用いて固体状もし くはゲル状の組成物としてもよい。 水の含有量は液体組成物又はゲル状組成物の場合は好 ましくは 10〜98重量%、 より好ましくは 20〜 95重量%である。 固体状組成物の 場合は好ましくは 30%以下、 より好ましくは 20%以下である。 実施例 The form of the sterilizing and antifouling detergent of the present invention at the time of use is not particularly limited, but is preferably a liquid composition containing component (a), component (b) and optional components, with the balance being water. When used as a solid, a solid or gel composition may be formed using a coagulant such as polyethylene glycol, polyethylene glycol fatty acid ester, polyethylene glycol fatty acid diester, fatty acid, or salt. The content of water is preferably 10 to 98% by weight, more preferably 20 to 95% by weight in the case of a liquid composition or a gel composition. In the case of a solid composition, it is preferably at most 30%, more preferably at most 20%. Example
ぐ実施例 1 > Example 1>
表 1に示す組成の殺菌防汚洗浄剤を調製し、 その防汚性及び殺菌性について下記の方法 で評価した。 結果を表 1に示す。 A germicidal antifouling detergent having the composition shown in Table 1 was prepared, and its antifouling property and bactericidal property were evaluated by the following methods. Table 1 shows the results.
<防汚性の評価 > <Evaluation of antifouling property>
(1) 易洗浄性 (1) Easy cleaning
殺菌防汚剤 lmLを、 面積 10 cm2の陶器タイル表面に塗布し、 5分間放置した後、 水After sterilizing antifouling agent LML, applied to porcelain tiles surface area 10 cm 2, left for 5 minutes, water
20 01111^を45° の角度で流速 25mL/秒の割合で流し、 乾燥させることを 5回繰り 返して行った後、 陶器タイル表面にスポット状にォレイン酸を 0. 5 g滴下する。 ォレイ ン酸を滴下した陶器タイルを、 ォレイン酸が流れないよう、 水槽の底に静置し、 陶器夕ィ ルに直接水がかからないよう、 静かに水槽中に水を満たしていく。 その際のォレイン酸が 陶器タイル表面から除去される面積の割合を判定し、 次の 5段階で評価した。 なお、 汚れ 落ちの%はモデル汚染板 5枚の平均値を採用した 20 Flow of 01111 ^ at an angle of 45 ° at a flow rate of 25 mL / sec, and drying is repeated 5 times. Then, 0.5 g of oleic acid is dropped on the surface of the ceramic tile in the form of spots. The pottery tiles with the drop of oleic acid are allowed to stand at the bottom of the tank so that the oleic acid does not flow, and the tank is gently filled with water so that the pottery tiles are not directly exposed to water. At that time, the ratio of the area where oleic acid was removed from the ceramic tile surface was determined, and evaluated in the following five steps. The percentage of dirt removal was the average value of five model contamination plates.
5 :汚れ落ちが 80 %以上である 5: Stain removal is 80% or more
4 :汚れ落ちが 60 %以上 80 %未満である 4: Stain removal is 60% or more and less than 80%
3 :汚れ落ちが 40%以上 60%未満である 3: Stain removal is 40% or more and less than 60%
2 :汚れ落ちが 20%以上 40 %未満である 2: Stain removal is 20% or more and less than 40%
1 :汚れ落ちが 20 %未満である。 1: Stain removal is less than 20%.
(2) 汚れ付着防止性 (2) Dirt adhesion prevention
市販の便器 (C 730 B、 東陶機器 (株) 製) を用い、 汚れの付きにくさの評価を行つ た。 即ち組成物で便器を洗浄し、 1週間放置した際の汚れの付きにくさを、 以下の基準を 基に肉眼で測定した。 Using a commercially available toilet bowl (C 730 B, manufactured by Tohoku Kiki Co., Ltd.), the evaluation of the difficulty of soiling was performed. That is, the toilet was washed with the composition, and the difficulty of attaching the stain after being left for one week was visually measured based on the following criteria.
(評価基準) (Evaluation criteria)
◎:汚れが付いていない。 A: No dirt.
〇:汚れが僅かに付いている。 〇: Slightly adhered.
△:汚れが少し付いている。 Δ: Slightly adhered.
X :汚れがかなり付いている。 X: There is considerable dirt.
<殺菌性評価 > <Evaluation of sterilization>
供試菌として大腸菌 (Es che r i ch i a c o l i : I FO 3972) と黄色ブド ゥ球菌 (S t aphy l ococ cu s aur eu s : I FO 12732) を用いた。 殺菌性試験は、表 1に示す殺菌防汚剤 2m 1中に 108〜 103個の細菌浮遊液 50 μ 1を 加えよく混合した後、 放置時間を 5分とした時の殺菌性を調べた。 放置後、 その混合液を
0. 1ml採取して 0. 9m 1の LP希釈液中に加えて十分混合し、 洗浄液の菌への影響 を低下させ、 次いでこの混合液を S CDLP寒天培地上に塗布し、 大腸菌は 37t:で 24 時間、 黄色ブドウ球菌は 37 °Cで 48時間培養する。 培養後の生育したコロニー数を数え る。 なお殺菌試験は、 同じ殺菌防汚剤について、 各放置時間毎にそれぞれ 5つの試験区に より行ない、 以下の評点で殺菌性を評価した。 Escherichia coli (IFO 3972) and Staphylococcus aureus (Staphylococcus cauruseus: IFO 12732) were used as test bacteria. The bactericidal test was conducted by adding 50 μl of 10 8 to 10 3 bacterial suspensions to 2 ml of the germicidal antifouling agent shown in Table 1 and mixing well. Was. After standing, the mixture 0.1 ml is collected and added to 0.9 ml of LP diluent and mixed well to reduce the effect of the washing solution on the bacteria, then this mixture is spread on S CDLP agar medium, and the E. coli is 37t: Incubate for 24 hours at 37 ° C for 48 hours. Count the number of grown colonies after culture. In the sterilization test, the same sterilizing and antifouling agent was tested in five test plots for each standing time, and the sterilizing property was evaluated according to the following scores.
なお、 前記規定以外の実験条件の詳細は、 防菌防黴ハンドブック (日本防菌防黴学会編、 技報堂出版) の P 686に記載されている浮遊試験法 (定量的検査法) に従う。 The details of the experimental conditions other than the above-mentioned rules conform to the floating test method (quantitative test method) described in P. 686 of the Bacterial and Fungicide Handbook (edited by the Japan Society of Bacterial and Fungicide, published by Gihodo).
〇:放置時間が 5分でのコロニー数が 104以下になる。 〇: The number of colonies becomes less than 10 4 in 5 minutes.
X:放置時間が 5分でのコロニー数が 104を超える 表中の成分は次の通りである。 X: The number of colonies exceeds 10 4 when the standing time is 5 minutes The components in the table are as follows.
'重合体 B:マーコート 550 [塩化ジァリルジメチルアンモニゥムとアクリルアミド(モ ル比 30/70)共重合体 (Ca 1 gon社製、 重量平均分子量 500万、 ゲルパーミエ ーシヨンクロマトグラムにより測定、 ポリエチレングリコールを標準として使用)] '重合体 A:マーコート 100 [塩化ジァリルジメチルアンモニゥムのホモポリマー (C a 1 gon社製、 重量平均分子量 40万、 ゲルパーミエーシヨンクロマトグラムで測定、 ポリエチレングリコールを標準として使用)] 'Polymer B: Mercoat 550 [diallyldimethylammonium chloride and acrylamide (mole ratio 30/70) copolymer (Ca1gon, weight average molecular weight 5,000,000, measured by gel permeation chromatogram, Polyethylene glycol is used as standard)] 'Polymer A: Mercoat 100 [Homopolymer of diaryldimethylammonium chloride (Ca1gon, weight average molecular weight 400,000, measured by gel permeation chromatogram) Use polyethylene glycol as standard)]
-重合体 C:マーコ一ト 280、 Ca l go n社製、 塩化ジァリルジメチルアンモニゥ ムとアクリル酸の共重合体 -Polymer C: Mercoto 280, manufactured by Calgon, a copolymer of diaryldimethylammonium chloride and acrylic acid
•重合体 D:アクリル酸 3. 59 g、 水 280 g、 35 %塩酸水溶液 32mlの溶液に N, N—ジメチルァミノプロピルメ夕クリル酸アミド 76. 41 gを冷却下添加し中和した 溶液を 70°Cまで加熱し、 窒素雰囲気下で重合開始剤 (和光純薬製 V— 50) を滴下し た。熟成後冷却し、有効分 18%の重合体を得た。重量平均分子量 40万、モノマー(a) / 〔モノマー (a) +モノマー (b)〕 =0. 9 (モル比) • Polymer D: A solution obtained by adding 76.41 g of N, N-dimethylaminopropylmethacrylic acid amide to a solution of 3.59 g of acrylic acid, 280 g of water, and 32 ml of 35% aqueous hydrochloric acid under cooling, and neutralized. Was heated to 70 ° C., and a polymerization initiator (W-50, manufactured by Wako Pure Chemical Industries, Ltd.) was added dropwise under a nitrogen atmosphere. After aging, the mixture was cooled to obtain a polymer having an effective content of 18%. Weight average molecular weight 400,000, monomer (a) / [monomer (a) + monomer (b)] = 0.9 (molar ratio)
•殺菌性化合物 A:サニゾール C [ココアルキルジメチルペンジルアンモニゥムクロリ ド (花王 (株) 製)] • Fungicidal compound A: Sanizole C [cocoalkyl dimethyl benzylammonium chloride (manufactured by Kao Corporation)]
-殺菌性化合物 B:コ一夕ミン D 10 P [ジデシルジメチルアンモニゥムクロリド (花 王 (株) 製)] -Bactericidal compound B: Koyinmin D 10 P [didecyldimethylammonium chloride (manufactured by Kao Corporation)]
•殺菌性化合物 C:塩化べンゼトニゥム [和光試薬、 下記構造のカチオン化合物] • Fungicidal compound C: Benzetonium chloride [Wako reagent, cationic compound with the following structure]
AO :アンヒトール 2 ON [ラウリルジメチルアミンォキシド (花王 (株) 製)] AO: Amphitol 2 ON [Lauryl dimethylamine oxide (Kao Corporation)]
AG:アルキルダルコシド (直鎖アルキル基の炭素数が 12と 14の混合物、 糖平均縮 合度 1. 2 [縮合度 1と 2の混合物]) AG: Alkyl darcoside (a mixture of straight chain alkyl groups with 12 and 14 carbon atoms, average saccharide condensation degree 1.2 [mixture of condensation degrees 1 and 2])
• ES: EO平均付加モル数が.2. 2モルのポリオキシエチレンラウリルエーテル硫酸 •ベタイン: N—ラウロイルァミノプロピル一 N, N—ジメチル一 N—力ルポキシメチ ルアンモニゥムベタイン
• E D TA- 4 N a :エチレンジァミン四酢酸四ナトリウム塩 • ES: Polyoxyethylene lauryl ether sulfate with an average number of moles of added EO of 2.2 moles • Betaine: N-lauroylaminopropyl-N, N-dimethyl-N-potoxymethylammonium betaine • ED TA-4 Na: Ethylenediaminetetraacetic acid tetrasodium salt
• p H調整剤:塩酸及び/又は水酸化ナトリウム (何れも水溶液で用いる) • pH adjuster: hydrochloric acid and / or sodium hydroxide (all used in aqueous solution)
<実施例 2 > <Example 2>
表 2に示すトイレ用オートクリーナー組成物を調整し、 カツコ内の数値 (ppm) になるよ うにスポィ卜でトイレタンク内に投入し、 フラッシュを行った際の防汚性について下記の 方法で評価した。 結果を表 2に示す。 The toilet auto-cleaner composition shown in Table 2 was prepared and poured into a toilet tank with a spot so that the value in Kazuko (ppm) was obtained. The antifouling property when flushing was evaluated by the following method did. Table 2 shows the results.
<防汚性の評価 > <Evaluation of antifouling property>
( 1 ) 易洗浄性 (1) Easy cleaning
フラッシュを 1 0回行った後の便器 (C730B 東陶機器 (株) 製) を用いォレイン酸 0 . 5 gをスポット状に 5力所滴下し、 フラッシュをした後のォレイン酸が除去さ れる面積の割合を判定し、 次の 5段階で評価した。 なお、 汚れ落ちの評価は 5回の 平均値を採用した。 After flushing 10 times, 0.5 g of oleic acid was dropped in five spots using a toilet (C730B manufactured by Tohoku Kikai Co., Ltd.) in spots, and the area from which the oleic acid was removed after flushing Was evaluated and evaluated in the following five steps. The average of five measurements was used for the evaluation of dirt removal.
(評価基準は表 1と同様) (Evaluation criteria are the same as Table 1.)
( 2 ) 汚れ付着防止性 (2) Dirt adhesion prevention
市販の便器 (C 7 3 0 B、 東陶機器 (株) 製) を用い、 汚れの付きにくさの評価 を行った。 即ち組成物で便器を洗浄し、 1週間放置した際の汚れの付きにくさを、 以下の 基準を基に肉眼で測定した。 A commercially available toilet bowl (C730B, manufactured by Tohoku Kikai Co., Ltd.) was used to evaluate the difficulty of getting dirty. That is, the toilet was washed with the composition, and the hardiness of the toilet when allowed to stand for one week was visually measured based on the following criteria.
(評価基準) (Evaluation criteria)
◎:汚れが付いていない。 A: No dirt.
〇:汚れが僅かに付いている。 〇: Slightly adhered.
△:汚れが少し付いている。 Δ: Slightly adhered.
X :汚れがかなり付いている。 X: There is considerable dirt.
( 3 ) 細菌の発育抑制効果 (3) Bacterial growth inhibitory effect
表 2のカツコ内の濃度に調整した組成物 2 ml に 104cfu/ral に調整した Staphylococcus aureusの懸濁液 0. 05ml と SCD培地 0. lmlを加えよく拡販し、 3 7。Cで 1 8時間静置し、 以下のような式で静菌活性値を求めた。 Table 2 of well sales added a suspension 0. 05Ml and SCD medium 0. lml of Staphylococcus aureus which had been adjusted to 10 4 cfu / ral to adjust the composition 2 ml concentration in Katsuko, 3 7. After standing at C for 18 hours, the bacteriostatic activity value was determined by the following formula.
なお、 ブランクとしては滅菌水を用いた。 静菌活性値 = log (ブランクの培養後の生菌数) —log (評価サンプル培養後の生菌数) <評価〉 Sterile water was used as a blank. Bacteriostatic activity value = log (number of viable cells after blank culture)-log (number of viable cells after culture of evaluation sample) <evaluation>
〇:静菌活性値: 0より大きい 〇: Bacteriostatic activity value: greater than 0
X :静菌活性値: 0以下
X: Bacteriostatic activity value: 0 or less
配合例 Formulation example
つ One
1 . o 4 Ό D 1 b y I o u "r α o 1 Ί o 20 1. O 4 Ό D 1 by I o u "r α o 1 Ί o 20
M口 1 A n U. u. M mouth 1 A n U. u.
里番ム σ / 1女小 tit 0.1 0.3 1 3 Satoban Mu σ / 1 female small tit 0.1 0.3 1 3
(a)成分 (A) component
坐口 1平し 0.1 0.3 1 ■) 1 1 1 3 Sitting mouth 1 flat 0.1 0.3 1 ■) 1 1 1 3
ム女 n Woman n
里 α 1小 U 0.1 1 1 5 3 ネ又困 Ί土 1 C口 ク JA 0.01 1 0.1 0.3 1 0.05 0.1 0.1 0.1 0.05 殺菌性化合物 Β 0.3 0.3 Sato α 1 small U 0.1 1 1 5 3 Neither soil 1 C mouth JA 0.01 1 0.1 0.3 1 0.05 0.1 0.1 0.1 0.05 Fungicidal compound Β 0.3 0.3
硬 (b)成分 Hard (b) component
殺菌性化合物 C 1 Fungicidal compound C 1
殺菌性化合物 D 0.1 0.3 0.5 1 1 0.5 1 1 2 Fungicidal compound D 0.1 0.3 0.5 1 1 0.5 1 1 2
AO 1 1 1 1 1 1 2 ' 1 1 1 AO 1 1 1 1 1 1 2 '1 1 1
AG 1 3 1 1 1 1 1 3 1 1 1 3 1 1 1.5 1 0.5 AG 1 3 1 1 1 1 1 3 1 1 1 3 1 1 1.5 1 0.5
(c)成分 (c) ingredient
ぺ'タイン 1 1 1 1 1 1 1 1 1 1 1 0.5 1 ぺ 'tine 1 1 1 1 1 1 1 1 1 1 1 0.5 1
ES 0.5 0.5 0.3 0.5 エタノ-ル 3 3 5 3 3 3 2 5 5 5 5 2 5 5 2 フ'ロビレンゲリコール 3 5 5 3 3 ES 0.5 0.5 0.3 0.5 Ethanol 3 3 5 3 3 3 2 5 5 5 5 2 5 5 2 Phylobilenguelicol 3 5 5 3 3
(d)成分 5 3 (d) Component 5 3
Jim ブロビレンゲリコ—ルモノメ Jim Brovilengeliko
5 Five
チルエーテル Chill ether
クエリ酸 2 2 2 5 1 1 1 1 2 2 4 2 2 2 2 5 2 2 Query acid 2 2 2 5 1 1 1 1 2 2 4 2 2 2 2 5 2 2
( 成分 (Ingredients
EDTA- 4N a 3 3 3 2 2 5 2 2 2 3 3 3 イオン交換水 残部残部残部残部残部残部残部残部残部残部残部残部残部残部残部残部残部残部残部残部 合計 100 100 100 100 100 100 100 100 100 100 100 1.00 100 100 100 100 100 100 100 100 pH 7 7 11 3 7 7 7 7 7 7 7 7 3 10 7 7 7 3 6 6 易洗浄性 4.0 5.0 5.0 5.0 4.0 5.0 5.0 5.0 4.6 5.0 5.0 5.0 4.6 4.6 5.0 5.0 4.2 4.2 5.0 5.0 汚れ付着防止性 〇 ◎ ◎ ◎ 〇 ◎ ◎ ◎ 〇 ◎ ◎ ◎ ◎ ◎ ◎ ◎ 〇 〇 ◎ ◎ 殺菌性 〇 〇 〇 O 〇 〇 〇 〇 O 〇 〇 〇 〇 o Ο 〇 〇 〇 〇 〇
EDTA- 4N a 3 3 3 2 2 5 2 2 2 3 3 3 Ion-exchanged water Remaining Remaining Remaining Remaining Remaining Remaining Remaining Remaining Remaining Remaining Remaining Remaining Remaining Remaining Remaining Remaining Remaining Total 100 100 100 100 100 100 100 100 100 100 100 1.00 100 100 100 100 100 100 100 100 pH 7 7 11 3 7 7 7 7 7 7 7 7 3 10 7 7 7 3 6 6 Easy cleaning 4.0 5.0 5.0 5.0 4.0 5.0 5.0 5.0 4.6 5.0 5.0 5.0 4.6 4.6 5.0 5.0 4.2 4.2 5.0 5.0 Anti-fouling properties 〇 ◎ ◎ ◎ 〇 ◎ ◎ ◎ 〇 ◎ ◎ ◎ ◎ ◎ ◎ ◎ ◎ 〇 〇 ◎ ◎ Sterilization
瑯 ¾ £ 瑯 ¾
比 ϋ .配合例 Comparison example
1 2 3 4 5 6 フ 重合体 A 1 1 2 3 4 5 6 F Polymer A 1
重合体 B 1 Polymer B 1
(a)成分 (A) component
重合体 C 1 Polymer C 1
重合体 D 1 殺菌性化合物 A 0.1 Polymer D 1 Fungicidal compound A 0.1
殺菌性化合物 B 0.3 Bactericidal compound B 0.3
硬 (b〉成分 Hard (b) component
殺菌 1生化合物 G Sterilization 1 Raw compound G
質配 Pledge
表 ネ ¾_菌1玍化 n物 D 1 1 面成 AO 1 用 分 Table ¾ _ Bacteria monomerized n D 1 1 AO 1
1.5 1 1 殺 ' *~、 1.5 1 1 kill '* ~,
(c)成分 η (c) component η
菌 ヘ メ 1ノ 1 U.0 1 1 防量 ES Bacterium 1 1 U.0 1 1 ES
汚 % Dirty%
エタノ-ル Ethanol
洗 Washing
浄 (d)成分フ'ロビレンゲリコマル 5 ο Pure (d) Ingredients
剤 プロピレンゲリコールモノメ Agent Propylene gericol monomer
チルエーテル Chill ether
クェン酸 1 1 2 2 2 Cuenoic acid 1 1 2 2 2
(e)成分 (e) component
EDTA- 4Na 2 3 . 5 2 イオン交換水 残部残部残部残部残部残部残部 EDTA-4Na 2 3.5 2 Ion-exchanged water Remaining Remaining Remaining Remaining Remaining Remaining Remaining Remaining
C3。丁 100 100 100 100 100 100 100C3. 100 100 100 100 100 100 100
ΡΗ . 7 . 7 7 7 7 7 7 易洗浄性 2.0 1.0 2.0 2.0 2.0 2.0 2.4 汚れ付着防止性 △ X Δ X X X XΡΗ. 7.7 7 7 7 7 7 7 Easy cleaning 2.0 1.0 2.0 2.0 2.0 2.0 2.4 Stain adhesion prevention △ X Δ X X X X
¥£菌性 X X X X 〇 X X
¥ £ Bacterial XXXX 〇 XX
表 2 Table 2
-15-
-15-
Claims
1. (a) 重量平均分子量が 1, 000〜 6, 000, 000であって、 4級アンモニ ゥム基及び 3級ァミノ基より選ばれた少なくとも 1ケの基を有するモノマ一単位をその比 率が全モノマー単位に対して 10~100モル%含む重合体、 (b) 分子量が 1, 000未 満であって、 4級アンモニゥム基を有する殺菌性化合物、 及び (c) 界面活性剤を含有し、 界面活性剤として (cA) 陰イオン界面活性剤を含有する場合、 (cA) / (b) が重量比 率で、 1. 0を越えない硬質表面用殺菌防汚洗浄剤。 1. (a) A monomer unit having a weight average molecular weight of 1,000 to 6,000,000 and having at least one group selected from quaternary ammonium groups and tertiary amino groups (B) a bactericidal compound having a molecular weight of less than 1,000 and having a quaternary ammonium group, and (c) a surfactant. When (cA) an anionic surfactant is contained as a surfactant, a (cA) / (b) weight ratio of (cA) / (b) does not exceed 1.0, which is a bactericidal and antifouling detergent for hard surfaces.
2. (b) が下記式 (1) 〜 (3) で表される化合物から選ばれる少なくとも一種の殺 菌性化合物である請求項 1記載の硬質表面用殺菌防汚洗浄剤。 2. The germicidal and antifouling detergent for hard surfaces according to claim 1, wherein (b) is at least one bactericidal compound selected from the compounds represented by the following formulas (1) to (3).
〔式中、 R1及び R6は、 それぞれ独立して炭素数 6〜18のアルキル基又はアルケニル基 であり、 1 3及び14は、 それぞれ独立して炭素数 1~ 3のアルキル基又はヒドロキシアル キル基である。 Xは芳香環又は— COO—、 一 CONH—、 一OCO—、 —NHCO—か ら選ばれるエステル基あるいはアミド基であり、 R2は、 Xがエステル基又はアミド基であ る場合には水酸基で置換されていてもよい炭素数 1〜 6のアルキレン基であり、 Xが芳香 環の場合には、 水酸基で置換されていてもよい炭素数 1〜6のアルキレン基又は一(O— R n)k—である。 ここで R11はエチレン基又はプロピレン基であり、 kは平均 1〜10の数 である。 R5は炭素数 1〜3のアルキレン ¾である。 !¾7〜1^1 )はこれらの内1っ以上が炭 素数 8~18のアルキル基であり、 残りが炭素数 1~3のアルギル基又はヒドロキシアル キル基である。 また、 mは 0又は 1の数である。 さらに Y—は、 陰イオンである。〕 Wherein, R 1 and R 6 are each independently an alkyl group or alkenyl group having 6 to 18 carbon atoms, 1 3 and 1 4 are each independently alkyl or hydroxyalkyl of 1 to 3 carbon atoms It is an alkyl group. X is an aromatic ring or an ester group or an amide group selected from —COO—, one CONH—, one OCO—, and —NHCO—, and R 2 is a hydroxyl group when X is an ester group or an amide group. And when X is an aromatic ring, an alkylene group having 1 to 6 carbon atoms which may be substituted with a hydroxyl group or one (O—R n ) k —. Here, R 11 is an ethylene group or a propylene group, and k is a number of 1 to 10 on average. R 5 is alkylene having 1 to 3 carbon atoms. ! ¾ 7 to 1 ^ 1) is an alkyl group of 1 Tsu or more of these carbon number 8 to 18, the remainder being Argyle or hydroxy aralkyl kill groups of 1 to 3 carbon atoms. M is a number of 0 or 1. Furthermore, Y— is an anion. ]
3. (a) の 4級アンモニゥム基を有するモノマー単位が下記式 (4) の化合物に由来 する請求項 1記載の硬質表面用殺菌防汚洗浄剤。 3. The germicidal and antifouling detergent for hard surfaces according to claim 1, wherein the monomer unit having a quaternary ammonium group in (a) is derived from a compound represented by the following formula (4).
-16-
〔式中、 R12、 R13、 R14は、 それぞれ独立して、 7K素原子、 水酸基又は炭素数 1~3の アルキル基である。 Xは炭素数 1〜12のアルキレン基、 —COOR18—、 -CONHR1 8—、 一 OCOR18—、 一 R19— OC〇一 R18—から選ばれる基である。 ここで R18、 R 19は、 それぞれ独立して、 炭素数 1〜5のアルキレン基である。 1¾15は炭素数1〜3のァ ルキル基もしくはヒドロキシアルキル基又は R12R13C = C (R14)一 X—である。 R16 は炭素数 1~3のアルキル基、 ヒドロキシアルキル基、 ベンジル基であり、 R 17はヒドロ キシ基、 力ルポキシル基、 スルホン酸基、 硫酸エステル基で置換されていてもよい炭素数 1~10のアルキル基、 又はべンジル基であり、 R17がアルキル基、 ヒドロキシアルキル 基、 又はべンジル基の場合は、 Y—は陰イオンを示す。〕 -16- [Wherein, R 12 , R 13 and R 14 are each independently a 7K element atom, a hydroxyl group or an alkyl group having 1 to 3 carbon atoms. X is an alkylene group having 1 to 12 carbon atoms, -COOR 18 -, -CONHR 1 8 - one OCOR 18 - a group selected from - one R 19 - OC_〇 one R 18. Here, R 18 and R 19 are each independently an alkylene group having 1 to 5 carbon atoms. 1 to 15 are an alkyl group or hydroxyalkyl group having 1 to 3 carbon atoms or R 12 R 13 C = C (R 14 ) -X—. R 16 is an alkyl group having 1 to 3 carbon atoms, a hydroxyalkyl group, or a benzyl group; and R 17 is a C 1 to C 3 group which may be substituted with a hydroxy group, a carbonyl group, a sulfonic acid group, or a sulfate group. When R 17 is an alkyl group, a hydroxyalkyl group, or a benzyl group, Y— represents an anion. ]
4. (a) の 3級アミノ基を有するモノマー単位が下記式 (5) で示される化合物に由 来する請求項 1記載の硬質表面用殺菌防汚洗浄剤。 4. The germicidal and antifouling detergent for hard surfaces according to claim 1, wherein the monomer unit having a tertiary amino group in (a) is derived from a compound represented by the following formula (5).
R15 (5) R 15 (5)
R12R13c_cf R14 ノ R 12 R 13 c _ cf R 14 no
■X— N ■ X—N
R16 R 16
[式中、 R.12、 R13、 R14、 R15及び R16は、 前記記載と同じ。〕 Wherein, R. 12, R 13, R 14, R 15 and R 16 are the same as above described. ]
5. (a) 成分の重合体が 4級アンモニゥム基及び 3級ァミノ基より選ばれた少なく とも 1ケの基を有するモノマ一単位 A及びカルボン酸基およびスルホン酸基から選ばれた 少なくとも 1つの基を有する [但し 4級アンモニゥム基を有さない] モノマー単位 B' を 含み、 かつモノマ一単位 Aと B, の合計が全モノマー単位に対して 50~100モル%を 占める重合体である請求項 1記載の硬質表面用殺菌防汚洗浄剤。 5. (a) The polymer of component is a monomer unit A having at least one group selected from quaternary ammonium groups and tertiary amino groups, and at least one selected from carboxylic acid groups and sulfonic acid groups. Is a polymer containing a monomer unit B 'having a group [but not having a quaternary ammonium group] and wherein the sum of monomer units A and B accounts for 50 to 100 mol% of all monomer units. Item 6. The sterilizing and antifouling detergent for hard surfaces according to Item 1.
6. (a)成分を 0. 01~30重量%、 (b)成分を 0. 001 ~ 30重量%及び( c ) 成分を 0. 01〜 50重量%含有する請求項 1記載の硬質表面用殺菌防汚洗狰剤。 6. The hard surface according to claim 1, wherein the component (a) contains 0.01 to 30% by weight, the component (b) contains 0.001 to 30% by weight, and the component (c) contains 0.01 to 50% by weight. Sterilizing and antifouling detergent.
7. 請求項 1に記載した辑成物を硬質表面に適用することにより硬質表面を洗浄し殺 菌し、 そして硬質表面への汚れの付着を防止する方法。 7. A method for cleaning and disinfecting a hard surface by applying the composition according to claim 1 to the hard surface and preventing adhesion of dirt to the hard surface.
8. 請求項 1に記載した組成物を硬質表面を洗铮し、 殺菌しそして硬質表面への汚れ の付着を防止する用途。 8. Use of the composition according to claim 1 for cleaning and disinfecting hard surfaces and preventing the adhesion of dirt to hard surfaces.
■ 17-
■ 17-
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-252284 | 2000-08-23 | ||
JP2000252284A JP2002060786A (en) | 2000-08-23 | 2000-08-23 | Germicidal stainproofing agent for hard surface |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002016536A1 true WO2002016536A1 (en) | 2002-02-28 |
Family
ID=18741548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/006869 WO2002016536A1 (en) | 2000-08-23 | 2001-08-09 | Bactericidal antifouling detergent for hard surface |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP2002060786A (en) |
TW (1) | TWI283267B (en) |
WO (1) | WO2002016536A1 (en) |
Cited By (270)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003070866A1 (en) * | 2002-02-22 | 2003-08-28 | Kao Corporation | Antifouling detergent for hard surfaces |
WO2005014791A2 (en) | 2003-08-08 | 2005-02-17 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
JP2005232241A (en) * | 2004-02-18 | 2005-09-02 | Toyo Aluminium Foil Products Kk | Coating agent for removing greasy dirt |
US7544649B2 (en) | 2002-02-22 | 2009-06-09 | Kao Corporation | Antifouling detergent for hard surfaces |
WO2009151591A2 (en) | 2008-06-10 | 2009-12-17 | Sangamo Biosciences, Inc. | Methods and compositions for generation of bax- and bak-deficient cell lines |
WO2010021692A1 (en) | 2008-08-22 | 2010-02-25 | Sangamo Biosciences, Inc. | Methods and compositions for targeted single-stranded cleavage and targeted integration |
WO2010065123A1 (en) | 2008-12-04 | 2010-06-10 | Sangamo Biosciences, Inc. | Genome editing in rats using zinc-finger nucleases |
WO2010077319A1 (en) | 2008-12-17 | 2010-07-08 | Dow Agrosciences Llc | Targeted integration into the zp15 locus |
EP2206782A1 (en) | 2006-05-25 | 2010-07-14 | Sangamo BioSciences, Inc. | Methods and compositions for gene inactivation |
EP2213731A1 (en) | 2006-05-25 | 2010-08-04 | Sangamo BioSciences, Inc. | Variant foki cleavage half-domains |
WO2010090744A1 (en) | 2009-02-04 | 2010-08-12 | Sangamo Biosciences, Inc. | Methods and compositions for treating neuropathies |
WO2011002503A1 (en) | 2009-06-30 | 2011-01-06 | Sangamo Biosciences, Inc. | Rapid screening of biologically active nucleases and isolation of nuclease-modified cells |
EP2292274A1 (en) | 2004-09-16 | 2011-03-09 | Sangamo BioSciences, Inc. | Compositions and methods for protein production |
US7919313B2 (en) | 2007-07-12 | 2011-04-05 | Sangamo Biosciences, Inc. | Methods and compositions for inactivating alpha 1,6 fucosyltransferase (FUT8) gene expression |
WO2011048600A1 (en) | 2009-10-21 | 2011-04-28 | Danziger Innovations Ltd. | Generating genotypic variations in plant genomes by gamete infection |
EP2395081A1 (en) | 2006-08-11 | 2011-12-14 | Dow AgroSciences LLC | Zinc finger nuclease-mediated homologous recombination |
WO2012012667A2 (en) | 2010-07-21 | 2012-01-26 | Sangamo Biosciences, Inc. | Methods and compositions for modification of a hla locus |
EP2412812A1 (en) | 2006-12-14 | 2012-02-01 | Dow AgroSciences LLC | Optimized non-canonical zinc finger proteins |
US8110379B2 (en) | 2007-04-26 | 2012-02-07 | Sangamo Biosciences, Inc. | Targeted integration into the PPP1R12C locus |
US8153399B2 (en) | 2008-10-29 | 2012-04-10 | Sangamo Biosciences, Inc. | Methods and compositions for inactivating glutamine synthetase gene expression |
WO2012047598A1 (en) | 2010-09-27 | 2012-04-12 | Sangamo Biosciences, Inc. | Methods and compositions for inhibiting viral entry into cells |
WO2012051343A1 (en) | 2010-10-12 | 2012-04-19 | The Children's Hospital Of Philadelphia | Methods and compositions for treating hemophilia b |
US8313925B2 (en) | 2005-07-26 | 2012-11-20 | Sangamo Biosciences, Inc. | Zinc finger proteins and method for inactivating a dhfr gene in a chinese hamster ovary cell |
US8399218B2 (en) | 2007-09-27 | 2013-03-19 | Dow Agrosciences, Llc | Engineered zinc finger proteins targeting 5-enolpyruvyl shikimate-3-phosphate synthase genes |
WO2013044008A2 (en) | 2011-09-21 | 2013-03-28 | Sangamo Biosciences, Inc. | Methods and compositions for regulation of transgene expression |
EP2597155A1 (en) | 2007-10-25 | 2013-05-29 | Sangamo BioSciences, Inc. | Methods and compositions for targeted integration |
EP2615106A1 (en) | 2010-02-08 | 2013-07-17 | Sangamo BioSciences, Inc. | Engineered cleavage half-domains |
WO2013130824A1 (en) | 2012-02-29 | 2013-09-06 | Sangamo Biosciences, Inc. | Methods and compositions for treating huntington's disease |
US8563314B2 (en) | 2007-09-27 | 2013-10-22 | Sangamo Biosciences, Inc. | Methods and compositions for modulating PD1 |
EP2660318A1 (en) | 2010-02-09 | 2013-11-06 | Sangamo BioSciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
WO2013166315A1 (en) | 2012-05-02 | 2013-11-07 | Dow Agrosciences Llc | Targeted modification of malate dehydrogenase |
WO2013169802A1 (en) | 2012-05-07 | 2013-11-14 | Sangamo Biosciences, Inc. | Methods and compositions for nuclease-mediated targeted integration of transgenes |
US8592645B2 (en) | 2009-10-22 | 2013-11-26 | Dow Agrosciences Llc | Engineered zinc finger proteins targeting plant genes involved in fatty acid biosynthesis |
WO2014011901A2 (en) | 2012-07-11 | 2014-01-16 | Sangamo Biosciences, Inc. | Methods and compositions for delivery of biologics |
WO2014011237A1 (en) | 2012-07-11 | 2014-01-16 | Sangamo Biosciences, Inc. | Methods and compositions for the treatment of lysosomal storage diseases |
WO2014036219A2 (en) | 2012-08-29 | 2014-03-06 | Sangamo Biosciences, Inc. | Methods and compositions for treatment of a genetic condition |
WO2014039692A2 (en) | 2012-09-07 | 2014-03-13 | Dow Agrosciences Llc | Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
WO2014039872A1 (en) | 2012-09-07 | 2014-03-13 | Dow Agrosciences Llc | Engineered transgene integration platform (etip) for gene targeting and trait stacking |
WO2014059173A2 (en) | 2012-10-10 | 2014-04-17 | Sangamo Biosciences, Inc. | T cell modifying compounds and uses thereof |
EP2727600A1 (en) | 2009-07-28 | 2014-05-07 | Sangamo BioSciences, Inc. | Methods and compositions for treating trinucleotide repeat disorders |
US8772008B2 (en) | 2009-05-18 | 2014-07-08 | Sangamo Biosciences, Inc. | Methods and compositions for increasing nuclease activity |
US8771985B2 (en) | 2010-04-26 | 2014-07-08 | Sangamo Biosciences, Inc. | Genome editing of a Rosa locus using zinc-finger nucleases |
US8772453B2 (en) | 2010-05-03 | 2014-07-08 | Sangamo Biosciences, Inc. | Compositions for linking zinc finger modules |
WO2014130955A1 (en) | 2013-02-25 | 2014-08-28 | Sangamo Biosciences, Inc. | Methods and compositions for enhancing nuclease-mediated gene disruption |
WO2014165612A2 (en) | 2013-04-05 | 2014-10-09 | Dow Agrosciences Llc | Methods and compositions for integration of an exogenous sequence within the genome of plants |
US8871905B2 (en) | 2009-03-20 | 2014-10-28 | Sangamo Biosciences, Inc. | Modification of CXCR4 using engineered zinc finger proteins |
US8895264B2 (en) | 2011-10-27 | 2014-11-25 | Sangamo Biosciences, Inc. | Methods and compositions for modification of the HPRT locus |
US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
WO2015031619A1 (en) | 2013-08-28 | 2015-03-05 | Sangamo Biosciences, Inc. | Compositions for linking dna-binding domains and cleavage domains |
WO2015057976A1 (en) | 2013-10-17 | 2015-04-23 | Sangamo Biosciences, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells |
WO2015057980A1 (en) | 2013-10-17 | 2015-04-23 | Sangamo Biosciences, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
WO2015066643A1 (en) | 2013-11-04 | 2015-05-07 | Dow Agrosciences Llc | Optimal soybean loci |
WO2015066636A2 (en) | 2013-11-04 | 2015-05-07 | Dow Agrosciences Llc | Optimal maize loci |
WO2015066638A2 (en) | 2013-11-04 | 2015-05-07 | Dow Agrosciences Llc | Optimal maize loci |
WO2015070212A1 (en) | 2013-11-11 | 2015-05-14 | Sangamo Biosciences, Inc. | Methods and compositions for treating huntington's disease |
US9045763B2 (en) | 2005-07-26 | 2015-06-02 | Sangamo Biosciences, Inc. | Linear donor constructs for targeted integration |
WO2015117081A2 (en) | 2014-02-03 | 2015-08-06 | Sangamo Biosciences, Inc. | Methods and compositions for treatment of a beta thalessemia |
WO2015130931A1 (en) | 2014-02-28 | 2015-09-03 | Dow Agrosciences Llc | Root specific expression conferred by chimeric gene regulatory elements |
WO2015143046A2 (en) | 2014-03-18 | 2015-09-24 | Sangamo Biosciences, Inc. | Methods and compositions for regulation of zinc finger protein expression |
US9161995B2 (en) | 2011-07-25 | 2015-10-20 | Sangamo Biosciences, Inc. | Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (CFTR) gene |
EP2936976A1 (en) | 2008-04-21 | 2015-10-28 | Danziger Innovations Ltd. | Plant viral expression vectors and use of same for generating genotypic variations in plant genomes |
EP2947146A1 (en) | 2004-02-05 | 2015-11-25 | Sangamo BioSciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US9217026B2 (en) | 2006-11-13 | 2015-12-22 | Sangamo Biosciences, Inc. | Method of inactivating a glucocorticoid receptor gene in an isolated cell |
WO2016005449A1 (en) | 2014-07-08 | 2016-01-14 | Vib Vzw | Means and methods to increase plant yield |
WO2016011381A1 (en) | 2014-07-18 | 2016-01-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Reducing cxcr4 expression and/or function to enhance engraftment of hematopoietic stem cells |
WO2016011029A2 (en) | 2014-07-14 | 2016-01-21 | Washington State University | Nanos knock-out that ablates germline cells |
US9249428B2 (en) | 2003-08-08 | 2016-02-02 | Sangamo Biosciences, Inc. | Methods and compositions for targeted genomic deletion |
US9255250B2 (en) | 2012-12-05 | 2016-02-09 | Sangamo Bioscience, Inc. | Isolated mouse or human cell having an exogenous transgene in an endogenous albumin gene |
US9267123B2 (en) | 2011-01-05 | 2016-02-23 | Sangamo Biosciences, Inc. | Methods and compositions for gene correction |
WO2016044416A1 (en) | 2014-09-16 | 2016-03-24 | Sangamo Biosciences, Inc. | Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells |
US9394531B2 (en) | 2008-05-28 | 2016-07-19 | Sangamo Biosciences, Inc. | Compositions for linking DNA-binding domains and cleavage domains |
WO2016118726A2 (en) | 2015-01-21 | 2016-07-28 | Sangamo Biosciences, Inc. | Methods and compositions for identification of highly specific nucleases |
US9458205B2 (en) | 2011-11-16 | 2016-10-04 | Sangamo Biosciences, Inc. | Modified DNA-binding proteins and uses thereof |
WO2016161446A1 (en) | 2015-04-03 | 2016-10-06 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b-cells |
WO2016168229A1 (en) | 2015-04-15 | 2016-10-20 | Dow Agrosciences Llc | Plant promoter for transgene expression |
WO2016168230A2 (en) | 2015-04-15 | 2016-10-20 | Dow Agrosciences Llc | Plant promoter for transgene expression |
WO2016178207A1 (en) | 2015-05-04 | 2016-11-10 | Ramot At Tel-Aviv University Ltd. | Methods and kits for fragmenting dna |
US9506120B2 (en) | 2007-09-27 | 2016-11-29 | Sangamo Biosciences, Inc. | Rapid in vivo identification of biologically active nucleases |
WO2016196388A1 (en) | 2015-05-29 | 2016-12-08 | Juno Therapeutics, Inc. | Composition and methods for regulating inhibitory interactions in genetically engineered cells |
WO2017011519A1 (en) | 2015-07-13 | 2017-01-19 | Sangamo Biosciences, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
WO2017023570A1 (en) | 2015-08-06 | 2017-02-09 | The Curators Of The University Of Missouri | Pathogen-resistant animals having modified cd163 genes |
US9574211B2 (en) | 2014-05-13 | 2017-02-21 | Sangamo Biosciences, Inc. | Methods and compositions for prevention or treatment of a disease |
WO2017053164A1 (en) | 2015-09-22 | 2017-03-30 | Dow Agrosciences Llc | Plant promoter and 3' utr for transgene expression |
US9616090B2 (en) | 2014-07-30 | 2017-04-11 | Sangamo Biosciences, Inc. | Gene correction of SCID-related genes in hematopoietic stem and progenitor cells |
EP3156504A1 (en) | 2009-08-11 | 2017-04-19 | Sangamo BioSciences, Inc. | Organisms homozygous for targeted modification |
WO2017070298A1 (en) | 2015-10-22 | 2017-04-27 | Dow Agrosciences Llc | Plant promoter for transgene expression |
WO2017079673A1 (en) | 2015-11-04 | 2017-05-11 | Fate Therapeutics, Inc. | Genomic engineering of pluripotent cells |
WO2017078935A1 (en) | 2015-11-04 | 2017-05-11 | Dow Agrosciences Llc | Plant promoter for transgene expression |
WO2017106537A2 (en) | 2015-12-18 | 2017-06-22 | Sangamo Biosciences, Inc. | Targeted disruption of the mhc cell receptor |
WO2017106528A2 (en) | 2015-12-18 | 2017-06-22 | Sangamo Biosciences, Inc. | Targeted disruption of the t cell receptor |
WO2017123757A1 (en) | 2016-01-15 | 2017-07-20 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of neurologic disease |
US9757420B2 (en) | 2014-07-25 | 2017-09-12 | Sangamo Therapeutics, Inc. | Gene editing for HIV gene therapy |
US9771403B2 (en) | 2013-12-09 | 2017-09-26 | Sangamo Therapeutics, Inc. | Methods and compositions for treating hemophilia |
WO2017165655A1 (en) | 2016-03-23 | 2017-09-28 | Dana-Farber Cancer Institute, Inc. | Methods for enhancing the efficiency of gene editing |
WO2017180180A2 (en) | 2015-09-22 | 2017-10-19 | Dow Agrosciences Llc | Plant promoter and 3' utr for transgene expression |
US9816074B2 (en) | 2014-07-25 | 2017-11-14 | Sangamo Therapeutics, Inc. | Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells |
US9834787B2 (en) | 2009-04-09 | 2017-12-05 | Sangamo Therapeutics, Inc. | Targeted integration into stem cells |
WO2018005559A1 (en) | 2016-06-27 | 2018-01-04 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
WO2018005556A1 (en) | 2016-06-27 | 2018-01-04 | Juno Therapeutics, Inc. | Mhc-e restricted epitopes, binding molecules and related methods and uses |
WO2018013840A1 (en) | 2016-07-13 | 2018-01-18 | Vertex Pharmaceuticals Incorporated | Methods, compositions and kits for increasing genome editing efficiency |
US9873894B2 (en) | 2013-05-15 | 2018-01-23 | Sangamo Therapeutics, Inc. | Methods and compositions for treatment of a genetic condition |
WO2018029034A1 (en) | 2016-08-09 | 2018-02-15 | Vib Vzw | Cellulose synthase inhibitors and mutant plants |
WO2018039448A1 (en) | 2016-08-24 | 2018-03-01 | Sangamo Therapeutics, Inc. | Engineered target specific nucleases |
WO2018039440A1 (en) | 2016-08-24 | 2018-03-01 | Sangamo Therapeutics, Inc. | Regulation of gene expression using engineered nucleases |
US9914930B2 (en) | 2012-09-07 | 2018-03-13 | Dow Agrosciences Llc | FAD3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
US9932607B2 (en) | 2013-11-15 | 2018-04-03 | The Board Of Trustees Of The Leland Stanford Junior University | Site-specific integration of transgenes into human cells |
US9937207B2 (en) | 2013-03-21 | 2018-04-10 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell receptor genes using talens |
WO2018067826A1 (en) | 2016-10-05 | 2018-04-12 | Cellular Dynamics International, Inc. | Generating mature lineages from induced pluripotent stem cells with mecp2 disruption |
WO2018067265A1 (en) | 2016-10-03 | 2018-04-12 | Dow Agrosciences Llc | Plant promoter for transgene expression |
WO2018067264A1 (en) | 2016-10-03 | 2018-04-12 | Dow Agrosciences Llc | Plant promoter for transgene expression |
WO2018067618A1 (en) | 2016-10-03 | 2018-04-12 | Juno Therapeutics, Inc. | Hpv-specific binding molecules |
WO2018071873A2 (en) | 2016-10-13 | 2018-04-19 | Juno Therapeutics, Inc. | Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators |
US9957501B2 (en) | 2015-06-18 | 2018-05-01 | Sangamo Therapeutics, Inc. | Nuclease-mediated regulation of gene expression |
WO2018081775A1 (en) | 2016-10-31 | 2018-05-03 | Sangamo Therapeutics, Inc. | Gene correction of scid-related genes in hematopoietic stem and progenitor cells |
US9970001B2 (en) | 2014-06-05 | 2018-05-15 | Sangamo Therapeutics, Inc. | Methods and compositions for nuclease design |
WO2018102612A1 (en) | 2016-12-02 | 2018-06-07 | Juno Therapeutics, Inc. | Engineered b cells and related compositions and methods |
WO2018106782A1 (en) | 2016-12-08 | 2018-06-14 | Case Western Reserve University | Methods and compositions for enhancing functional myelin production |
WO2018106732A1 (en) | 2016-12-05 | 2018-06-14 | Juno Therapeutics, Inc. | Production of engineered cells for adoptive cell therapy |
WO2018195418A1 (en) | 2017-04-20 | 2018-10-25 | Oregon Health & Science University | Human gene correction |
US10179918B2 (en) | 2015-05-07 | 2019-01-15 | Sangamo Therapeutics, Inc. | Methods and compositions for increasing transgene activity |
GB201820109D0 (en) | 2018-12-11 | 2019-01-23 | Vib Vzw | Plants with a lignin trait and udp-glycosyltransferase mutation |
US10233465B2 (en) | 2013-11-04 | 2019-03-19 | Dow Agrosciences Llc | Optimal soybean loci |
WO2019070541A1 (en) | 2017-10-03 | 2019-04-11 | Juno Therapeutics, Inc. | Hpv-specific binding molecules |
US10260062B2 (en) | 2010-01-22 | 2019-04-16 | Sangamo Therapeutics, Inc. | Targeted genomic alteration |
WO2019089982A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
EP3492593A1 (en) | 2013-11-13 | 2019-06-05 | Children's Medical Center Corporation | Nuclease-mediated regulation of gene expression |
WO2019143677A1 (en) | 2018-01-17 | 2019-07-25 | Vertex Pharmaceuticals Incorporated | Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency |
WO2019143675A1 (en) | 2018-01-17 | 2019-07-25 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
WO2019143678A1 (en) | 2018-01-17 | 2019-07-25 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
US10370680B2 (en) | 2014-02-24 | 2019-08-06 | Sangamo Therapeutics, Inc. | Method of treating factor IX deficiency using nuclease-mediated targeted integration |
US10415046B2 (en) | 2012-12-13 | 2019-09-17 | Dow Agrosciences Llc | Precision gene targeting to a particular locus in maize |
WO2019191495A1 (en) | 2018-03-29 | 2019-10-03 | Fate Therapeutics, Inc. | Engineered immune effector cells and use thereof |
US10435441B2 (en) | 2015-09-23 | 2019-10-08 | Sangamo Therapeutics, Inc. | HTT repressors and uses thereof |
WO2019195491A1 (en) | 2018-04-05 | 2019-10-10 | Juno Therapeutics, Inc. | T cells expressing a recombinant receptor, related polynucleotides and methods |
WO2019195492A1 (en) | 2018-04-05 | 2019-10-10 | Juno Therapeutics, Inc. | Methods of producing cells expressing a recombinant receptor and related compositions |
WO2019215500A1 (en) | 2018-05-11 | 2019-11-14 | Crispr Therapeutics Ag | Methods and compositions for treating cancer |
WO2019234750A1 (en) | 2018-06-07 | 2019-12-12 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Methods of regenerating and transforming cannabis |
WO2019234141A1 (en) | 2018-06-06 | 2019-12-12 | Vib Vzw | NOVEL MUTANT PLANT CINNAMOYL-CoA REDUCTASE PROTEINS |
WO2019234754A1 (en) | 2018-06-07 | 2019-12-12 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Nucleic acid constructs and methods of using same |
US10507232B2 (en) | 2014-04-02 | 2019-12-17 | University Of Florida Research Foundation, Incorporated | Materials and methods for the treatment of latent viral infection |
US10612041B2 (en) | 2014-03-21 | 2020-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Genome editing without nucleases |
US10626372B1 (en) | 2015-01-26 | 2020-04-21 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
US10639383B2 (en) | 2015-11-23 | 2020-05-05 | Sangamo Therapeutics, Inc. | Methods and compositions for engineering immunity |
US10648001B2 (en) | 2012-07-11 | 2020-05-12 | Sangamo Therapeutics, Inc. | Method of treating mucopolysaccharidosis type I or II |
WO2020095248A1 (en) | 2018-11-07 | 2020-05-14 | Crispr Therapeutics Ag | Anti-ptk7 immune cell cancer therapy |
WO2020095249A1 (en) | 2018-11-07 | 2020-05-14 | Crispr Therapeutics Ag | Anti-liv1 immune cell cancer therapy |
WO2020095107A1 (en) | 2018-11-07 | 2020-05-14 | Crispr Therapeutics Ag | Anti-cd33 immune cell cancer therapy |
WO2020118073A1 (en) | 2018-12-05 | 2020-06-11 | Vertex Pharmaceuticals Incorporated | Gene-editing systems for editing a cystic fibrosis transmembrane regulator (cftr) gene |
US10724020B2 (en) | 2016-02-02 | 2020-07-28 | Sangamo Therapeutics, Inc. | Compositions for linking DNA-binding domains and cleavage domains |
US10738278B2 (en) | 2014-07-15 | 2020-08-11 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
WO2020185628A1 (en) | 2019-03-08 | 2020-09-17 | Obsidian Therapeutics, Inc. | Cd40l compositions and methods for tunable regulation |
US10786533B2 (en) | 2015-07-15 | 2020-09-29 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
WO2020205838A1 (en) | 2019-04-02 | 2020-10-08 | Sangamo Therapeutics, Inc. | Methods for the treatment of beta-thalassemia |
US10808020B2 (en) | 2015-05-12 | 2020-10-20 | Sangamo Therapeutics, Inc. | Nuclease-mediated regulation of gene expression |
WO2020219726A1 (en) | 2019-04-23 | 2020-10-29 | Sangamo Therapeutics, Inc. | Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof |
WO2020223571A1 (en) | 2019-05-01 | 2020-11-05 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods |
WO2020223535A1 (en) | 2019-05-01 | 2020-11-05 | Juno Therapeutics, Inc. | Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods |
US10858628B2 (en) | 2015-11-04 | 2020-12-08 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
WO2020261219A1 (en) | 2019-06-27 | 2020-12-30 | Crispr Therapeutics Ag | Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer |
US10889834B2 (en) | 2014-12-15 | 2021-01-12 | Sangamo Therapeutics, Inc. | Methods and compositions for enhancing targeted transgene integration |
WO2021022223A1 (en) | 2019-08-01 | 2021-02-04 | Sana Biotechnology, Inc. | Dux4 expressing cells and uses thereof |
US10927346B2 (en) | 2017-12-22 | 2021-02-23 | Fate Therapeutics, Inc. | Enhanced immune effector cells and use thereof |
WO2021041316A1 (en) | 2019-08-23 | 2021-03-04 | Sana Biotechnology, Inc. | Cd24 expressing cells and uses thereof |
WO2021044378A1 (en) | 2019-09-06 | 2021-03-11 | Crispr Therapeutics Ag | Genetically engineered t cells having improved persistence in culture |
US10960085B2 (en) | 2016-09-07 | 2021-03-30 | Sangamo Therapeutics, Inc. | Modulation of liver genes |
WO2021067871A1 (en) | 2019-10-02 | 2021-04-08 | Sangamo Therapeutics, Inc. | Zinc finger protein transcription factors for repressing alpha-synuclein expression |
WO2021067864A1 (en) | 2019-10-02 | 2021-04-08 | Sangamo Therapeutics, Inc. | Zinc finger protein transcription factors for treatment of prion disease |
WO2021087366A1 (en) | 2019-11-01 | 2021-05-06 | Sangamo Therapeutics, Inc. | Compositions and methods for genome engineering |
WO2021087358A1 (en) | 2019-11-01 | 2021-05-06 | Sangamo Therapeutics, Inc. | Gin recombinase variants |
EP3839050A2 (en) | 2012-04-18 | 2021-06-23 | The Board of Trustees of the Leland Stanford Junior University | Non-disruptive gene targeting |
EP3838287A2 (en) | 2016-07-27 | 2021-06-23 | Case Western Reserve University | Compounds and methods of promoting myelination |
WO2021142376A1 (en) | 2020-01-08 | 2021-07-15 | Obsidian Therapeutics, Inc. | Compositions and methods for tunable regulation of transcription |
WO2021151012A1 (en) | 2020-01-22 | 2021-07-29 | Sangamo Therapeutics, Inc. | Zinc finger protein transcription factors for repressing tau expression |
WO2021155065A1 (en) | 2020-01-28 | 2021-08-05 | The Broad Institute, Inc. | Base editors, compositions, and methods for modifying the mitochondrial genome |
US11110154B2 (en) | 2014-05-08 | 2021-09-07 | Sangamo Therapeutics, Inc. | Methods and compositions for treating Huntington's Disease |
WO2021195426A1 (en) | 2020-03-25 | 2021-09-30 | Sana Biotechnology, Inc. | Hypoimmunogenic neural cells for the treatment of neurological disorders and conditions |
US11155796B2 (en) | 2015-02-09 | 2021-10-26 | Duke University | Compositions and methods for epigenome editing |
WO2021224395A1 (en) | 2020-05-06 | 2021-11-11 | Cellectis S.A. | Methods for targeted insertion of exogenous sequences in cellular genomes |
WO2021224416A1 (en) | 2020-05-06 | 2021-11-11 | Cellectis S.A. | Methods to genetically modify cells for delivery of therapeutic proteins |
WO2021231661A2 (en) | 2020-05-13 | 2021-11-18 | Juno Therapeutics, Inc. | Process for producing donor-batched cells expressing a recombinant receptor |
WO2021236852A1 (en) | 2020-05-20 | 2021-11-25 | Sana Biotechnology, Inc. | Methods and compositions for treatment of viral infections |
WO2021247836A1 (en) | 2020-06-03 | 2021-12-09 | Board Of Regents, The University Of Texas System | Methods for targeting shp-2 to overcome resistance |
WO2021260186A1 (en) | 2020-06-26 | 2021-12-30 | Juno Therapeutics Gmbh | Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods |
US11219695B2 (en) | 2016-10-20 | 2022-01-11 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of Fabry disease |
US11235026B2 (en) | 2007-09-27 | 2022-02-01 | Sangamo Therapeutics, Inc. | Methods and compositions for modulating PD1 |
WO2022036150A1 (en) | 2020-08-13 | 2022-02-17 | Sana Biotechnology, Inc. | Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions |
WO2022046760A2 (en) | 2020-08-25 | 2022-03-03 | Kite Pharma, Inc. | T cells with improved functionality |
WO2022064428A1 (en) | 2020-09-23 | 2022-03-31 | Crispr Therapeutics Ag | Genetically engineered t cells with regnase-1 and/or tgfbrii disruption have improved functionality and persistence |
WO2022067122A1 (en) | 2020-09-25 | 2022-03-31 | Sangamo Therapeutics, Inc. | Zinc finger fusion proteins for nucleobase editing |
WO2022072826A1 (en) | 2020-10-02 | 2022-04-07 | Sangamo Therapeutics, Inc. | Novel zinc finger protein transcription factors for repressing alpha-synuclein expression |
WO2022098787A1 (en) | 2020-11-04 | 2022-05-12 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods |
WO2022101641A1 (en) | 2020-11-16 | 2022-05-19 | Pig Improvement Company Uk Limited | Influenza a-resistant animals having edited anp32 genes |
WO2022120334A1 (en) | 2020-12-03 | 2022-06-09 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
WO2022137181A1 (en) | 2020-12-23 | 2022-06-30 | Crispr Therapeutics Ag | Co-use of lenalidomide with car-t cells |
WO2022146891A2 (en) | 2020-12-31 | 2022-07-07 | Sana Biotechnology, Inc. | Methods and compositions for modulating car-t activity |
US11401512B2 (en) | 2018-02-08 | 2022-08-02 | Sangamo Therapeutics, Inc. | Engineered target specific nucleases |
US11421007B2 (en) | 2018-04-18 | 2022-08-23 | Sangamo Therapeutics, Inc. | Zinc finger protein compositions for modulation of huntingtin (Htt) |
WO2022189967A1 (en) | 2021-03-09 | 2022-09-15 | Crispr Therapeutics Ag | Genetically engineered t cells with ptpn2 knockout have improved functionality and anti-tumor activity |
US11453639B2 (en) | 2019-01-11 | 2022-09-27 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
WO2022204071A1 (en) | 2021-03-22 | 2022-09-29 | Juno Therapeutics, Inc. | Method to assess potency of viral vector particles |
WO2022216524A1 (en) | 2021-04-07 | 2022-10-13 | Century Therapeutics, Inc. | Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof |
WO2022216514A1 (en) | 2021-04-07 | 2022-10-13 | Century Therapeutics, Inc. | Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells |
WO2022216624A1 (en) | 2021-04-07 | 2022-10-13 | Century Therapeutics, Inc. | Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells |
US11471489B2 (en) | 2018-04-05 | 2022-10-18 | Juno Therapeutics, Inc. | T cell receptors and engineered cells expressing same |
WO2022235911A1 (en) | 2021-05-05 | 2022-11-10 | FUJIFILM Cellular Dynamics, Inc. | Methods and compositions for ipsc-derived microglia |
US11504389B2 (en) | 2016-12-01 | 2022-11-22 | Sangamo Therapeutics, Inc. | Tau modulators and methods and compositions for delivery thereof |
US11512287B2 (en) | 2017-06-16 | 2022-11-29 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell and/or HLA receptors |
WO2022251443A1 (en) | 2021-05-26 | 2022-12-01 | FUJIFILM Cellular Dynamics, Inc. | Methods to prevent rapid silencing of genes in pluripotent stem cells |
WO2022251367A1 (en) | 2021-05-27 | 2022-12-01 | Sana Biotechnology, Inc. | Hypoimmunogenic cells comprising engineered hla-e or hla-g |
WO2023287827A2 (en) | 2021-07-14 | 2023-01-19 | Sana Biotechnology, Inc. | Altered expression of y chromosome-linked antigens in hypoimmunogenic cells |
WO2023010135A1 (en) | 2021-07-30 | 2023-02-02 | Tune Therapeutics, Inc. | Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) |
WO2023010133A2 (en) | 2021-07-30 | 2023-02-02 | Tune Therapeutics, Inc. | Compositions and methods for modulating expression of frataxin (fxn) |
WO2023019225A2 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions |
WO2023019226A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy |
WO2023019203A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Inducible systems for altering gene expression in hypoimmunogenic cells |
WO2023019229A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified primary cells for allogeneic cell therapy |
WO2023019227A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions |
WO2023039567A2 (en) | 2021-09-10 | 2023-03-16 | FUJIFILM Cellular Dynamics, Inc. | Compositions of induced pluripotent stem cell-derived cells and methods of use thereof |
WO2023042079A1 (en) | 2021-09-14 | 2023-03-23 | Crispr Therapeutics Ag | Genetically engineered immune cells having a disrupted cd83 gene |
WO2023070019A1 (en) | 2021-10-21 | 2023-04-27 | Vertex Pharmaceuticals Incorporated | Hypoimmune cells |
WO2023069790A1 (en) | 2021-10-22 | 2023-04-27 | Sana Biotechnology, Inc. | Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods |
WO2023076880A1 (en) | 2021-10-25 | 2023-05-04 | Board Of Regents, The University Of Texas System | Foxo1-targeted therapy for the treatment of cancer |
WO2023077050A1 (en) | 2021-10-29 | 2023-05-04 | FUJIFILM Cellular Dynamics, Inc. | Dopaminergic neurons comprising mutations and methods of use thereof |
WO2023081900A1 (en) | 2021-11-08 | 2023-05-11 | Juno Therapeutics, Inc. | Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods |
US11655275B2 (en) | 2017-05-03 | 2023-05-23 | Sangamo Therapeutics, Inc. | Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene |
US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
US11661611B2 (en) | 2017-11-09 | 2023-05-30 | Sangamo Therapeutics, Inc. | Genetic modification of cytokine inducible SH2-containing protein (CISH) gene |
WO2023105244A1 (en) | 2021-12-10 | 2023-06-15 | Pig Improvement Company Uk Limited | Editing tmprss2/4 for disease resistance in livestock |
WO2023111913A1 (en) | 2021-12-15 | 2023-06-22 | Crispr Therapeutics Ag | Engineered anti-liv1 cell with regnase-1 and/or tgfbrii disruption |
WO2023119201A2 (en) | 2021-12-22 | 2023-06-29 | Crispr Therapeutics Ag | Genetically engineered t cells with disrupted casitas b-lineage lymphoma proto-oncogene-b (cblb) and uses thereof |
WO2023122337A1 (en) | 2021-12-23 | 2023-06-29 | Sana Biotechnology, Inc. | Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods |
WO2023122722A1 (en) | 2021-12-22 | 2023-06-29 | Sangamo Therapeutics, Inc. | Novel zinc finger fusion proteins for nucleobase editing |
US11690921B2 (en) | 2018-05-18 | 2023-07-04 | Sangamo Therapeutics, Inc. | Delivery of target specific nucleases |
WO2023129937A1 (en) | 2021-12-29 | 2023-07-06 | Century Therapeutics, Inc. | Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof |
WO2023131637A1 (en) | 2022-01-06 | 2023-07-13 | Vib Vzw | Improved silage grasses |
WO2023131616A1 (en) | 2022-01-05 | 2023-07-13 | Vib Vzw | Means and methods to increase abiotic stress tolerance in plants |
WO2023137471A1 (en) | 2022-01-14 | 2023-07-20 | Tune Therapeutics, Inc. | Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation |
WO2023137472A2 (en) | 2022-01-14 | 2023-07-20 | Tune Therapeutics, Inc. | Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression |
WO2023144199A1 (en) | 2022-01-26 | 2023-08-03 | Vib Vzw | Plants having reduced levels of bitter taste metabolites |
WO2023154578A1 (en) | 2022-02-14 | 2023-08-17 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
WO2023158836A1 (en) | 2022-02-17 | 2023-08-24 | Sana Biotechnology, Inc. | Engineered cd47 proteins and uses thereof |
EP4234570A2 (en) | 2018-09-18 | 2023-08-30 | Sangamo Therapeutics, Inc. | Programmed cell death 1 (pd1) specific nucleases |
WO2023164688A1 (en) | 2022-02-28 | 2023-08-31 | Kite Pharma, Inc. | Allogeneic therapeutic cells |
WO2023166425A1 (en) | 2022-03-01 | 2023-09-07 | Crispr Therapeutics Ag | Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions |
WO2023173123A1 (en) | 2022-03-11 | 2023-09-14 | Sana Biotechnology, Inc. | Genetically modified cells and compositions and uses thereof |
WO2023180968A1 (en) | 2022-03-23 | 2023-09-28 | Crispr Therapeutics Ag | Anti-cd19 car-t cells with multiple gene edits and therapeutic uses thereof |
WO2023180904A1 (en) | 2022-03-21 | 2023-09-28 | Crispr Therapeutics Ag | Methods and compositions for treating lipoprotein-related diseases |
WO2023180967A1 (en) | 2022-03-23 | 2023-09-28 | Crispr Therapeutics Ag | Anti-cd83 car-t cells with regnase-1 and/or tgfbrii disruption |
WO2023230613A1 (en) | 2022-05-27 | 2023-11-30 | The Broad Institute, Inc. | Improved mitochondrial base editors and methods for editing mitochondrial dna |
US11834686B2 (en) | 2018-08-23 | 2023-12-05 | Sangamo Therapeutics, Inc. | Engineered target specific base editors |
WO2023240212A2 (en) | 2022-06-08 | 2023-12-14 | Century Therapeutics, Inc. | Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof |
WO2023240147A1 (en) | 2022-06-08 | 2023-12-14 | Century Therapeutics, Inc. | Genetically engineered cells expressing cd16 variants and nkg2d and uses thereof |
WO2023240169A1 (en) | 2022-06-08 | 2023-12-14 | Century Therapeutics, Inc. | Immunoeffector cells derived from induced pluripotent stem cells genetically engineered with membrane bound il12 and uses thereof |
WO2023242827A2 (en) | 2022-06-17 | 2023-12-21 | Crispr Therapeutics Ag | LIPID NANOPARTICLES (LNPs)-BASED OCULAR DELIVERY |
WO2023248145A1 (en) | 2022-06-21 | 2023-12-28 | Crispr Therapeutics Ag | Compositions and methods for treating human immunodeficiency virus |
WO2023248147A1 (en) | 2022-06-21 | 2023-12-28 | Crispr Therapeutics Ag | Methods and compositions for in vivo editing of stem cells |
WO2023250511A2 (en) | 2022-06-24 | 2023-12-28 | Tune Therapeutics, Inc. | Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression |
US11857641B2 (en) | 2019-02-06 | 2024-01-02 | Sangamo Therapeutics, Inc. | Method for the treatment of mucopolysaccharidosis type I |
WO2024006911A1 (en) | 2022-06-29 | 2024-01-04 | FUJIFILM Holdings America Corporation | Ipsc-derived astrocytes and methods of use thereof |
WO2024003786A1 (en) | 2022-06-29 | 2024-01-04 | Crispr Therapeutics Ag | Chimeric antigen receptor targeting gpc-3 and immune cells expressing such for therapeutic uses |
WO2024015881A2 (en) | 2022-07-12 | 2024-01-18 | Tune Therapeutics, Inc. | Compositions, systems, and methods for targeted transcriptional activation |
WO2024013514A2 (en) | 2022-07-15 | 2024-01-18 | Pig Improvement Company Uk Limited | Gene edited livestock animals having coronavirus resistance |
WO2024023804A2 (en) | 2022-07-29 | 2024-02-01 | Crispr Therapeutics Ag | Genetically engineered immune cells having disrupted transporter associated with antigen processing binding protein (tapbp) gene |
WO2024023802A2 (en) | 2022-07-29 | 2024-02-01 | Crispr Therapeutics Ag | Genetically engineered immune cells having disrupted transporter associated with antigen processing-2 (tap-2) gene |
WO2024023801A2 (en) | 2022-07-29 | 2024-02-01 | Crispr Therapeutics Ag | Genetically engineered immune cells having disrupted transporter associated with antigen processing-1 (tap-1) gene |
WO2024040254A2 (en) | 2022-08-19 | 2024-02-22 | Tune Therapeutics, Inc. | Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression |
US11920148B2 (en) | 2017-02-22 | 2024-03-05 | Crispr Therapeutics Ag | Compositions and methods for gene editing |
WO2024064642A2 (en) | 2022-09-19 | 2024-03-28 | Tune Therapeutics, Inc. | Compositions, systems, and methods for modulating t cell function |
WO2024062388A2 (en) | 2022-09-20 | 2024-03-28 | Crispr Therapeutics Ag | Genetically engineered immune cells expressing chimeric antigen receptor targeting cd20 |
US11965022B2 (en) | 2021-12-23 | 2024-04-23 | Sana Biotechnology, Inc. | Methods and compositions for modulating CAR-T activity |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3980447B2 (en) * | 2002-08-14 | 2007-09-26 | 花王株式会社 | Hard surface cleaning composition |
JP2004155803A (en) * | 2002-11-01 | 2004-06-03 | Kao Corp | Solid cleaning agent composition for flush toilet |
JP4130387B2 (en) * | 2003-07-11 | 2008-08-06 | 花王株式会社 | Toilet cleaner |
JP4271524B2 (en) * | 2003-07-11 | 2009-06-03 | 花王株式会社 | Aqueous liquid composition |
JP5342126B2 (en) | 2006-10-31 | 2013-11-13 | 花王株式会社 | Bleach composition |
JP5252826B2 (en) * | 2007-04-17 | 2013-07-31 | ディバーシー株式会社 | Cleaning composition for hard surface |
JP5281420B2 (en) * | 2009-01-20 | 2013-09-04 | 花王株式会社 | Liquid detergent composition for hard surfaces |
JP5642429B2 (en) * | 2010-05-31 | 2014-12-17 | 上野製薬株式会社 | Cleaning disinfectant composition |
JP5769570B2 (en) * | 2010-09-28 | 2015-08-26 | 小林製薬株式会社 | Biofilm remover, biofilm removal composition, and biofilm removal method |
JP5705510B2 (en) * | 2010-11-25 | 2015-04-22 | 大日本除蟲菊株式会社 | Acidic antibacterial detergent composition |
GB201022132D0 (en) * | 2010-12-31 | 2011-02-02 | Byotrol Plc | Anti-microbial composition |
JP6000514B2 (en) * | 2011-03-17 | 2016-09-28 | 株式会社Adeka | Oil stain cleaning composition |
JP5659087B2 (en) * | 2011-06-08 | 2015-01-28 | 花王株式会社 | Liquid detergent composition for hard surfaces |
JP5832189B2 (en) * | 2011-07-25 | 2015-12-16 | 大日本除蟲菊株式会社 | Rinsing accelerator for hard surface cleaner |
GB2501341B (en) * | 2011-12-29 | 2014-10-22 | Byotrol Plc | Anti-microbial composition |
JP6052957B2 (en) * | 2012-07-03 | 2016-12-27 | 花王株式会社 | Liquid fragrance composition for flush toilet |
JP5752220B2 (en) * | 2013-12-16 | 2015-07-22 | 花王株式会社 | Bactericidal detergent composition for hard surfaces |
JP6516353B2 (en) * | 2014-12-26 | 2019-05-22 | ライオン株式会社 | Liquid cleaning agent for bathroom |
JP7075655B2 (en) * | 2018-03-14 | 2022-05-26 | 株式会社ニイタカ | Detergent composition, spray bottle, wet wiper and deodorant disinfectant cleaning method |
EP3772947A4 (en) | 2018-04-09 | 2021-12-01 | Rhodia Operations | Compositions and methods for long lasting disinfection |
JP2020041074A (en) * | 2018-09-12 | 2020-03-19 | ライオン株式会社 | Liquid detergent composition for clothing |
JP7335068B2 (en) * | 2018-12-20 | 2023-08-29 | 中国塗料株式会社 | Antifouling paint composition, antifouling coating film, substrate with antifouling coating film, antifouling method for substrate, and method for producing substrate with antifouling coating film |
JP6700453B1 (en) * | 2019-03-22 | 2020-05-27 | 株式会社Adeka | Hard surface cleaner composition and hard surface cleaning method |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4014808A (en) * | 1973-06-04 | 1977-03-29 | Tennant Company | Detergent composition |
EP0311343A2 (en) * | 1987-10-09 | 1989-04-12 | The Procter & Gamble Company | Toilet composition |
EP0342997A2 (en) * | 1988-05-20 | 1989-11-23 | Unilever Plc | General-purpose cleaning compositions |
JPH02145697A (en) * | 1988-11-25 | 1990-06-05 | Kao Corp | Cleaning agent composition for flush toilet |
WO1991000332A1 (en) * | 1989-06-23 | 1991-01-10 | Unilever Plc | Cleaning composition |
JPH07233394A (en) * | 1993-12-28 | 1995-09-05 | Kao Corp | Cleaner composition for hard surface |
JPH09169995A (en) * | 1995-12-20 | 1997-06-30 | Kao Corp | Stain-proofing cleaning agent composition for toilet |
JPH101697A (en) * | 1996-06-14 | 1998-01-06 | Kao Corp | Detergent composition for toilet |
JPH10195498A (en) * | 1996-12-27 | 1998-07-28 | Lion Corp | Liquid detergent composition |
WO1998042815A1 (en) * | 1997-03-21 | 1998-10-01 | Unilever Plc | Personal cleansing bar with enhanced deposition |
WO1999014308A1 (en) * | 1997-09-12 | 1999-03-25 | Izabella Bogacka | Method of obtaining everyday hygiene agents |
JPH11140491A (en) * | 1997-09-02 | 1999-05-25 | Kao Corp | Bactericidal cleansing agent composition for floor |
WO2000022077A1 (en) * | 1998-10-13 | 2000-04-20 | The Procter & Gamble Company | Laundry detergent compositions with a cationically charged dye maintenance polymer |
WO2001042415A1 (en) * | 1999-12-08 | 2001-06-14 | Unilever N.V. | Use of polymeric material in the treatment of hard surfaces |
-
2000
- 2000-08-23 JP JP2000252284A patent/JP2002060786A/en active Pending
-
2001
- 2001-08-09 WO PCT/JP2001/006869 patent/WO2002016536A1/en active Application Filing
- 2001-08-20 TW TW90120399A patent/TWI283267B/en not_active IP Right Cessation
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4014808A (en) * | 1973-06-04 | 1977-03-29 | Tennant Company | Detergent composition |
EP0311343A2 (en) * | 1987-10-09 | 1989-04-12 | The Procter & Gamble Company | Toilet composition |
EP0342997A2 (en) * | 1988-05-20 | 1989-11-23 | Unilever Plc | General-purpose cleaning compositions |
JPH02145697A (en) * | 1988-11-25 | 1990-06-05 | Kao Corp | Cleaning agent composition for flush toilet |
WO1991000332A1 (en) * | 1989-06-23 | 1991-01-10 | Unilever Plc | Cleaning composition |
JPH07233394A (en) * | 1993-12-28 | 1995-09-05 | Kao Corp | Cleaner composition for hard surface |
JPH09169995A (en) * | 1995-12-20 | 1997-06-30 | Kao Corp | Stain-proofing cleaning agent composition for toilet |
JPH101697A (en) * | 1996-06-14 | 1998-01-06 | Kao Corp | Detergent composition for toilet |
JPH10195498A (en) * | 1996-12-27 | 1998-07-28 | Lion Corp | Liquid detergent composition |
WO1998042815A1 (en) * | 1997-03-21 | 1998-10-01 | Unilever Plc | Personal cleansing bar with enhanced deposition |
JPH11140491A (en) * | 1997-09-02 | 1999-05-25 | Kao Corp | Bactericidal cleansing agent composition for floor |
WO1999014308A1 (en) * | 1997-09-12 | 1999-03-25 | Izabella Bogacka | Method of obtaining everyday hygiene agents |
WO2000022077A1 (en) * | 1998-10-13 | 2000-04-20 | The Procter & Gamble Company | Laundry detergent compositions with a cationically charged dye maintenance polymer |
WO2001042415A1 (en) * | 1999-12-08 | 2001-06-14 | Unilever N.V. | Use of polymeric material in the treatment of hard surfaces |
Cited By (491)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7501387B2 (en) | 2002-02-22 | 2009-03-10 | Kao Corporation | Antifouling detergent for hard surfaces |
US7544649B2 (en) | 2002-02-22 | 2009-06-09 | Kao Corporation | Antifouling detergent for hard surfaces |
WO2003070866A1 (en) * | 2002-02-22 | 2003-08-28 | Kao Corporation | Antifouling detergent for hard surfaces |
EP2927318A1 (en) | 2003-08-08 | 2015-10-07 | Sangamo BioSciences, Inc. | Methods and compositions for targeted cleavage and recombination |
WO2005014791A2 (en) | 2003-08-08 | 2005-02-17 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
EP3222715A1 (en) | 2003-08-08 | 2017-09-27 | Sangamo BioSciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US9752140B2 (en) | 2003-08-08 | 2017-09-05 | Sangamo Therapeutics, Inc. | Methods and compostions for targeted genomic deletion |
US9260726B2 (en) | 2003-08-08 | 2016-02-16 | Sangamo Biosciences, Inc. | Targeted integration and expression on exogenous nucleic acid sequences |
US9249428B2 (en) | 2003-08-08 | 2016-02-02 | Sangamo Biosciences, Inc. | Methods and compositions for targeted genomic deletion |
EP2947146A1 (en) | 2004-02-05 | 2015-11-25 | Sangamo BioSciences, Inc. | Methods and compositions for targeted cleavage and recombination |
JP2005232241A (en) * | 2004-02-18 | 2005-09-02 | Toyo Aluminium Foil Products Kk | Coating agent for removing greasy dirt |
US8771986B2 (en) | 2004-08-06 | 2014-07-08 | Sangamo Biosciences, Inc. | Engineered cleavage half-domains |
US8034598B2 (en) | 2004-08-06 | 2011-10-11 | Sangamo Biosciences, Inc. | Engineered cleavage half-domains |
EP2292274A1 (en) | 2004-09-16 | 2011-03-09 | Sangamo BioSciences, Inc. | Compositions and methods for protein production |
US8313925B2 (en) | 2005-07-26 | 2012-11-20 | Sangamo Biosciences, Inc. | Zinc finger proteins and method for inactivating a dhfr gene in a chinese hamster ovary cell |
US9045763B2 (en) | 2005-07-26 | 2015-06-02 | Sangamo Biosciences, Inc. | Linear donor constructs for targeted integration |
US9765360B2 (en) | 2005-07-26 | 2017-09-19 | Sangamo Therapeutics, Inc. | Linear donor constructs for targeted integration |
US9376685B2 (en) | 2005-07-26 | 2016-06-28 | Sangamo Biosciences, Inc. | Linear donor constructs for targeted integration |
US7914796B2 (en) | 2006-05-25 | 2011-03-29 | Sangamo Biosciences, Inc. | Engineered cleavage half-domains |
EP2213731A1 (en) | 2006-05-25 | 2010-08-04 | Sangamo BioSciences, Inc. | Variant foki cleavage half-domains |
EP2206782A1 (en) | 2006-05-25 | 2010-07-14 | Sangamo BioSciences, Inc. | Methods and compositions for gene inactivation |
US11648267B2 (en) | 2006-05-25 | 2023-05-16 | Sangamo Therapeutics, Inc. | Methods and compositions for gene inactivation |
US8569253B2 (en) | 2006-05-25 | 2013-10-29 | Sangamo Biosciences, Inc. | Methods and compositions for gene inactivation |
US9434776B2 (en) | 2006-05-25 | 2016-09-06 | Sangamo Biosciences, Inc. | Methods and compositions for gene inactivation |
US7951925B2 (en) * | 2006-05-25 | 2011-05-31 | Sangamo Biosciences, Inc. | Methods and compositions for gene inactivation |
US8524221B2 (en) | 2006-05-25 | 2013-09-03 | Sangamo Biosciences, Inc. | Methods and compositions for gene inactivation |
EP2765195A1 (en) | 2006-05-25 | 2014-08-13 | Sangamo BioSciences, Inc. | Methods and compositions for gene inactivation |
EP2447279A1 (en) | 2006-05-25 | 2012-05-02 | Sangamo BioSciences, Inc. | Methods and compositions for gene inactivation |
EP2395081A1 (en) | 2006-08-11 | 2011-12-14 | Dow AgroSciences LLC | Zinc finger nuclease-mediated homologous recombination |
US10907175B2 (en) * | 2006-11-13 | 2021-02-02 | Sangamo Therapeutics, Inc. | Isolated human cell with an inactivated glucocorticoid receptor gene |
US11884930B2 (en) | 2006-11-13 | 2024-01-30 | Sangamo Biosciences, Inc. | Method of inactivating a glucocorticoid receptor gene in an isolated cell |
US9217026B2 (en) | 2006-11-13 | 2015-12-22 | Sangamo Biosciences, Inc. | Method of inactivating a glucocorticoid receptor gene in an isolated cell |
US20160076056A1 (en) * | 2006-11-13 | 2016-03-17 | Sangamo Biosciences, Inc. | Method of inactivating a glucocorticoid receptor gene in an isolated cell |
EP2415873A1 (en) | 2006-12-14 | 2012-02-08 | Dow AgroSciences LLC | Optimized non-canonical zinc finger proteins |
EP2412812A1 (en) | 2006-12-14 | 2012-02-01 | Dow AgroSciences LLC | Optimized non-canonical zinc finger proteins |
EP2415872A1 (en) | 2006-12-14 | 2012-02-08 | Dow AgroSciences LLC | Optimized non-canonical zinc finger proteins |
EP3070169A1 (en) | 2006-12-14 | 2016-09-21 | Dow AgroSciences LLC | Optimized non-canonical zinc finger proteins |
US8110379B2 (en) | 2007-04-26 | 2012-02-07 | Sangamo Biosciences, Inc. | Targeted integration into the PPP1R12C locus |
US11649468B2 (en) | 2007-04-26 | 2023-05-16 | Sangamo Therapeutics, Inc. | Targeted integration into the PPP1R12C locus |
US9267154B2 (en) | 2007-04-26 | 2016-02-23 | Sangamo Biosciences, Inc. | Targeted integration into the PPP1R12C locus |
US8822221B2 (en) | 2007-04-26 | 2014-09-02 | Sangamo Biosciences, Inc. | Targeted integration into the PPP1R12C locus |
US9914940B2 (en) | 2007-04-26 | 2018-03-13 | Sangamo Therapeutics, Inc. | Targeted integration into the PPP1R12C locus |
US9322036B2 (en) | 2007-07-12 | 2016-04-26 | Sangamo Biosciences, Inc. | Methods and compositions for inactivating alpha 1,6 fucosyltransferase (FUT8) gene expression |
US9890395B2 (en) | 2007-07-12 | 2018-02-13 | Sangamo Therapeutics, Inc. | Methods and compositions for inactivating alpha 1,6 fucosyltransferase (FUT8) gene expression |
EP2527435A2 (en) | 2007-07-12 | 2012-11-28 | Sangamo BioSciences, Inc. | Methods and compositions for inactivating alpha 1,6 fucosyltransferase (FUT 8) gene expression |
US7919313B2 (en) | 2007-07-12 | 2011-04-05 | Sangamo Biosciences, Inc. | Methods and compositions for inactivating alpha 1,6 fucosyltransferase (FUT8) gene expression |
US8772025B2 (en) | 2007-07-12 | 2014-07-08 | Sangamo Biosciences, Inc. | Methods and compositions for inactivating alpha 1,6 fucosyltransferase (FUT8) gene expression |
US11235026B2 (en) | 2007-09-27 | 2022-02-01 | Sangamo Therapeutics, Inc. | Methods and compositions for modulating PD1 |
US10046028B2 (en) | 2007-09-27 | 2018-08-14 | Sangamo Therapeutics, Inc. | Methods and compositions for modulating PD1 |
US8563314B2 (en) | 2007-09-27 | 2013-10-22 | Sangamo Biosciences, Inc. | Methods and compositions for modulating PD1 |
US9506120B2 (en) | 2007-09-27 | 2016-11-29 | Sangamo Biosciences, Inc. | Rapid in vivo identification of biologically active nucleases |
US8889390B2 (en) | 2007-09-27 | 2014-11-18 | Dow Agrosciences Llc | Engineered zinc finger proteins targeting 5-enolpyruvyl shikimate-3-phosphate synthase genes |
US10344289B2 (en) | 2007-09-27 | 2019-07-09 | Dow Agrosciences Llc | Engineered zinc finger proteins targeting 5-enolpyruvyl shikimate-3-phosphate synthase genes |
US8399218B2 (en) | 2007-09-27 | 2013-03-19 | Dow Agrosciences, Llc | Engineered zinc finger proteins targeting 5-enolpyruvyl shikimate-3-phosphate synthase genes |
US9402879B2 (en) | 2007-09-27 | 2016-08-02 | Sangamo Biosciences, Inc. | Methods and compositions for modulating PD1 |
US9121072B2 (en) | 2007-09-27 | 2015-09-01 | Sangamo Biosciences, Inc. | Rapid screening of biologically active nucleases and isolation of nuclease-modified cells |
EP3072973A1 (en) | 2007-09-27 | 2016-09-28 | Dow AgroSciences LLC | Engineered zinc finger proteins targeting 5-enolpyruvyl shikimate-3-phosphate synthase genes |
US9115409B2 (en) | 2007-09-27 | 2015-08-25 | Sangamo Biosciences, Inc. | Rapid screening of biologically active nucleases and isolation of nuclease-modified cells |
EP2597155A1 (en) | 2007-10-25 | 2013-05-29 | Sangamo BioSciences, Inc. | Methods and compositions for targeted integration |
US8936936B2 (en) | 2007-10-25 | 2015-01-20 | Sangamo Biosciences, Inc. | Methods and compositions for targeted integration |
EP2936976A1 (en) | 2008-04-21 | 2015-10-28 | Danziger Innovations Ltd. | Plant viral expression vectors and use of same for generating genotypic variations in plant genomes |
US11608492B2 (en) | 2008-05-28 | 2023-03-21 | Sangamo Therapeutics, Inc. | Compositions for linking DNA-binding domains and cleavage domains |
US10822599B2 (en) | 2008-05-28 | 2020-11-03 | Sangamo Therapeutics, Inc. | Compositions for linking DNA-binding domains and cleavage domains |
US9982245B2 (en) | 2008-05-28 | 2018-05-29 | Sangamo Therapeutics, Inc. | Compositions for linking DNA-binding domains and cleavage domains |
US9394531B2 (en) | 2008-05-28 | 2016-07-19 | Sangamo Biosciences, Inc. | Compositions for linking DNA-binding domains and cleavage domains |
EP2910568A2 (en) | 2008-06-10 | 2015-08-26 | Sangamo BioSciences, Inc. | Methods and compositions for generation of BAX- and BAK-deficient cell lines |
WO2009151591A2 (en) | 2008-06-10 | 2009-12-17 | Sangamo Biosciences, Inc. | Methods and compositions for generation of bax- and bak-deficient cell lines |
US8597912B2 (en) | 2008-06-10 | 2013-12-03 | Sangamo Biosciences, Inc. | Methods and compositions for generation of Bax-and Bak-deficient cell lines |
US10689717B2 (en) | 2008-08-22 | 2020-06-23 | Sangamo Therapeutics, Inc. | Methods and compositions for targeted single-stranded cleavage and targeted integration |
US10113207B2 (en) | 2008-08-22 | 2018-10-30 | Sangamo Therapeutics, Inc. | Methods and compositions for targeted single-stranded cleavage and targeted integration |
EP2789691A1 (en) | 2008-08-22 | 2014-10-15 | Sangamo BioSciences, Inc. | Methods and compositions for targeted single-stranded cleavage and targeted integration |
US9631186B2 (en) | 2008-08-22 | 2017-04-25 | Sangamo Biosciences, Inc. | Methods and compositions for targeted single-stranded cleavage and targeted integration |
WO2010021692A1 (en) | 2008-08-22 | 2010-02-25 | Sangamo Biosciences, Inc. | Methods and compositions for targeted single-stranded cleavage and targeted integration |
US11149321B2 (en) | 2008-08-22 | 2021-10-19 | Sangamo Therapeutics, Inc. | Methods and compositions for targeted single-stranded cleavage and targeted integration |
US9200266B2 (en) | 2008-08-22 | 2015-12-01 | Sangamo Biosciences, Inc. | Methods and compositions for targeted single-stranded cleavage and targeted integration |
US8703489B2 (en) | 2008-08-22 | 2014-04-22 | Sangamo Biosciences, Inc. | Methods and compositions for targeted single-stranded cleavage and targeted integration |
US9388426B2 (en) | 2008-10-29 | 2016-07-12 | Sangamo Biosciences, Inc. | Methods and compositions for inactivating glutamine synthetase gene expression |
US8153399B2 (en) | 2008-10-29 | 2012-04-10 | Sangamo Biosciences, Inc. | Methods and compositions for inactivating glutamine synthetase gene expression |
US9206404B2 (en) | 2008-12-04 | 2015-12-08 | Sangamo Biosciences, Inc. | Method of deleting an IgM gene in an isolated rat cell |
EP3156494A1 (en) | 2008-12-04 | 2017-04-19 | Sangamo BioSciences, Inc. | Genome editing in rats using zinc-finger nucleases |
WO2010065123A1 (en) | 2008-12-04 | 2010-06-10 | Sangamo Biosciences, Inc. | Genome editing in rats using zinc-finger nucleases |
US8329986B2 (en) | 2008-12-17 | 2012-12-11 | Dow Agrosciences, Llc | Targeted integration into the Zp15 locus |
WO2010077319A1 (en) | 2008-12-17 | 2010-07-08 | Dow Agrosciences Llc | Targeted integration into the zp15 locus |
WO2010090744A1 (en) | 2009-02-04 | 2010-08-12 | Sangamo Biosciences, Inc. | Methods and compositions for treating neuropathies |
EP3354275A1 (en) | 2009-02-04 | 2018-08-01 | Sangamo Therapeutics, Inc. | Methods and compositions for treating neuropathies |
US8551945B2 (en) | 2009-02-04 | 2013-10-08 | Sangamo Biosciences, Inc. | Methods and compositions for treating neuropathies |
US9717759B2 (en) | 2009-03-20 | 2017-08-01 | Sangamo Therapeutics, Inc. | Modification of CXCR4 using engineered zinc finger proteins |
US8871905B2 (en) | 2009-03-20 | 2014-10-28 | Sangamo Biosciences, Inc. | Modification of CXCR4 using engineered zinc finger proteins |
US9834787B2 (en) | 2009-04-09 | 2017-12-05 | Sangamo Therapeutics, Inc. | Targeted integration into stem cells |
US8772008B2 (en) | 2009-05-18 | 2014-07-08 | Sangamo Biosciences, Inc. | Methods and compositions for increasing nuclease activity |
US8772009B2 (en) | 2009-05-18 | 2014-07-08 | Sangamo Biosciences, Inc. | Methods and compositions for increasing nuclease activity |
WO2011002503A1 (en) | 2009-06-30 | 2011-01-06 | Sangamo Biosciences, Inc. | Rapid screening of biologically active nucleases and isolation of nuclease-modified cells |
EP2727600A1 (en) | 2009-07-28 | 2014-05-07 | Sangamo BioSciences, Inc. | Methods and compositions for treating trinucleotide repeat disorders |
US9943565B2 (en) | 2009-07-28 | 2018-04-17 | Sangamo Therapeutics, Inc. | Methods and compositions for treating trinucleotide repeat disorders |
US10646543B2 (en) | 2009-07-28 | 2020-05-12 | Sangamo Therapeutics, Inc. | Methods and compositions for treating trinucleotide repeat disorders |
US9234016B2 (en) | 2009-07-28 | 2016-01-12 | Sangamo Biosciences, Inc. | Engineered zinc finger proteins for treating trinucleotide repeat disorders |
EP3156504A1 (en) | 2009-08-11 | 2017-04-19 | Sangamo BioSciences, Inc. | Organisms homozygous for targeted modification |
US10827731B2 (en) | 2009-08-11 | 2020-11-10 | Sangamo Therapeutics, Inc. | Method of inactivating the IPK1 gene in corn |
EP3428289A1 (en) | 2009-08-11 | 2019-01-16 | Sangamo Therapeutics, Inc. | Organisms homozygous for targeted modification |
WO2011048600A1 (en) | 2009-10-21 | 2011-04-28 | Danziger Innovations Ltd. | Generating genotypic variations in plant genomes by gamete infection |
US9631201B2 (en) | 2009-10-22 | 2017-04-25 | Sangamo Biosciences, Inc. | Engineered zinc finger proteins targeting plant genes involved in fatty acid biosynthesis |
US10017775B2 (en) | 2009-10-22 | 2018-07-10 | Dow Agrosciences Llc | Engineered zinc finger proteins targeting plant genes involved in fatty acid biosynthesis |
EP2722392A2 (en) | 2009-10-22 | 2014-04-23 | Dow AgroSciences LLC | Engineered zinc finger proteins targeting plant genes involved in fatty acid biosynthesis |
US8592645B2 (en) | 2009-10-22 | 2013-11-26 | Dow Agrosciences Llc | Engineered zinc finger proteins targeting plant genes involved in fatty acid biosynthesis |
US10155011B2 (en) | 2009-11-10 | 2018-12-18 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
US11439666B2 (en) | 2009-11-10 | 2022-09-13 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
US10260062B2 (en) | 2010-01-22 | 2019-04-16 | Sangamo Therapeutics, Inc. | Targeted genomic alteration |
US8623618B2 (en) | 2010-02-08 | 2014-01-07 | Sangamo Biosciences, Inc. | Engineered cleavage half-domains |
US10066242B2 (en) | 2010-02-08 | 2018-09-04 | Sangamo Therapeutics, Inc. | Artificial nucleases comprising engineered cleavage half-domains |
EP3594333A1 (en) | 2010-02-08 | 2020-01-15 | Sangamo Therapeutics, Inc. | Engineered cleavage half-domains |
US10640790B2 (en) | 2010-02-08 | 2020-05-05 | Sangamo Therapeutics, Inc. | Artificial nucleases including engineered FokI cleavage half-domains |
EP2615106A1 (en) | 2010-02-08 | 2013-07-17 | Sangamo BioSciences, Inc. | Engineered cleavage half-domains |
US11725218B2 (en) | 2010-02-08 | 2023-08-15 | Sangamo Therapeutics, Inc. | Artificial nucleases comprising engineered cleavage half-domains |
US9150879B2 (en) | 2010-02-08 | 2015-10-06 | Sangamo Biosciences, Inc. | Engineered cleavage half-domains |
EP4328304A2 (en) | 2010-02-08 | 2024-02-28 | Sangamo Therapeutics, Inc. | Engineered cleavage half-domains |
US9376689B2 (en) | 2010-02-08 | 2016-06-28 | Sangamo Biosciences, Inc. | Engineered cleavage half-domains |
US8962281B2 (en) | 2010-02-08 | 2015-02-24 | Sangamo Biosciences, Inc. | Engineered cleavage half-domains |
US11136599B2 (en) | 2010-02-08 | 2021-10-05 | Sangamo Therapeutics, Inc. | Artifical nucleases comprising engineered cleavage half-domains |
US9765361B2 (en) | 2010-02-08 | 2017-09-19 | Sangamo Therapeutics, Inc. | Engineered cleavage half-domains for generating nuclease-mediated genomic modifications in a cell |
EP2660318A1 (en) | 2010-02-09 | 2013-11-06 | Sangamo BioSciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
US9005973B2 (en) | 2010-02-09 | 2015-04-14 | Sangamo Biosciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
US9970028B2 (en) | 2010-02-09 | 2018-05-15 | Sangamo Therapeutics, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
US9255259B2 (en) | 2010-02-09 | 2016-02-09 | Sangamo Biosciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
US9567573B2 (en) | 2010-04-26 | 2017-02-14 | Sangamo Biosciences, Inc. | Genome editing of a Rosa locus using nucleases |
US8771985B2 (en) | 2010-04-26 | 2014-07-08 | Sangamo Biosciences, Inc. | Genome editing of a Rosa locus using zinc-finger nucleases |
EP3636766A1 (en) | 2010-05-03 | 2020-04-15 | Sangamo Therapeutics, Inc. | Compositions for linking zinc finger modules |
US9163245B2 (en) | 2010-05-03 | 2015-10-20 | Sangamo Biosciences, Inc. | Compositions for linking zinc finger modules |
US8772453B2 (en) | 2010-05-03 | 2014-07-08 | Sangamo Biosciences, Inc. | Compositions for linking zinc finger modules |
US10858416B2 (en) | 2010-07-21 | 2020-12-08 | Sangamo Therapeutics, Inc. | Methods and compositions for modification of a HLA locus |
US10072062B2 (en) | 2010-07-21 | 2018-09-11 | Sangamo Therapeutics, Inc. | Methods and compositions for modification of a HLA locus |
WO2012012667A2 (en) | 2010-07-21 | 2012-01-26 | Sangamo Biosciences, Inc. | Methods and compositions for modification of a hla locus |
US8945868B2 (en) | 2010-07-21 | 2015-02-03 | Sangamo Biosciences, Inc. | Methods and compositions for modification of a HLA locus |
EP3511420A1 (en) | 2010-09-27 | 2019-07-17 | Sangamo Therapeutics, Inc. | Methods and compositions for inhibiting viral entry into cells |
WO2012047598A1 (en) | 2010-09-27 | 2012-04-12 | Sangamo Biosciences, Inc. | Methods and compositions for inhibiting viral entry into cells |
US9566352B2 (en) | 2010-09-27 | 2017-02-14 | Sangamo Biosciences, Inc. | Methods and compositions for inhibiting viral entry into cells |
US9629930B2 (en) | 2010-10-12 | 2017-04-25 | Sangamo Biosciences, Inc. | Methods and compositions for treating hemophilia B |
US9175280B2 (en) | 2010-10-12 | 2015-11-03 | Sangamo Biosciences, Inc. | Methods and compositions for treating hemophilia B |
WO2012051343A1 (en) | 2010-10-12 | 2012-04-19 | The Children's Hospital Of Philadelphia | Methods and compositions for treating hemophilia b |
EP3311822A1 (en) | 2010-11-17 | 2018-04-25 | Sangamo Therapeutics, Inc. | Methods and compositions for modulating pd1 |
US9267123B2 (en) | 2011-01-05 | 2016-02-23 | Sangamo Biosciences, Inc. | Methods and compositions for gene correction |
US9631187B2 (en) | 2011-01-05 | 2017-04-25 | Sangamo Biosciences, Inc. | Methods and compositions for gene correction |
US9161995B2 (en) | 2011-07-25 | 2015-10-20 | Sangamo Biosciences, Inc. | Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (CFTR) gene |
US9150847B2 (en) | 2011-09-21 | 2015-10-06 | Sangamo Biosciences, Inc. | Methods and compositions for regulation of transgene expression |
EP3498833A1 (en) | 2011-09-21 | 2019-06-19 | Sangamo Therapeutics, Inc. | Methods and compositions for regulation of transgene expression |
WO2013044008A2 (en) | 2011-09-21 | 2013-03-28 | Sangamo Biosciences, Inc. | Methods and compositions for regulation of transgene expression |
US9394545B2 (en) | 2011-09-21 | 2016-07-19 | Sangamo Biosciences, Inc. | Methods and compositions for regulation of transgene expression |
US10975375B2 (en) | 2011-09-21 | 2021-04-13 | Sangamo Therapeutics, Inc. | Methods and compositions for regulation of transgene expression |
US11639504B2 (en) | 2011-09-21 | 2023-05-02 | Sangamo Therapeutics, Inc. | Methods and compositions for regulation of transgene expression |
US11859190B2 (en) | 2011-09-21 | 2024-01-02 | Sangamo Therapeutics, Inc. | Methods and compositions for regulation of transgene expression |
US9777281B2 (en) | 2011-09-21 | 2017-10-03 | Sangamo Therapeutics, Inc. | Methods and compositions for regulation of transgene expression |
US8895264B2 (en) | 2011-10-27 | 2014-11-25 | Sangamo Biosciences, Inc. | Methods and compositions for modification of the HPRT locus |
US9222105B2 (en) | 2011-10-27 | 2015-12-29 | Sangamo Biosciences, Inc. | Methods and compositions for modification of the HPRT locus |
US9458205B2 (en) | 2011-11-16 | 2016-10-04 | Sangamo Biosciences, Inc. | Modified DNA-binding proteins and uses thereof |
US9499597B2 (en) | 2012-02-29 | 2016-11-22 | Sangamo Biosciences, Inc. | Methods and compositions for treating Huntington's disease |
US8841260B2 (en) | 2012-02-29 | 2014-09-23 | Sangamo Biosciences, Inc. | Methods and compositions for treating Huntington's Disease |
US11723952B2 (en) | 2012-02-29 | 2023-08-15 | Sangamo Therapeutics, Inc. | Methods and compositions for treating Huntington's Disease |
WO2013130824A1 (en) | 2012-02-29 | 2013-09-06 | Sangamo Biosciences, Inc. | Methods and compositions for treating huntington's disease |
US10471123B2 (en) | 2012-02-29 | 2019-11-12 | Sangamo Therapeutics, Inc. | Methods and compositions for treating Huntington's disease |
US10857203B2 (en) | 2012-02-29 | 2020-12-08 | Sangamo Therapeutics, Inc. | Methods and compositions for treating Huntington's disease |
US10265377B2 (en) | 2012-02-29 | 2019-04-23 | Sangamo Therapeutics, Inc. | Methods and compositions for treating Huntington's Disease |
EP3839050A2 (en) | 2012-04-18 | 2021-06-23 | The Board of Trustees of the Leland Stanford Junior University | Non-disruptive gene targeting |
WO2013166315A1 (en) | 2012-05-02 | 2013-11-07 | Dow Agrosciences Llc | Targeted modification of malate dehydrogenase |
US10358684B2 (en) | 2012-05-02 | 2019-07-23 | Dow Agrosciences Llc | Targeted modification of malate dehydrogenase |
US11085092B2 (en) | 2012-05-02 | 2021-08-10 | Corteva Agriscience Llc | Targeted modification of malate dehydrogenase |
US9523098B2 (en) | 2012-05-02 | 2016-12-20 | Dow Agrosciences Llc | Targeted modification of malate dehydrogenase |
US10174331B2 (en) | 2012-05-07 | 2019-01-08 | Sangamo Therapeutics, Inc. | Methods and compositions for nuclease-mediated targeted integration of transgenes |
WO2013169802A1 (en) | 2012-05-07 | 2013-11-14 | Sangamo Biosciences, Inc. | Methods and compositions for nuclease-mediated targeted integration of transgenes |
EP3444342A1 (en) | 2012-07-11 | 2019-02-20 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of lysosomal storage diseases |
US9877988B2 (en) | 2012-07-11 | 2018-01-30 | Sangamo Therapeutics, Inc. | Method of treating lysosomal storage diseases using nucleases and a transgene |
US11898158B2 (en) | 2012-07-11 | 2024-02-13 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of lysosomal storage diseases |
US10293000B2 (en) | 2012-07-11 | 2019-05-21 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of lysosomal storage diseases |
WO2014011901A2 (en) | 2012-07-11 | 2014-01-16 | Sangamo Biosciences, Inc. | Methods and compositions for delivery of biologics |
EP3196301A1 (en) | 2012-07-11 | 2017-07-26 | Sangamo BioSciences, Inc. | Methods and compositions for the treatment of monogenic diseases |
US10648001B2 (en) | 2012-07-11 | 2020-05-12 | Sangamo Therapeutics, Inc. | Method of treating mucopolysaccharidosis type I or II |
US11040115B2 (en) | 2012-07-11 | 2021-06-22 | Sangamo Therapeutics, Inc. | Method for the treatment of lysosomal storage diseases |
EP3816281A1 (en) | 2012-07-11 | 2021-05-05 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of lysosomal storage diseases |
US9956247B2 (en) | 2012-07-11 | 2018-05-01 | Sangamo Therapeutics, Inc. | Method of treating lysosomal storage diseases |
US10883119B2 (en) | 2012-07-11 | 2021-01-05 | Sangamo Therapeutics, Inc. | Methods and compositions for delivery of biologics |
WO2014011237A1 (en) | 2012-07-11 | 2014-01-16 | Sangamo Biosciences, Inc. | Methods and compositions for the treatment of lysosomal storage diseases |
US9963715B2 (en) | 2012-08-29 | 2018-05-08 | Sangamo Therapeutics, Inc. | Methods and compositions for treatment of a genetic condition |
US11492643B2 (en) | 2012-08-29 | 2022-11-08 | Sangamo Therapeutics, Inc. | Methods and compositions for treatment of a genetic condition |
WO2014036219A2 (en) | 2012-08-29 | 2014-03-06 | Sangamo Biosciences, Inc. | Methods and compositions for treatment of a genetic condition |
US9650648B2 (en) | 2012-08-29 | 2017-05-16 | Sangamo Biosciences, Inc. | Methods and compositions for treatment of a genetic condition |
EP3404099A1 (en) | 2012-09-07 | 2018-11-21 | Dow AgroSciences LLC | Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
US9963711B2 (en) | 2012-09-07 | 2018-05-08 | Sangamo Therapeutics, Inc. | FAD2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
US9914930B2 (en) | 2012-09-07 | 2018-03-13 | Dow Agrosciences Llc | FAD3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
EP3431600A1 (en) | 2012-09-07 | 2019-01-23 | Dow AgroSciences LLC | Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
WO2014039692A2 (en) | 2012-09-07 | 2014-03-13 | Dow Agrosciences Llc | Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
EP3406715A1 (en) | 2012-09-07 | 2018-11-28 | Dow AgroSciences LLC | Fad3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
US9493779B2 (en) | 2012-09-07 | 2016-11-15 | Dow Agrosciences Llc | FAD2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
WO2014039872A1 (en) | 2012-09-07 | 2014-03-13 | Dow Agrosciences Llc | Engineered transgene integration platform (etip) for gene targeting and trait stacking |
US10844389B2 (en) | 2012-09-07 | 2020-11-24 | Dow Agrosciences Llc | FAD2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
WO2014039702A2 (en) | 2012-09-07 | 2014-03-13 | Dow Agrosciences Llc | Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
US10577616B2 (en) | 2012-09-07 | 2020-03-03 | Dow Agrosciences Llc | FAD2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
US10961540B2 (en) | 2012-09-07 | 2021-03-30 | Dow Agrosciences Llc | FAD3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
US10287595B2 (en) | 2012-09-07 | 2019-05-14 | Dow Agrosciences Llc | Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
US10526610B2 (en) | 2012-09-07 | 2020-01-07 | Dow Agrosciences Llc | FAD3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
WO2014059173A2 (en) | 2012-10-10 | 2014-04-17 | Sangamo Biosciences, Inc. | T cell modifying compounds and uses thereof |
US11236175B2 (en) | 2012-10-10 | 2022-02-01 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
US9597357B2 (en) | 2012-10-10 | 2017-03-21 | Sangamo Biosciences, Inc. | T cell modifying compounds and uses thereof |
EP3763810A2 (en) | 2012-10-10 | 2021-01-13 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
US9255250B2 (en) | 2012-12-05 | 2016-02-09 | Sangamo Bioscience, Inc. | Isolated mouse or human cell having an exogenous transgene in an endogenous albumin gene |
US10415046B2 (en) | 2012-12-13 | 2019-09-17 | Dow Agrosciences Llc | Precision gene targeting to a particular locus in maize |
US10227610B2 (en) | 2013-02-25 | 2019-03-12 | Sangamo Therapeutics, Inc. | Methods and compositions for enhancing nuclease-mediated gene disruption |
WO2014130955A1 (en) | 2013-02-25 | 2014-08-28 | Sangamo Biosciences, Inc. | Methods and compositions for enhancing nuclease-mediated gene disruption |
US10918668B2 (en) | 2013-03-21 | 2021-02-16 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
US9937207B2 (en) | 2013-03-21 | 2018-04-10 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell receptor genes using talens |
US11198883B2 (en) | 2013-04-05 | 2021-12-14 | Dow Agrosciences Llc | Methods and compositions for integration of an exogenous sequence within the genome of plants |
US10501748B2 (en) | 2013-04-05 | 2019-12-10 | Dow Agrosciences Llc | Methods and compositions for integration of an exogenous sequence within the genome of plants |
WO2014165612A2 (en) | 2013-04-05 | 2014-10-09 | Dow Agrosciences Llc | Methods and compositions for integration of an exogenous sequence within the genome of plants |
EP3679785A2 (en) | 2013-04-05 | 2020-07-15 | Dow AgroSciences LLC | Methods and compositions for integration of an exogenous sequence within the genome of plants |
US10196652B2 (en) | 2013-05-15 | 2019-02-05 | Sangamo Therapeutics, Inc. | Methods and compositions for treatment of a genetic condition |
US9873894B2 (en) | 2013-05-15 | 2018-01-23 | Sangamo Therapeutics, Inc. | Methods and compositions for treatment of a genetic condition |
US10196651B2 (en) | 2013-05-15 | 2019-02-05 | Sangamo Therapeutics, Inc. | Methods and compositions for treatment of a genetic condition |
US9902974B2 (en) | 2013-05-15 | 2018-02-27 | Sangamo Therapeutics, Inc. | Methods and compositions for treatment of a genetic condition |
EP3730615A2 (en) | 2013-05-15 | 2020-10-28 | Sangamo Therapeutics, Inc. | Methods and compositions for treatment of a genetic condition |
EP3591045A1 (en) | 2013-08-28 | 2020-01-08 | Sangamo Therapeutics, Inc. | Compositions for linking dna-binding domains and cleavage domains |
EP3988654A1 (en) | 2013-08-28 | 2022-04-27 | Sangamo Therapeutics, Inc. | Compositions for linking dna-binding domains and cleavage domains |
US9567609B2 (en) | 2013-08-28 | 2017-02-14 | Sangamo Biosciences, Inc. | Compositions for linking DNA-binding domains and cleavage domains |
WO2015031619A1 (en) | 2013-08-28 | 2015-03-05 | Sangamo Biosciences, Inc. | Compositions for linking dna-binding domains and cleavage domains |
US11041174B2 (en) | 2013-08-28 | 2021-06-22 | Sangamo Therapeutics, Inc. | Compositions for linking DNA-binding domains and cleavage domains |
US10538787B2 (en) | 2013-08-28 | 2020-01-21 | Sangamo Therapeutics, Inc. | Compositions for linking DNA-binding domains and cleavage domains |
US9957526B2 (en) | 2013-10-17 | 2018-05-01 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
US10117899B2 (en) | 2013-10-17 | 2018-11-06 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells |
WO2015057980A1 (en) | 2013-10-17 | 2015-04-23 | Sangamo Biosciences, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
US10494648B2 (en) | 2013-10-17 | 2019-12-03 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
WO2015057976A1 (en) | 2013-10-17 | 2015-04-23 | Sangamo Biosciences, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells |
EP3441468A2 (en) | 2013-10-17 | 2019-02-13 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
WO2015066638A2 (en) | 2013-11-04 | 2015-05-07 | Dow Agrosciences Llc | Optimal maize loci |
EP3862434A1 (en) | 2013-11-04 | 2021-08-11 | Dow AgroSciences LLC | Optimal soybean loci |
US11098317B2 (en) | 2013-11-04 | 2021-08-24 | Corteva Agriscience Llc | Optimal maize loci |
US11098316B2 (en) | 2013-11-04 | 2021-08-24 | Corteva Agriscience Llc | Optimal soybean loci |
US10233465B2 (en) | 2013-11-04 | 2019-03-19 | Dow Agrosciences Llc | Optimal soybean loci |
US11149287B2 (en) | 2013-11-04 | 2021-10-19 | Corteva Agriscience Llc | Optimal soybean loci |
WO2015066636A2 (en) | 2013-11-04 | 2015-05-07 | Dow Agrosciences Llc | Optimal maize loci |
US11198882B2 (en) | 2013-11-04 | 2021-12-14 | Corteva Agriscience Llc | Optimal maize loci |
US10273493B2 (en) | 2013-11-04 | 2019-04-30 | Dow Agrosciences Llc | Optimal maize loci |
US9909131B2 (en) | 2013-11-04 | 2018-03-06 | Dow Agrosciences Llc | Optimal soybean loci |
US10106804B2 (en) | 2013-11-04 | 2018-10-23 | Dow Agrosciences Llc | Optimal soybean loci |
WO2015066643A1 (en) | 2013-11-04 | 2015-05-07 | Dow Agrosciences Llc | Optimal soybean loci |
US10093940B2 (en) | 2013-11-04 | 2018-10-09 | Dow Agrosciences Llc | Optimal maize loci |
WO2015070212A1 (en) | 2013-11-11 | 2015-05-14 | Sangamo Biosciences, Inc. | Methods and compositions for treating huntington's disease |
US10369201B2 (en) | 2013-11-11 | 2019-08-06 | Sangamo Therapeutics, Inc. | Methods and compositions for treating Huntington's disease |
US11021696B2 (en) | 2013-11-13 | 2021-06-01 | Children's Medical Center Corporation | Nuclease-mediated regulation of gene expression |
EP3492593A1 (en) | 2013-11-13 | 2019-06-05 | Children's Medical Center Corporation | Nuclease-mediated regulation of gene expression |
US9932607B2 (en) | 2013-11-15 | 2018-04-03 | The Board Of Trustees Of The Leland Stanford Junior University | Site-specific integration of transgenes into human cells |
US10407476B2 (en) | 2013-12-09 | 2019-09-10 | Sangamo Therapeutics, Inc. | Methods and compositions for treating hemophilia |
US11634463B2 (en) | 2013-12-09 | 2023-04-25 | Sangamo Therapeutics, Inc. | Methods and compositions for treating hemophilia |
US10081661B2 (en) | 2013-12-09 | 2018-09-25 | Sangamo Therapeutics, Inc. | Methods and compositions for genome engineering |
US9771403B2 (en) | 2013-12-09 | 2017-09-26 | Sangamo Therapeutics, Inc. | Methods and compositions for treating hemophilia |
US10968261B2 (en) | 2013-12-09 | 2021-04-06 | Sangamo Therapeutics, Inc. | Methods and compositions for genome engineering |
EP3757116A1 (en) | 2013-12-09 | 2020-12-30 | Sangamo Therapeutics, Inc. | Methods and compositions for genome engineering |
US10072066B2 (en) | 2014-02-03 | 2018-09-11 | Sangamo Therapeutics, Inc. | Methods and compositions for treatment of a beta thalessemia |
WO2015117081A2 (en) | 2014-02-03 | 2015-08-06 | Sangamo Biosciences, Inc. | Methods and compositions for treatment of a beta thalessemia |
US10370680B2 (en) | 2014-02-24 | 2019-08-06 | Sangamo Therapeutics, Inc. | Method of treating factor IX deficiency using nuclease-mediated targeted integration |
US11591622B2 (en) | 2014-02-24 | 2023-02-28 | Sangamo Therapeutics, Inc. | Method of making and using mammalian liver cells for treating hemophilia or lysosomal storage disorder |
WO2015130931A1 (en) | 2014-02-28 | 2015-09-03 | Dow Agrosciences Llc | Root specific expression conferred by chimeric gene regulatory elements |
US9624498B2 (en) | 2014-03-18 | 2017-04-18 | Sangamo Biosciences, Inc. | Methods and compositions for regulation of zinc finger protein expression |
EP3929279A1 (en) | 2014-03-18 | 2021-12-29 | Sangamo Therapeutics, Inc. | Methods and compositions for regulation of zinc finger protein expression |
WO2015143046A2 (en) | 2014-03-18 | 2015-09-24 | Sangamo Biosciences, Inc. | Methods and compositions for regulation of zinc finger protein expression |
US10612041B2 (en) | 2014-03-21 | 2020-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Genome editing without nucleases |
US10507232B2 (en) | 2014-04-02 | 2019-12-17 | University Of Florida Research Foundation, Incorporated | Materials and methods for the treatment of latent viral infection |
US11110154B2 (en) | 2014-05-08 | 2021-09-07 | Sangamo Therapeutics, Inc. | Methods and compositions for treating Huntington's Disease |
US9574211B2 (en) | 2014-05-13 | 2017-02-21 | Sangamo Biosciences, Inc. | Methods and compositions for prevention or treatment of a disease |
US9970001B2 (en) | 2014-06-05 | 2018-05-15 | Sangamo Therapeutics, Inc. | Methods and compositions for nuclease design |
WO2016005449A1 (en) | 2014-07-08 | 2016-01-14 | Vib Vzw | Means and methods to increase plant yield |
WO2016011029A2 (en) | 2014-07-14 | 2016-01-21 | Washington State University | Nanos knock-out that ablates germline cells |
EP4335926A2 (en) | 2014-07-14 | 2024-03-13 | Washington State University | Nanos knock-out that ablates germline cells |
US10738278B2 (en) | 2014-07-15 | 2020-08-11 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
WO2016011381A1 (en) | 2014-07-18 | 2016-01-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Reducing cxcr4 expression and/or function to enhance engraftment of hematopoietic stem cells |
US9816074B2 (en) | 2014-07-25 | 2017-11-14 | Sangamo Therapeutics, Inc. | Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells |
US9757420B2 (en) | 2014-07-25 | 2017-09-12 | Sangamo Therapeutics, Inc. | Gene editing for HIV gene therapy |
US9833479B2 (en) | 2014-07-30 | 2017-12-05 | Sangamo Therapeutics, Inc. | Gene correction of SCID-related genes in hematopoietic stem and progenitor cells |
US9616090B2 (en) | 2014-07-30 | 2017-04-11 | Sangamo Biosciences, Inc. | Gene correction of SCID-related genes in hematopoietic stem and progenitor cells |
US10435677B2 (en) | 2014-09-16 | 2019-10-08 | Sangamo Therapeutics, Inc. | Genetically modified human cell with a corrected mutant sickle cell mutation |
WO2016044416A1 (en) | 2014-09-16 | 2016-03-24 | Sangamo Biosciences, Inc. | Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells |
EP3878948A1 (en) | 2014-09-16 | 2021-09-15 | Sangamo Therapeutics, Inc. | Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells |
US10889834B2 (en) | 2014-12-15 | 2021-01-12 | Sangamo Therapeutics, Inc. | Methods and compositions for enhancing targeted transgene integration |
WO2016118726A2 (en) | 2015-01-21 | 2016-07-28 | Sangamo Biosciences, Inc. | Methods and compositions for identification of highly specific nucleases |
US11634688B2 (en) | 2015-01-26 | 2023-04-25 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
US10626372B1 (en) | 2015-01-26 | 2020-04-21 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
US11155796B2 (en) | 2015-02-09 | 2021-10-26 | Duke University | Compositions and methods for epigenome editing |
WO2016161446A1 (en) | 2015-04-03 | 2016-10-06 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b-cells |
WO2017176806A1 (en) | 2015-04-03 | 2017-10-12 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b cells |
EP4335918A2 (en) | 2015-04-03 | 2024-03-13 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b-cells |
WO2016168230A2 (en) | 2015-04-15 | 2016-10-20 | Dow Agrosciences Llc | Plant promoter for transgene expression |
WO2016168229A1 (en) | 2015-04-15 | 2016-10-20 | Dow Agrosciences Llc | Plant promoter for transgene expression |
WO2016178207A1 (en) | 2015-05-04 | 2016-11-10 | Ramot At Tel-Aviv University Ltd. | Methods and kits for fragmenting dna |
US10179918B2 (en) | 2015-05-07 | 2019-01-15 | Sangamo Therapeutics, Inc. | Methods and compositions for increasing transgene activity |
US10808020B2 (en) | 2015-05-12 | 2020-10-20 | Sangamo Therapeutics, Inc. | Nuclease-mediated regulation of gene expression |
WO2016196388A1 (en) | 2015-05-29 | 2016-12-08 | Juno Therapeutics, Inc. | Composition and methods for regulating inhibitory interactions in genetically engineered cells |
US10619154B2 (en) | 2015-06-18 | 2020-04-14 | Sangamo Therapeutics, Inc. | Nuclease-mediated regulation of gene expression |
US9957501B2 (en) | 2015-06-18 | 2018-05-01 | Sangamo Therapeutics, Inc. | Nuclease-mediated regulation of gene expression |
WO2017011519A1 (en) | 2015-07-13 | 2017-01-19 | Sangamo Biosciences, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
US10450585B2 (en) | 2015-07-13 | 2019-10-22 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
US10786533B2 (en) | 2015-07-15 | 2020-09-29 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
WO2017023570A1 (en) | 2015-08-06 | 2017-02-09 | The Curators Of The University Of Missouri | Pathogen-resistant animals having modified cd163 genes |
WO2017053164A1 (en) | 2015-09-22 | 2017-03-30 | Dow Agrosciences Llc | Plant promoter and 3' utr for transgene expression |
WO2017180180A2 (en) | 2015-09-22 | 2017-10-19 | Dow Agrosciences Llc | Plant promoter and 3' utr for transgene expression |
US11123443B2 (en) | 2015-09-23 | 2021-09-21 | Sangamo Therapeutics, Inc. | Htt repressors and uses thereof |
US10435441B2 (en) | 2015-09-23 | 2019-10-08 | Sangamo Therapeutics, Inc. | HTT repressors and uses thereof |
WO2017070298A1 (en) | 2015-10-22 | 2017-04-27 | Dow Agrosciences Llc | Plant promoter for transgene expression |
US11072781B2 (en) | 2015-11-04 | 2021-07-27 | Fate Therapeutics, Inc. | Genomic engineering of pluripotent cells |
US10287606B2 (en) | 2015-11-04 | 2019-05-14 | Fate Therapeutics, Inc. | Genomic engineering of pluripotent cells |
US10858628B2 (en) | 2015-11-04 | 2020-12-08 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
EP4249074A2 (en) | 2015-11-04 | 2023-09-27 | Fate Therapeutics, Inc. | Genomic engineering of pluripotent cells |
US11352607B2 (en) | 2015-11-04 | 2022-06-07 | Fate Therapeutics, Inc. | Genomic engineering of pluripotent cells |
WO2017079673A1 (en) | 2015-11-04 | 2017-05-11 | Fate Therapeutics, Inc. | Genomic engineering of pluripotent cells |
US11162076B2 (en) | 2015-11-04 | 2021-11-02 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
US10947505B2 (en) | 2015-11-04 | 2021-03-16 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
WO2017078935A1 (en) | 2015-11-04 | 2017-05-11 | Dow Agrosciences Llc | Plant promoter for transgene expression |
US11162075B2 (en) | 2015-11-04 | 2021-11-02 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
US11793888B2 (en) | 2015-11-23 | 2023-10-24 | Sangamo Therapeutics, Inc. | Methods and compositions for engineering immunity |
US10639383B2 (en) | 2015-11-23 | 2020-05-05 | Sangamo Therapeutics, Inc. | Methods and compositions for engineering immunity |
US11285175B2 (en) | 2015-12-18 | 2022-03-29 | Sangamo Therapeutics, Inc. | Targeted disruption of the MHC cell receptor |
WO2017106528A2 (en) | 2015-12-18 | 2017-06-22 | Sangamo Biosciences, Inc. | Targeted disruption of the t cell receptor |
WO2017106537A2 (en) | 2015-12-18 | 2017-06-22 | Sangamo Biosciences, Inc. | Targeted disruption of the mhc cell receptor |
US11352631B2 (en) | 2015-12-18 | 2022-06-07 | Sangamo Therapeutics, Inc. | Targeted disruption of the T cell receptor |
US10500229B2 (en) | 2015-12-18 | 2019-12-10 | Sangamo Therapeutics, Inc. | Targeted disruption of the MHC cell receptor |
WO2017123757A1 (en) | 2016-01-15 | 2017-07-20 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of neurologic disease |
US10724020B2 (en) | 2016-02-02 | 2020-07-28 | Sangamo Therapeutics, Inc. | Compositions for linking DNA-binding domains and cleavage domains |
US11920169B2 (en) | 2016-02-02 | 2024-03-05 | Sangamo Therapeutics, Inc. | Compositions for linking DNA-binding domains and cleavage domains |
EP3769775A2 (en) | 2016-02-02 | 2021-01-27 | Sangamo Therapeutics, Inc. | Compositions for linking dna-binding domains and cleavage domains |
WO2017165655A1 (en) | 2016-03-23 | 2017-09-28 | Dana-Farber Cancer Institute, Inc. | Methods for enhancing the efficiency of gene editing |
US11421218B2 (en) | 2016-03-23 | 2022-08-23 | Dana-Farber Cancer Institute, Inc. | Methods for enhancing the efficiency of gene editing |
WO2018005559A1 (en) | 2016-06-27 | 2018-01-04 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
EP3992632A1 (en) | 2016-06-27 | 2022-05-04 | Juno Therapeutics, Inc. | Mhc-e restricted epitopes, binding molecules and related methods and uses |
WO2018005556A1 (en) | 2016-06-27 | 2018-01-04 | Juno Therapeutics, Inc. | Mhc-e restricted epitopes, binding molecules and related methods and uses |
WO2018013840A1 (en) | 2016-07-13 | 2018-01-18 | Vertex Pharmaceuticals Incorporated | Methods, compositions and kits for increasing genome editing efficiency |
EP4219462A1 (en) | 2016-07-13 | 2023-08-02 | Vertex Pharmaceuticals Incorporated | Methods, compositions and kits for increasing genome editing efficiency |
EP3838287A2 (en) | 2016-07-27 | 2021-06-23 | Case Western Reserve University | Compounds and methods of promoting myelination |
WO2018029034A1 (en) | 2016-08-09 | 2018-02-15 | Vib Vzw | Cellulose synthase inhibitors and mutant plants |
EP3995574A1 (en) | 2016-08-24 | 2022-05-11 | Sangamo Therapeutics, Inc. | Regulation of gene expression using engineered nucleases |
US10975393B2 (en) | 2016-08-24 | 2021-04-13 | Sangamo Therapeutics, Inc. | Engineered target specific nucleases |
WO2018039448A1 (en) | 2016-08-24 | 2018-03-01 | Sangamo Therapeutics, Inc. | Engineered target specific nucleases |
US11827900B2 (en) | 2016-08-24 | 2023-11-28 | Sangamo Therapeutics, Inc. | Engineered target specific nucleases |
US10563184B2 (en) | 2016-08-24 | 2020-02-18 | Sangamo Therapeutics, Inc. | Regulation of gene expression using engineered nucleases |
EP3964573A1 (en) | 2016-08-24 | 2022-03-09 | Sangamo Therapeutics, Inc. | Engineered target specific nucleases |
WO2018039440A1 (en) | 2016-08-24 | 2018-03-01 | Sangamo Therapeutics, Inc. | Regulation of gene expression using engineered nucleases |
US11845965B2 (en) | 2016-08-24 | 2023-12-19 | Sangamo Therapeutics, Inc. | Regulation of gene expression using engineered nucleases |
US10960085B2 (en) | 2016-09-07 | 2021-03-30 | Sangamo Therapeutics, Inc. | Modulation of liver genes |
WO2018067264A1 (en) | 2016-10-03 | 2018-04-12 | Dow Agrosciences Llc | Plant promoter for transgene expression |
WO2018067618A1 (en) | 2016-10-03 | 2018-04-12 | Juno Therapeutics, Inc. | Hpv-specific binding molecules |
WO2018067265A1 (en) | 2016-10-03 | 2018-04-12 | Dow Agrosciences Llc | Plant promoter for transgene expression |
US11072660B2 (en) | 2016-10-03 | 2021-07-27 | Juno Therapeutics, Inc. | HPV-specific binding molecules |
WO2018067826A1 (en) | 2016-10-05 | 2018-04-12 | Cellular Dynamics International, Inc. | Generating mature lineages from induced pluripotent stem cells with mecp2 disruption |
WO2018071873A2 (en) | 2016-10-13 | 2018-04-19 | Juno Therapeutics, Inc. | Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators |
US11896615B2 (en) | 2016-10-13 | 2024-02-13 | Juno Therapeutics, Inc. | Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators |
EP4190335A1 (en) | 2016-10-13 | 2023-06-07 | Juno Therapeutics, Inc. | Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators |
US11219695B2 (en) | 2016-10-20 | 2022-01-11 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of Fabry disease |
US11020492B2 (en) | 2016-10-31 | 2021-06-01 | Sangamo Therapeutics, Inc. | Gene correction of SCID-related genes in hematopoietic stem and progenitor cells |
WO2018081775A1 (en) | 2016-10-31 | 2018-05-03 | Sangamo Therapeutics, Inc. | Gene correction of scid-related genes in hematopoietic stem and progenitor cells |
US11504389B2 (en) | 2016-12-01 | 2022-11-22 | Sangamo Therapeutics, Inc. | Tau modulators and methods and compositions for delivery thereof |
US11793833B2 (en) | 2016-12-02 | 2023-10-24 | Juno Therapeutics, Inc. | Engineered B cells and related compositions and methods |
WO2018102612A1 (en) | 2016-12-02 | 2018-06-07 | Juno Therapeutics, Inc. | Engineered b cells and related compositions and methods |
WO2018106732A1 (en) | 2016-12-05 | 2018-06-14 | Juno Therapeutics, Inc. | Production of engineered cells for adoptive cell therapy |
EP4276187A2 (en) | 2016-12-08 | 2023-11-15 | Case Western Reserve University | Methods and compositions for enhancing functional myelin production |
WO2018106782A1 (en) | 2016-12-08 | 2018-06-14 | Case Western Reserve University | Methods and compositions for enhancing functional myelin production |
US11920148B2 (en) | 2017-02-22 | 2024-03-05 | Crispr Therapeutics Ag | Compositions and methods for gene editing |
WO2018195418A1 (en) | 2017-04-20 | 2018-10-25 | Oregon Health & Science University | Human gene correction |
US11655275B2 (en) | 2017-05-03 | 2023-05-23 | Sangamo Therapeutics, Inc. | Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene |
US11512287B2 (en) | 2017-06-16 | 2022-11-29 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell and/or HLA receptors |
EP4215543A2 (en) | 2017-10-03 | 2023-07-26 | Juno Therapeutics, Inc. | Hpv-specific binding molecules |
WO2019070541A1 (en) | 2017-10-03 | 2019-04-11 | Juno Therapeutics, Inc. | Hpv-specific binding molecules |
US11952408B2 (en) | 2017-10-03 | 2024-04-09 | Juno Therapeutics, Inc. | HPV-specific binding molecules |
WO2019089982A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
US11661611B2 (en) | 2017-11-09 | 2023-05-30 | Sangamo Therapeutics, Inc. | Genetic modification of cytokine inducible SH2-containing protein (CISH) gene |
US10927346B2 (en) | 2017-12-22 | 2021-02-23 | Fate Therapeutics, Inc. | Enhanced immune effector cells and use thereof |
EP4083192A1 (en) | 2017-12-22 | 2022-11-02 | Fate Therapeutics, Inc. | Enhanced immune effector cells and use thereof |
US11365394B2 (en) | 2017-12-22 | 2022-06-21 | Fate Therapeutics, Inc. | Enhanced immune effector cells and use thereof |
WO2019143678A1 (en) | 2018-01-17 | 2019-07-25 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
WO2019143675A1 (en) | 2018-01-17 | 2019-07-25 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
WO2019143677A1 (en) | 2018-01-17 | 2019-07-25 | Vertex Pharmaceuticals Incorporated | Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency |
US11401512B2 (en) | 2018-02-08 | 2022-08-02 | Sangamo Therapeutics, Inc. | Engineered target specific nucleases |
WO2019191495A1 (en) | 2018-03-29 | 2019-10-03 | Fate Therapeutics, Inc. | Engineered immune effector cells and use thereof |
WO2019195492A1 (en) | 2018-04-05 | 2019-10-10 | Juno Therapeutics, Inc. | Methods of producing cells expressing a recombinant receptor and related compositions |
US11471489B2 (en) | 2018-04-05 | 2022-10-18 | Juno Therapeutics, Inc. | T cell receptors and engineered cells expressing same |
WO2019195491A1 (en) | 2018-04-05 | 2019-10-10 | Juno Therapeutics, Inc. | T cells expressing a recombinant receptor, related polynucleotides and methods |
US11421007B2 (en) | 2018-04-18 | 2022-08-23 | Sangamo Therapeutics, Inc. | Zinc finger protein compositions for modulation of huntingtin (Htt) |
WO2019215500A1 (en) | 2018-05-11 | 2019-11-14 | Crispr Therapeutics Ag | Methods and compositions for treating cancer |
US11690921B2 (en) | 2018-05-18 | 2023-07-04 | Sangamo Therapeutics, Inc. | Delivery of target specific nucleases |
WO2019234141A1 (en) | 2018-06-06 | 2019-12-12 | Vib Vzw | NOVEL MUTANT PLANT CINNAMOYL-CoA REDUCTASE PROTEINS |
WO2019234750A1 (en) | 2018-06-07 | 2019-12-12 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Methods of regenerating and transforming cannabis |
WO2019234754A1 (en) | 2018-06-07 | 2019-12-12 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Nucleic acid constructs and methods of using same |
US11834686B2 (en) | 2018-08-23 | 2023-12-05 | Sangamo Therapeutics, Inc. | Engineered target specific base editors |
EP4234570A2 (en) | 2018-09-18 | 2023-08-30 | Sangamo Therapeutics, Inc. | Programmed cell death 1 (pd1) specific nucleases |
WO2020095248A1 (en) | 2018-11-07 | 2020-05-14 | Crispr Therapeutics Ag | Anti-ptk7 immune cell cancer therapy |
WO2020095249A1 (en) | 2018-11-07 | 2020-05-14 | Crispr Therapeutics Ag | Anti-liv1 immune cell cancer therapy |
WO2020095107A1 (en) | 2018-11-07 | 2020-05-14 | Crispr Therapeutics Ag | Anti-cd33 immune cell cancer therapy |
WO2020118073A1 (en) | 2018-12-05 | 2020-06-11 | Vertex Pharmaceuticals Incorporated | Gene-editing systems for editing a cystic fibrosis transmembrane regulator (cftr) gene |
GB201820109D0 (en) | 2018-12-11 | 2019-01-23 | Vib Vzw | Plants with a lignin trait and udp-glycosyltransferase mutation |
US11453639B2 (en) | 2019-01-11 | 2022-09-27 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
US11857641B2 (en) | 2019-02-06 | 2024-01-02 | Sangamo Therapeutics, Inc. | Method for the treatment of mucopolysaccharidosis type I |
WO2020185628A1 (en) | 2019-03-08 | 2020-09-17 | Obsidian Therapeutics, Inc. | Cd40l compositions and methods for tunable regulation |
WO2020205838A1 (en) | 2019-04-02 | 2020-10-08 | Sangamo Therapeutics, Inc. | Methods for the treatment of beta-thalassemia |
WO2020219726A1 (en) | 2019-04-23 | 2020-10-29 | Sangamo Therapeutics, Inc. | Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof |
WO2020223535A1 (en) | 2019-05-01 | 2020-11-05 | Juno Therapeutics, Inc. | Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods |
WO2020223571A1 (en) | 2019-05-01 | 2020-11-05 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods |
WO2020261219A1 (en) | 2019-06-27 | 2020-12-30 | Crispr Therapeutics Ag | Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer |
WO2021022223A1 (en) | 2019-08-01 | 2021-02-04 | Sana Biotechnology, Inc. | Dux4 expressing cells and uses thereof |
WO2021041316A1 (en) | 2019-08-23 | 2021-03-04 | Sana Biotechnology, Inc. | Cd24 expressing cells and uses thereof |
WO2021044378A1 (en) | 2019-09-06 | 2021-03-11 | Crispr Therapeutics Ag | Genetically engineered t cells having improved persistence in culture |
WO2021067871A1 (en) | 2019-10-02 | 2021-04-08 | Sangamo Therapeutics, Inc. | Zinc finger protein transcription factors for repressing alpha-synuclein expression |
WO2021067864A1 (en) | 2019-10-02 | 2021-04-08 | Sangamo Therapeutics, Inc. | Zinc finger protein transcription factors for treatment of prion disease |
WO2021087361A1 (en) | 2019-11-01 | 2021-05-06 | Sangamo Therapeutics, Inc. | Zinc finger nuclease variants for treating or preventing lysosomal storage diseases |
WO2021087358A1 (en) | 2019-11-01 | 2021-05-06 | Sangamo Therapeutics, Inc. | Gin recombinase variants |
WO2021087366A1 (en) | 2019-11-01 | 2021-05-06 | Sangamo Therapeutics, Inc. | Compositions and methods for genome engineering |
WO2021142376A1 (en) | 2020-01-08 | 2021-07-15 | Obsidian Therapeutics, Inc. | Compositions and methods for tunable regulation of transcription |
WO2021151012A1 (en) | 2020-01-22 | 2021-07-29 | Sangamo Therapeutics, Inc. | Zinc finger protein transcription factors for repressing tau expression |
WO2021155065A1 (en) | 2020-01-28 | 2021-08-05 | The Broad Institute, Inc. | Base editors, compositions, and methods for modifying the mitochondrial genome |
WO2021195426A1 (en) | 2020-03-25 | 2021-09-30 | Sana Biotechnology, Inc. | Hypoimmunogenic neural cells for the treatment of neurological disorders and conditions |
WO2021224416A1 (en) | 2020-05-06 | 2021-11-11 | Cellectis S.A. | Methods to genetically modify cells for delivery of therapeutic proteins |
WO2021224395A1 (en) | 2020-05-06 | 2021-11-11 | Cellectis S.A. | Methods for targeted insertion of exogenous sequences in cellular genomes |
WO2021231661A2 (en) | 2020-05-13 | 2021-11-18 | Juno Therapeutics, Inc. | Process for producing donor-batched cells expressing a recombinant receptor |
WO2021236852A1 (en) | 2020-05-20 | 2021-11-25 | Sana Biotechnology, Inc. | Methods and compositions for treatment of viral infections |
WO2021247836A1 (en) | 2020-06-03 | 2021-12-09 | Board Of Regents, The University Of Texas System | Methods for targeting shp-2 to overcome resistance |
WO2021260186A1 (en) | 2020-06-26 | 2021-12-30 | Juno Therapeutics Gmbh | Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods |
WO2022036150A1 (en) | 2020-08-13 | 2022-02-17 | Sana Biotechnology, Inc. | Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions |
WO2022046760A2 (en) | 2020-08-25 | 2022-03-03 | Kite Pharma, Inc. | T cells with improved functionality |
WO2022064428A1 (en) | 2020-09-23 | 2022-03-31 | Crispr Therapeutics Ag | Genetically engineered t cells with regnase-1 and/or tgfbrii disruption have improved functionality and persistence |
WO2022067122A1 (en) | 2020-09-25 | 2022-03-31 | Sangamo Therapeutics, Inc. | Zinc finger fusion proteins for nucleobase editing |
WO2022072826A1 (en) | 2020-10-02 | 2022-04-07 | Sangamo Therapeutics, Inc. | Novel zinc finger protein transcription factors for repressing alpha-synuclein expression |
WO2022098787A1 (en) | 2020-11-04 | 2022-05-12 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods |
WO2022101641A1 (en) | 2020-11-16 | 2022-05-19 | Pig Improvement Company Uk Limited | Influenza a-resistant animals having edited anp32 genes |
US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
WO2022120334A1 (en) | 2020-12-03 | 2022-06-09 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
WO2022137181A1 (en) | 2020-12-23 | 2022-06-30 | Crispr Therapeutics Ag | Co-use of lenalidomide with car-t cells |
WO2022146891A2 (en) | 2020-12-31 | 2022-07-07 | Sana Biotechnology, Inc. | Methods and compositions for modulating car-t activity |
US11802157B2 (en) | 2020-12-31 | 2023-10-31 | Sana Biotechnology, Inc. | Methods and compositions for modulating CAR-T activity |
WO2022189967A1 (en) | 2021-03-09 | 2022-09-15 | Crispr Therapeutics Ag | Genetically engineered t cells with ptpn2 knockout have improved functionality and anti-tumor activity |
WO2022204071A1 (en) | 2021-03-22 | 2022-09-29 | Juno Therapeutics, Inc. | Method to assess potency of viral vector particles |
WO2022216624A1 (en) | 2021-04-07 | 2022-10-13 | Century Therapeutics, Inc. | Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells |
WO2022216514A1 (en) | 2021-04-07 | 2022-10-13 | Century Therapeutics, Inc. | Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells |
WO2022216524A1 (en) | 2021-04-07 | 2022-10-13 | Century Therapeutics, Inc. | Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof |
WO2022235911A1 (en) | 2021-05-05 | 2022-11-10 | FUJIFILM Cellular Dynamics, Inc. | Methods and compositions for ipsc-derived microglia |
WO2022251443A1 (en) | 2021-05-26 | 2022-12-01 | FUJIFILM Cellular Dynamics, Inc. | Methods to prevent rapid silencing of genes in pluripotent stem cells |
WO2022251367A1 (en) | 2021-05-27 | 2022-12-01 | Sana Biotechnology, Inc. | Hypoimmunogenic cells comprising engineered hla-e or hla-g |
WO2023287827A2 (en) | 2021-07-14 | 2023-01-19 | Sana Biotechnology, Inc. | Altered expression of y chromosome-linked antigens in hypoimmunogenic cells |
WO2023010135A1 (en) | 2021-07-30 | 2023-02-02 | Tune Therapeutics, Inc. | Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) |
WO2023010133A2 (en) | 2021-07-30 | 2023-02-02 | Tune Therapeutics, Inc. | Compositions and methods for modulating expression of frataxin (fxn) |
WO2023019203A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Inducible systems for altering gene expression in hypoimmunogenic cells |
WO2023019227A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions |
WO2023019226A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy |
WO2023019225A2 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions |
WO2023019229A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified primary cells for allogeneic cell therapy |
WO2023039567A2 (en) | 2021-09-10 | 2023-03-16 | FUJIFILM Cellular Dynamics, Inc. | Compositions of induced pluripotent stem cell-derived cells and methods of use thereof |
WO2023042079A1 (en) | 2021-09-14 | 2023-03-23 | Crispr Therapeutics Ag | Genetically engineered immune cells having a disrupted cd83 gene |
WO2023070019A1 (en) | 2021-10-21 | 2023-04-27 | Vertex Pharmaceuticals Incorporated | Hypoimmune cells |
WO2023069790A1 (en) | 2021-10-22 | 2023-04-27 | Sana Biotechnology, Inc. | Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods |
WO2023076880A1 (en) | 2021-10-25 | 2023-05-04 | Board Of Regents, The University Of Texas System | Foxo1-targeted therapy for the treatment of cancer |
WO2023077050A1 (en) | 2021-10-29 | 2023-05-04 | FUJIFILM Cellular Dynamics, Inc. | Dopaminergic neurons comprising mutations and methods of use thereof |
WO2023081900A1 (en) | 2021-11-08 | 2023-05-11 | Juno Therapeutics, Inc. | Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods |
WO2023105244A1 (en) | 2021-12-10 | 2023-06-15 | Pig Improvement Company Uk Limited | Editing tmprss2/4 for disease resistance in livestock |
WO2023111913A1 (en) | 2021-12-15 | 2023-06-22 | Crispr Therapeutics Ag | Engineered anti-liv1 cell with regnase-1 and/or tgfbrii disruption |
WO2023119201A2 (en) | 2021-12-22 | 2023-06-29 | Crispr Therapeutics Ag | Genetically engineered t cells with disrupted casitas b-lineage lymphoma proto-oncogene-b (cblb) and uses thereof |
WO2023122722A1 (en) | 2021-12-22 | 2023-06-29 | Sangamo Therapeutics, Inc. | Novel zinc finger fusion proteins for nucleobase editing |
WO2023122337A1 (en) | 2021-12-23 | 2023-06-29 | Sana Biotechnology, Inc. | Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods |
US11965022B2 (en) | 2021-12-23 | 2024-04-23 | Sana Biotechnology, Inc. | Methods and compositions for modulating CAR-T activity |
WO2023129937A1 (en) | 2021-12-29 | 2023-07-06 | Century Therapeutics, Inc. | Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof |
WO2023131616A1 (en) | 2022-01-05 | 2023-07-13 | Vib Vzw | Means and methods to increase abiotic stress tolerance in plants |
WO2023131637A1 (en) | 2022-01-06 | 2023-07-13 | Vib Vzw | Improved silage grasses |
WO2023137471A1 (en) | 2022-01-14 | 2023-07-20 | Tune Therapeutics, Inc. | Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation |
WO2023137472A2 (en) | 2022-01-14 | 2023-07-20 | Tune Therapeutics, Inc. | Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression |
WO2023144199A1 (en) | 2022-01-26 | 2023-08-03 | Vib Vzw | Plants having reduced levels of bitter taste metabolites |
WO2023154578A1 (en) | 2022-02-14 | 2023-08-17 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
WO2023158836A1 (en) | 2022-02-17 | 2023-08-24 | Sana Biotechnology, Inc. | Engineered cd47 proteins and uses thereof |
WO2023164688A1 (en) | 2022-02-28 | 2023-08-31 | Kite Pharma, Inc. | Allogeneic therapeutic cells |
WO2023166425A1 (en) | 2022-03-01 | 2023-09-07 | Crispr Therapeutics Ag | Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions |
WO2023173123A1 (en) | 2022-03-11 | 2023-09-14 | Sana Biotechnology, Inc. | Genetically modified cells and compositions and uses thereof |
WO2023180904A1 (en) | 2022-03-21 | 2023-09-28 | Crispr Therapeutics Ag | Methods and compositions for treating lipoprotein-related diseases |
WO2023180967A1 (en) | 2022-03-23 | 2023-09-28 | Crispr Therapeutics Ag | Anti-cd83 car-t cells with regnase-1 and/or tgfbrii disruption |
WO2023180968A1 (en) | 2022-03-23 | 2023-09-28 | Crispr Therapeutics Ag | Anti-cd19 car-t cells with multiple gene edits and therapeutic uses thereof |
WO2023230613A1 (en) | 2022-05-27 | 2023-11-30 | The Broad Institute, Inc. | Improved mitochondrial base editors and methods for editing mitochondrial dna |
WO2023240169A1 (en) | 2022-06-08 | 2023-12-14 | Century Therapeutics, Inc. | Immunoeffector cells derived from induced pluripotent stem cells genetically engineered with membrane bound il12 and uses thereof |
WO2023240147A1 (en) | 2022-06-08 | 2023-12-14 | Century Therapeutics, Inc. | Genetically engineered cells expressing cd16 variants and nkg2d and uses thereof |
WO2023240212A2 (en) | 2022-06-08 | 2023-12-14 | Century Therapeutics, Inc. | Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof |
WO2023242827A2 (en) | 2022-06-17 | 2023-12-21 | Crispr Therapeutics Ag | LIPID NANOPARTICLES (LNPs)-BASED OCULAR DELIVERY |
WO2023248145A1 (en) | 2022-06-21 | 2023-12-28 | Crispr Therapeutics Ag | Compositions and methods for treating human immunodeficiency virus |
WO2023248147A1 (en) | 2022-06-21 | 2023-12-28 | Crispr Therapeutics Ag | Methods and compositions for in vivo editing of stem cells |
WO2023250511A2 (en) | 2022-06-24 | 2023-12-28 | Tune Therapeutics, Inc. | Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression |
WO2024003786A1 (en) | 2022-06-29 | 2024-01-04 | Crispr Therapeutics Ag | Chimeric antigen receptor targeting gpc-3 and immune cells expressing such for therapeutic uses |
WO2024006911A1 (en) | 2022-06-29 | 2024-01-04 | FUJIFILM Holdings America Corporation | Ipsc-derived astrocytes and methods of use thereof |
WO2024015881A2 (en) | 2022-07-12 | 2024-01-18 | Tune Therapeutics, Inc. | Compositions, systems, and methods for targeted transcriptional activation |
WO2024013514A2 (en) | 2022-07-15 | 2024-01-18 | Pig Improvement Company Uk Limited | Gene edited livestock animals having coronavirus resistance |
WO2024023801A2 (en) | 2022-07-29 | 2024-02-01 | Crispr Therapeutics Ag | Genetically engineered immune cells having disrupted transporter associated with antigen processing-1 (tap-1) gene |
WO2024023802A2 (en) | 2022-07-29 | 2024-02-01 | Crispr Therapeutics Ag | Genetically engineered immune cells having disrupted transporter associated with antigen processing-2 (tap-2) gene |
WO2024023804A2 (en) | 2022-07-29 | 2024-02-01 | Crispr Therapeutics Ag | Genetically engineered immune cells having disrupted transporter associated with antigen processing binding protein (tapbp) gene |
WO2024040254A2 (en) | 2022-08-19 | 2024-02-22 | Tune Therapeutics, Inc. | Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression |
WO2024064642A2 (en) | 2022-09-19 | 2024-03-28 | Tune Therapeutics, Inc. | Compositions, systems, and methods for modulating t cell function |
WO2024062388A2 (en) | 2022-09-20 | 2024-03-28 | Crispr Therapeutics Ag | Genetically engineered immune cells expressing chimeric antigen receptor targeting cd20 |
Also Published As
Publication number | Publication date |
---|---|
TWI283267B (en) | 2007-07-01 |
JP2002060786A (en) | 2002-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002016536A1 (en) | Bactericidal antifouling detergent for hard surface | |
JP2003096493A (en) | Germicidal antifouling detergent for rigid surface | |
JP2020147586A (en) | Disinfectant composition containing quaternary ammonium compounds | |
USRE44058E1 (en) | Cleaning composition comprising a water-soluble or water-dispersible polymer | |
JP5818546B2 (en) | Antibacterial agent | |
US6395698B1 (en) | Corrosion resistant sanitizing/disinfecting cleaning and wood preservative formulation | |
JP4907327B2 (en) | Detergent composition for dishwasher | |
CN110591833B (en) | Toilet cleaning agent and preparation method thereof | |
CN117050817A (en) | Antimicrobial multipurpose cleaners and methods of making and using the same | |
JP3422978B2 (en) | Cleaning composition for hard surfaces | |
US7544649B2 (en) | Antifouling detergent for hard surfaces | |
JP2003238991A (en) | Stainproofing detergent for hard surface | |
JP3617813B2 (en) | Cleaning composition for hard surface | |
JP4008364B2 (en) | Antifouling cleaner for hard surfaces | |
JP7315948B2 (en) | Disinfectant detergent composition | |
JP5926482B2 (en) | Biofilm removing agent and biofilm removing composition | |
JP2004315691A (en) | Germicidal detergent composition | |
JP4781664B2 (en) | Antibacterial agent | |
JP2009149858A (en) | Cleaning agent composition for hard surface | |
JP3986846B2 (en) | Concentrated liquid detergent for flush toilet | |
JP4912859B2 (en) | Dishwasher finish composition | |
JP3198079B2 (en) | Solid cleaning composition for hard surfaces | |
JP3558907B2 (en) | Hard surface antifouling antibacterial detergent composition | |
JP3405970B2 (en) | Cleaning composition for hard surfaces | |
JP2012092320A (en) | Biofilm removing agent, composition for removing biofilm, and method for removing biofilm |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CN US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |